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i 
Abstract 
 
Rare diseases are debilitating conditions often leading to severe clinical manifestations 
for affected patients. Orphan drugs have been developed to treat these rare diseases 
affecting a small number of individuals. Incentives in the legal framework aimed to 
recoup the research and development cost of orphan drugs for pharmaceutical companies 
have been implemented in the United States and the European Union. At the present 
time, Canada is still lacking a legal and policy framework for orphan drugs. Several 
problems at the federal and provincial levels remain: lack of research funds for rare 
diseases, discrepancies on orphan drug policies between provinces, difficulties to access 
and reimburse these high price drugs. Recommendations and measures are proposed, 
such as a pan-Canadian (national) scientific committee to establish evidence-based 
guidelines for patients to access orphan drugs uniformly in all provinces with a disease 
specific registry, a formal agreement for a centralized Canadian public funding 
reimbursement procedure, and increasing the role of “guardian” for prices by the 
Patented Medicines Review Board in Canada. These recommendations and measures 
will be beneficial for the implementation of a policy framework for orphan drugs in 
Canada. 
 
Résumé 
 
Les maladies rares sont des maladies sérieuses pouvant causer des manifestations 
cliniques sévères chez les patients atteints. Les médicaments orphelins ont été 
développés pour le traitement de ces maladies rares qui touchent un petit nombre 
d’individus. Un cadre légal permettant des incitatifs pour les compagnies 
pharmaceutiques aux États-Unis et au niveau de l’Union Européenne a favorisé la 
recherche et le développement desdits médicaments. Présentement, il n’existe pas de 
cadre juridique et de politiques spécifiques au Canada entourant les médicaments 
orphelins. Ceci a mené à plusieurs problèmes tant au niveau fédéral que provincial dont: 
un manque de support financier consacré à la recherche pour les maladies rares, des 
disparités entre les provinces concernant les politiques pour les médicaments orphelins, 
des difficultés d’accès et de remboursement desdits médicaments dont les coûts sont 
élevés. Des recommandations et mesures sont proposées, telles l’implantation d’un 
comité scientifique pancanadien (national) afin d’établir des lignes directrices fondées 
sur des données probantes pour faciliter un accès uniforme aux médicaments orphelins 
pour les patients, y compris un registre spécifique élaboré pour chaque maladie, établir 
une entente formelle centralisée pour tout le Canada pour un financement public de 
remboursement des médicaments orphelins, augmenter le rôle de « gardien » des prix 
par le Conseil d’examen du prix des médicaments brevetés au Canada. Ces 
recommandations et mesures serviront à l’implantation d’un cadre de politiques pour les 
médicaments orphelins au Canada.   
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Glossary  
Adverse event: Any undesirable experience associated with the use of a medical 
product in a patient.  
Biomarkers: A measurable substance in an organism whose presence is indicative of 
some phenomenon such as disease, infection, or environmental exposure. 
Chelation process: A type of bonding of ions and molecules to metal ions. 
Cryopyrin-Associated Periodic Syndrome: A group of rare, inherited, 
autoinflammatory diseases with the same genetic basis and overlapping 
symptomatology. 
Enzyme replacement therapy: A generic term for therapeutic administration of a 
congenitally defectiveor absent enzyme, which may be adminstered: directly, by 
coupling the enzyme to a carrier molecule or by organ transplantation; or indirectly, by 
introducing the gene into the recipient. 
Fabry disease: A rare genetic disease; it is an X-linked lysosomal storage disorder 
caused by the deficiency of the alpha-Galactosidase A enzyme leading to accumulation 
of glycosphingolipids in biological fluids, organs and the vascular endothelium. 
Gaucher Disease: A rare, inherited metabolic disorder in which deficiency of the 
enzyme glucocerebrosidase results in the accumulation of harmful quantities of certain 
fats (lipids), specifically the glycolipid glucocerebroside, throughout the body especially 
within the bone marrow, spleen and liver. The symptoms and physical findings vary 
greatly from patient to patient. 
Genome: The complete set of genes or genetic material present in a cell or organism. 
Genotype: The genetic constitution of an individual. 
Health Technology Assessment procedures: The systematic evaluation of properties, 
effects, and/or impacts of health technology. It is a multidisciplinary process to evaluate 
the social, economic, organizational and ethical issues of a health intervention or health 
technology. The main purpose of conducting an assessment is to inform a policy 
decision-making.  
Lysosomal storage disorders: are inherited metabolic diseases that are characterized by 
an abnormal build-up of various toxic materials in the lysosomes of body's cells as a 
result of enzyme deficiencies. 
Mucopolysaccharidosis: Any of a group of inherited metabolic disorders in which 
mucopolysaccharides accumulate in various tissues, often leading to skeletal 
abnormalities, mental retardation, and reduced life expectancy. These conditions are also 
referred to by their original names, which are Hurler, Hurler-Scheie, Scheie (all MPS I), 
  
 
 
xiii 
Hunter (MPS II), Sanfilippo (MPS III), Morquio (MPS IV), Maroteaux-Lamy (MPS VI), 
Sly (MPS VII), and Hyaluronidase deficiency (MPS IX). 
Niemann-Pick type C disease: A type of Niemann-Pick disease inherited in an 
autosomal recessive manner, resulting in lipid storage in the brain and body. At the 
cellular level, the disorder is characterized by the accumulation of cholesterol and 
glycolipid. Most (about 95%) of patients have mutations in the NPC1 gene in 
chromosome 18q11, which encodes a large membrane glycoprotein.  
Pharmacoeconomics: the branch of economics that uses cost-benefit, cost-
effectiveness, cost-minimization, cost-of-illness and cost-utility analyses to compare 
pharmaceutical products and treatment strategies. 
Pharmacokinetics: the branch of pharmacology concerned with the movement of drugs 
within the body. 
Phenotype: The physical and/or biochemical characteristics of a person, an animal or 
other organism, which are determined by their genetic make-up and/or environment. 
Pompe Disease: a rare multisystem genetic disorder that is characterized by absence or 
deficiency of the lysosomal enzyme alpha-glucosidase. This enzyme is required to 
breakdown (metabolize) the complex carbohydrate glycogen and convert it into the 
simple glucose sugar. 
Prevalence: The proportion of a whole population affected by a certain condition. 
Quality-adjusted life year (QALY): A measure of the state of health of a person or 
group in which the benefits, in terms of length of life, are adjusted to reflect the quality 
of life. One QALY is equal to 1 year of life in perfect health. QALYs are calculated by 
estimating the years of life remaining for a patient following a particular treatment or 
intervention and weighting each year with a quality-of-life score (on a 0 to 1 scale). It is 
often measured in terms of the person’s ability to carry out the activities of daily life, 
and freedom from pain and mental disturbance. 
Side effects: A secondary, typically undesirable effect of a drug or medical treatment. 
Statistical power analysis: Statistical power is the likelihood that a study will detect an 
effect when there is an effect there to be detected. Statistical power is affected chiefly by 
the size of the effect and the size of the sample used to detect it. In general, the larger the 
sample size, the higher statistical power in the analysis.  
  
 
 
1 
Introduction  
 
There is still ongoing debate over how to define “rare” or “orphan” diseases, and 
the “orphan” drugs often used to treat them.  
So, how to define “rare” or “orphan” diseases?  
In the Oxford Dictionary, the term “rare” refers to an event, a situation or 
condition not occurring very often, and provides the following example: a rare genetic 
disorder1. The definition or the word “rare” has been the subject of conflicting debate, as 
early as in the 1970s. The word “rare” - as in the rarity of a disorder - was used by 
doctors up until the late 1960s as an attribute of a complex diagnosis, such as a rare 
localization of a condition, a rare form of a disease, a rare cause of a disease, a rare 
complication or simply an unusual case report. In fact, it was used by clinicians to refer 
to a specific organ disease, such as a “rare kidney disease” or a “rare brain disorder”2. It 
is worth clarifying that this work will not examine “neglected diseases”, a group of 
communicable diseases which prevail in tropical and subtropical nations, but can also be 
occasionally found in developed countries, such as Canada and the United States (US) 
(i.e. Dengue fever, malaria)3.  
A recent sociological approach reports that in the 1980s, in order to better 
understand rare diseases, the views of different groups of individuals had to be taken 
into account: patients, physicians, public bodies and the pharmaceutical industry4. The 
                                                             
1  “rare – definition of rare in English from the Oxford dictionary”,  online: 
<http://www.oxforddictionaries.com/definition/english/> 
2 Caroline Huyard, “How did uncommon disorders become ‘rare diseases’? History of a boundary object”, 
(2009) 31:4 Sociology of Health & Illness 463. doi: 10.1111/j.1467-9566.2008.01143.x  
3 World Health Organization, online: <www.who.int/neglected_diseases/diseases/en> (Accessed April 3 
2016). 
4 Huyard, supra note 2 at 465. 
  
 
 
2 
author alleged that rare diseases are “a meaningless category for physicians, it relates to 
the patients’ experience of illness, whereas the pharmaceutical industry first considered 
it as being synonymous with small markets, and then with innovation. Public bodies 
contributed to framing a common and blurred use, based on a statistical definition whose 
purpose was to foster cooperation between the four groups involved in the issue”5. 
The term “rare” diseases and the category of rare diseases seem to have surfaced 
in the United States in the mid-1970s subsequent to the orphan drug issue, a 
consequence of the Kefauver-Harris Amendments in 1962 to the Food, Drug and 
Cosmetic Act of 19386.  
These amendments insisting on proof of the effectiveness, safety and reliability 
of drugs available since 1938 in the United States were necessary following the 
thalidomide tragedy, and also, in order to protect the health of the public7. Therefore, 
drugs had to be reviewed to meet the criteria of the new legislation to be approved, or be 
taken off the market8. These 1962 amendments were part of a major restructuring of the 
approval process for drugs in the United States, but they also affected the development 
of drugs and the ongoing process of alterations of the policies regulating the industry9. In 
fact, the Drug Efficacy Study Implementation program created by the Food and Drug 
Administration (FDA) in 1962 reviewed and re-evaluated the effectiveness of drug 
products, which resulted in the removal of more than 1000 medicines that were on the 
                                                             
5 Ibid. 
6 Drug Amendments Act of 1962, Public Law No 87-78, 76 Stat 780. 
7 Jeremy A Greene & Scott H Podolsky, “Reform, Regulation, and Pharmaceuticals — The Kefauver–
Harris Amendments at 50” (2012) 367:16 New England Journal of Medicine at 1482. 
8 Drug Amendments Act of 1962, supra note 6. 
9 Carolyn H. Asbury, Orphan Drugs:medical versus market value (Lexington, Mass: Lexington Books, 
1985), at 21.  
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market 10 . Different aspects of drug efficacy and safety were evaluated “through 
provisions affecting drug testing and approval, labeling, advertising and monitoring of 
firms”11. Moreover, a Library of Congress study approved by Kefauver evaluated 34 
trade-named drugs extensively used by physicians and advertised in scientific medical 
journals between July 1958 and March 1959. This study revealed that 89% of these 
advertisements did not indicate or had minimal indications of adverse effects12. This 
situation was troubling for physicians prescribing these drugs, since it meant they might 
not have had the adequate information for their patients.  
Although certain drugs were taken off the market for their inefficacy, some of 
them were neither reviewed nor withdrawn. In fact, hospital pharmacies were becoming 
part of a major concern because of their usage of non-approved substances, which had 
no label for drug indication. Some of these chemical substances used in hospital 
pharmacies would have been commercially unprofitable through a New Drug 
Application and therefore, were labeled as “manufacturing use only”, “for chemical 
purposes”, “for research use only, not for clinical use”, or “for investigational use only, 
not for drug use” 13. Researchers coined the term “homeless” or “orphan” drugs to refer 
to substances whose usage was not approved or labeled as a drug and so, metaphorically 
speaking, they had no home14.  
Some examples of orphan drugs at that time were the corticosteroid ACTH 
(Adreno Cortico Trophic Hormone) for multiple sclerosis, pentamidine for the treatment 
                                                             
10 Office of the Commissioner, “Overviews on FDA History - FDA and Clinical Drug Trials: A Short 
History”,online:<http://www.fda.gov/AboutFDA/WhatWeDo/History/Overviews/ucm304485.htm>(Acces
sed April 12 2016); See also supra note 7.  
11 Asbury, supra note 9 at 21 
12 Ibid at 23. 
13  George P. Provost,“Homeless’ or ‘orphan’ drugs” (1968) 25:11 Am J Hosp Pharm 609. 
14 Ibid. 
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of a rare form of pneumonia and the development of anticancer agents by the National 
Cancer Institute15. The major issue with orphan drugs for rare diseases in the ‘80s, and 
even before, was that, although medically important, they were found to be unprofitable 
by the pharmaceutical industry.  
Nevertheless, in some cases, lone individuals were successful in bringing a drug 
to market for treating patients affected with rare diseases. The 1956 story of J.M. 
Walshe, a neurologist, merits attention. He introduced one drug called penicillamine to 
treat Wilson’s disease, an autosomal recessive rare disorder leading to the accumulation 
of copper in tissues and severe clinical manifestations16 (it was later introduced for other 
diseases as well). Briefly, penicillamine binds to copper as part of a chelation process 
followed by copper excretion in urine. The drug is efficient for treating the disease, but 
there is a possibility of a toxic effect when administered to patients over the long term. 
Therefore, Walshe decided to introduce a new oral drug in 1966 called triethylene 
tetramine dihydrochloride, which was a copper-chelating compound. Since this drug was 
not supported or manufactured by the pharma industry, he had to produce it in his own 
laboratory without any toxicity studies. However, his efforts led to a medication that 
saved the lives of those affected with this rare disease17.  
In 1983, the term “rare diseases” was officially adopted by the Orphan Drug Act 
(ODA)18. Rare diseases or orphan diseases are often interchangeable terms but the core 
of the definition is important, even though there is no consensual definition at the 
moment. The usage and the definition of the term are relevant when it comes to the 
                                                             
15 Asbury, supra note 9. 
16 J.M. “Letter: Drugs for rare diseases” (1975) 3:5985 Br Med. J. 701. 
17 Anon. Drugs for rare diseases, (1976) The Lancet, 2, 7990, 835–6.  
18 Orphan Drug Act, Pub L. No. 97-414, 96 Stat 2049 (1983). 
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designation of a particular drug and its policies, especially, when introducing new 
legislation.  
An estimate of 7,00019 to 8,000 rare diseases have been recognized affecting 
altogether 6-8% of the general population20. It should be emphasized that even if they 
are called “rare or orphan diseases”, the clinical manifestations can be severe, in some 
cases leading to the death of the affected individuals21. These diseases are found in 
significant numbers (75%) in newborns and children22. Some are detected early through 
neonatal screening, while others are detected later on in life23. Eighty percent of rare 
diseases are of genetic origin24. A marked heterogeneity in the phenotype and genotype 
of most rare diseases increases the complexity of monitoring, management and follow-
up of affected patients. According to the Canadian Organization for Rare Disorders 
(CORD), the number of persons affected with a rare disease in Canada is estimated at 1 
in 12, or approximately 3 million Canadians25. This gives the impression that, when all 
these diseases are taken together, the descriptor no longer seems appropriate and 
therefore, these diseases are not so rare after all.  
                                                             
19  “About CORD | Canadian Organization for Rare Disorders”, online: 
<https://www.raredisorders.ca/about-cord/>. > (Accessed April 12 2016). 
20 Domenica Taruscio, Linda Agresta & Et Al, “The Italian National Centre for Rare Diseases: where 
research and public health translate into action” Blood Transfusion (2014) 12 Suppl 3: s591-605 doi 
10.2450/2014.0040-14s. 
21 Wim Pinxten et al, “A fair share for the orphans: ethical guidelines for a fair distribution of resources 
within the bounds of the 10-year-old European Orphan Drug Regulation” (2012) 38:3 J Med Ethics 148. 
22  “EURODIS What is a rare disease? - Rare Diseases Europe”, 2015, online: 
<http://www.eurordis.org/sites/default/files/publications/Fact_Sheet_RD.pdf> (Accessed 7 April 2016.) 
23  “MSSS - Sujets - Santé publique - Dépistage néonatal - Sanguin et urinaire - Description et 
admissibilité”, online: <http://www.msss.gouv.qc.ca/sujets/santepub/depistage-neonatal/>. (Accessed 10 
March 2016). 
24  “About Rare Diseases | www.eurordis.org”, online: <http://www.eurordis.org/about-rare-diseases>. 
(Accessed May 21 2016). 
25  “Canada’s Rare Disease Strategy | Canadian Organization for Rare Disorders”, online: 
<https://www.raredisorders.ca/canadas-rare-disease-strategy/>. (Accessed April 12 2016). 
  
 
 
6 
However, there are different groups of rare disorders, such as autoimmune 
diseases, infectious diseases, genetic diseases, rare cancers, congenital malformations, 
and sometimes, diseases of unknown nature26. An alphabetical list of rare diseases is 
available from Orphanet 27 . Orphanet is the “reference portal” designed to provide 
specific information on rare diseases to affected patients, as well as caregivers 28. This 
list provides at a glance the disparity of diseases ranging from Acheiria (a congenital 
disease characterized by the absence of one or both hands) to Progeria (also known as 
Hutchinson-Gilford syndrome, a genetic condition characterized by dramatic aging in 
childhood). It also offers the latest news and developments on orphan drugs. Orphanet is 
comprised of a consortium of 40 countries working together under the coordinating 
endeavor of the “Institut national de la santé et de la recherche médicale” (INSERM) in 
France29. The main objective of the Orphanet consortium is to improve the diagnosis, 
monitoring, treatment and overall care of patients with rare diseases.  
Even if Orphanet maintains an updated survey of the scientific literature to 
estimate the prevalence (the proportion of the population that has any given disease at a 
specific point in time) and incidence (it measures the rate of occurrence of new cases of 
a disease or condition in a particular population in a specific time period) of rare 
                                                             
26 Stéphanie Elger et al, Prise en charge des maladies rares expériences étrangères: rapport (Québec: 
Institut national d’excellence en santé et en services sociaux, Québec, 2011). 
27 Orphanet Report Series - List of rare diseases and synonyms listed in alphabetical order - March 2016 
online: 
<http://www.orpha.net/orphacom/cahiers/docs/GB/List_of_rare_diseases_in_alphabetical_order.pdf> 
(Accessed 14 April 2016). 
28 “Orphanet: About Orphanet”, online: <http://www.orpha.net/consor/cgi-
bin/Education_AboutOrphanet.php?lng=EN>.(Accessed 14 April 2016). 
29 INSERM: it is a public scientific and technological body operating in France and oriented towards 
medical research. It is under the Ministry of Research and the Ministry of Health, online: “Inserm – 
French National Institute of Health and Medical Research”, online: < http://english.inserm.fr/> (Accessed 
14 April 2016). 
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diseases30, surprisingly, there is no real consensus about the definition of a rare disease 
in terms of the number of patients affected. In the United States, according to the “U.S 
Orphan Drug Act”, a rare disease is one that affects less than one individual per 
200,00031. In the European Union, “The European Orphan Drug Regulation” states that 
it is 1 in 200032. In 2014, Health Canada, through its then-Minister of Health, Rona 
Ambrose, stipulated the following definition for orphan drugs, rare diseases, and the 
frequency of a rare disease (which is similar to the frequency established by the 
European Union): 
Orphan drugs are those drugs used to treat rare diseases. A 
rare disease is a life-threatening, seriously debilitating, or 
serious chronic condition that only affects a very small 
number of patients (typically less than 5 in 10,000 persons) 
33. 
 
A few years earlier, in 2012, another definition of rare diseases was presented during a 
press conference by Leona Aglukkaq, then-Minister of Health. It offers somewhat more 
information regarding the definition of a rare disease: 
A rare disease is a life-threatening, seriously debilitating, 
or serious chronic condition that only affects a very small 
number of patients. It's estimated that there over 7,000 
unique rare disorders, many of which are genetic. While 
some of these rare disorders may affect only a handful of 
Canadians, in all, hundreds of thousands of Canadians are 
dealing with these conditions and need effective 
                                                             
30 Orphanet - Prevalence, incidence or reported number of published cases listed in alphabetical order of 
disease March 2016 - n°1, online: <http://www.orpha.net/orphacom/cahiers/docs/GB /Prevalence 
_of_rare_diseases _by_alphabetical_list.pdf > (Accessed 14 April 2016) 
31 Orphan Drug Act, supra note 18.  
32  “European Medicines Agency - Human regulatory - Orphan designation”, May 22 2013 online: 
<http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp&m
id=WC0b01ac05800240ce>.(Accessed 14 April 2016) 
33  Health Canada Government of Canada, “Canada News Centre - Archived - Minister Ambrose 
Announces Patient Involvement Pilot for Orphan Drugs”, (August 6, 2014), online: 
<http://news.gc.ca/web/article-en.do?nid=873619>.(Accessed 12 March  2016) 
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treatments.  Drugs used to treat rare diseases are often 
referred to as orphan drugs34. 
 
One major issue faced in rare disease research studies is the fact that it is often 
quite difficult to find a sufficiently large number of patients to participate in clinical 
trials. Without a powerful statistical analysis, agencies such as Health Canada have little 
on which to guide the decision whether to authorize an orphan drug35. Some solutions 
have been proposed36, but still, governmental agencies, such as Health Canada, are 
reluctant to accept orphan drugs without large cohorts of patients.  
Another issue is the major financial investment necessary on the part of 
pharmaceutical companies for drug development for rare disorders until it reaches the 
final marketing process37. There are thus major pharmacoeconomic issues to overcome 
before an orphan drug reaches market.  
Rare diseases have become somewhat of a legal and political quandary. Patients 
affected with rare diseases have advocated their needs, which have consequently 
generated major concerns throughout the media for quite some time now, especially 
regarding drug reimbursement. The decision-making for reimbursing drugs in Canada is 
based mainly on the efficacy of the drug, its cost, and on the quality-adjusted life-year 
(QALY).  
                                                             
34 A statement by the Minister of Health in Canada, Leona Aglukkaq, in 2012, Health Canada Government 
of Canada, “Canada News Centre - Archived - Harper Government Takes Action to Help Canadians with 
Rare Diseases - Launch of First Ever Canadian Framework to Increase Access to New Treatments and 
Information and Orphanet-Canada Online Portal”, (3 October 2012), online: 
<http://news.gc.ca/web/article-en.do?nid=698449>.(Accessed 15 April 2016) 
35 Joe TR Clarke et al, "Toward a Functional Definition of a “Rare Disease” for Regulatory Authorities 
and Funding Agencies” (2014) 17:8 Value in Health 757. 
36 Mohamed Amine Bayar et al, “New insights into the evaluation of randomized controlled trials for rare 
diseases over a long-term research horizon: a simulation study: A new strategy for clinical trial design in 
rare diseases” (2016) Statistics in Medicine. doi: 10.1002/sim.6942    
37 Evaluate Pharma Orphan Drug Report 2015, 3rd Edition-October 2015. 
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Moreover, there is an important need to move towards personalized medicine, 
and access to new drugs where patients may substantially benefit. With the advancement 
of technology, it is now possible to use genomic applications in daily clinical practice38. 
Patients affected with the same rare disease might have a variable genotype necessitating 
a different treatment approach, a different dose of an orphan drug, at a different 
frequency. This might affect the cost of the lifelong treatment for these life-threatening 
diseases.     
The main objective of this thesis will be to evaluate some of the difficulties 
regarding the legal and policy framework, considering the fact that there is no orphan 
drug legislation in Canada. Possible solutions, as well as recommendations, will be 
proposed for a policy framework for orphan drugs. In order to attain this goal, a 
thorough evaluation of the current framework at the federal and provincial levels will be 
evaluated, as well as the legal situation in the United States and European communities.  
1. Legal and Policy Challenges Relating to Orphan Drugs in Canada  
 Recent statistics about the overall pharmaceutical market performance in Canada 
in comparison with global growth revealed astounding negative data (Figure 1)39. In 
fact, the decline in the performance is problematic reaching a low of -0.9% in 2011, and 
just barely above the positive rate (0.5%) in 2012. Different reasons have been suggested 
to account for this lagging growth in the performance of the pharmaceutical Canadian 
market: 
                                                             
38 Casey Lynnette Overby, et al., Opportunities for genomic clinical decision support interventions, Genet 
Med. 2013 October ; 15(10) doi:10.1038/gim.2013.128. 
39 Innovation Government of Canada, “Canada’s Pharmaceutical Industry and Prospects”, IMS Brogan, 
2016, online: <https://www.ic.gc.ca/eic/site/lsg-pdsv.nsf/eng/hn01768.html>. (Accessed 15  May 2016).  
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For the most part, the factors contributing to the slowdown 
in Canadian market growth since the second half of the 
past decade have also been responsible for dampening 
growth in other developed markets and the overall global 
rate. These factors include: record levels of loss of 
exclusivity for major brand products, a lack of new 
blockbuster products, sluggish uptake of new products, a 
slowdown in new product approvals and longer processing 
time to access public formularies. More recently, these 
market factors have been compounded in Canada and other 
global markets by declining R&D productivity, the global 
financial crisis and economic downturn, downward 
pressure on prices and cost containment policies from 
payers, and the shift in business operations towards 
emerging countries40.  
 
 
Figure 1. Comparison between Overall Global and Canadian Pharmaceutical 
Market Performance 
 
 
Source: Pharmafocus 2016, IMS Brogan 
                                                             
40 Ibid.  
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Why has Canada lowered its R&D productivity over the last few years? Research and 
development productivity in the pharmaceutical industry is a key factor assuring growth, 
development and innovation. The importance of research and development in the 
pharmaceutical field, and in particular in orphan drugs for rare diseases, is equivalent to 
long-term success for a company41, but it also improves the lives of patients who will 
benefit from these drugs. In addition, there are still issues to overcome: 
Delineating the general value of multiplier effect of 
research on specific rare diseases is important because such 
research may otherwise be undervalued when policy 
makers consider the absolute numbers of people likely to 
benefit from a particular public investment in research42.  
 
Unfortunately, Canada has seen a decline in its endeavours in the pharmaceutical 
field affecting a major part of its economy. The commitment of the government towards 
research and development (R&D) policies focusing on academia should thus be 
prioritized.  
  
1.1 At the Federal Level  
1.1.1. Research Stage: a Major Hurdle to Obtain Funds for Rare Diseases 
As mentioned above, the research stage is one of the most important and often 
the most complex step in the development of a new drug. It involves academic, as well 
as industry-related research. For pharmaceutical companies, it involves a large capital 
investment, which has been estimated at billions of dollars over decades of research and 
                                                             
41 Mark Howard, The Importance of Continued Investment in R&D, Pharmaceutical Technology, Volume 
37, Issue 9, Sep 2013. Online: <http://www.pharmtech.com/importance-continued-investment-rd> 
(Accessed May 20 2016). 
42 Marilyn J Field et al, eds, Rare diseases and orphan products: accelerating research and development 
(Washington, DC: National Academies Press, 2010) at 16. 
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the development of complex processes for drugs to reach the market43. More than 1,673 
planned, ongoing or completed research studies on rare diseases have been reported 
around the world in 2015 44 . There is lack of information on the etiology and 
pathophysiology of many rare diseases. Unfortunately, knowledge about the natural 
history of diseases has often been missing over the years. In fact, natural history of 
diseases is a key factor in understanding how different diseases progress in patients 
without treatment starting from the presymptomatic phase until the final outcome of the 
disease. Therefore, data collection during natural history studies will provide 
longitudinal information and support product development and their eventual approval. 
Nonetheless, a paradigm shift has recently occurred favouring the understanding of these 
rare diseases: 
 Knowledge from these studies is essential for the 
development of research hypotheses, identification of 
potential biomarkers, and phenotype variations in patients. 
Due to the high cost of initiating and maintaining studies 
for many years, there has been a reluctance to support 
these studies. Only in recent years has the values of these 
studies been accepted by the research community as a 
generator of new research hypotheses and information for 
research and treatment for rare diseases45.   
  
There is a tremendous need for financial support for orphan diseases research. 
Canada is part of the “International Rare Diseases Research Consortium (IRDiRC)”, a 
group devised by the European Commission and the National Institutes of Health (NIH) 
in 2011 46 . It focuses on international collaborative research aiming to hasten the 
                                                             
43 Supra note 37. 
44  “Clinicaltrials.gov, - A Service of the US National Institutes of Health”, online: 
<https://clinicaltrials.gov/> (Accessed April 15 2015). 
45Manuel Posada de la Paz & Stephen C Groft, Rare Diseases Epidemiology, Advances in Experimental 
Medicine and Biology, vol. 686 (Dordrecht: Springer Netherlands, 2010) at 8 doi:10.1007/978-90-481-
9485-8 
46 “Governance Structure & Members”, (16 January 2013), online: IRDiRC 
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development of diagnostic tools and therapies for orphan diseases. This consortium is 
comprised of “regulatory agencies, researchers, patient group representatives, members 
of the biopharmaceutical industry, and health professionals” 47 . Members of the 
consortium are working together to share information and facilitate networking for 
researchers to better understand the pathophysiology of these diseases, develop specific 
models which can be useful in drug discovery, evaluate the response to treatment by the 
discovery of novel biomarkers, and support the registries of patients. However, it is not a 
funding agency, but it is a facilitator for international research endeavour in rare 
diseases48.   
In Canada, the availability of research funding for rare diseases for biomarker 
discovery, for detection, diagnosis, monitoring the efficacy and safety of treatment is a 
major issue. Patients affected with rare diseases are often unaware of the difficulties 
encountered to better understand the fundamental basis of a rare disease. Canadian 
governmental funding bodies often prioritize their research funds to common diseases 
considering the public health issues involved due to the high number of affected 
individuals (e.g. Diabetes mellitus type 2). Therefore, a researcher requesting funding 
for rare diseases through the Canadian Institutes of Health Research (CIHR) open-grant 
applications will definitely be disadvantaged considering the small population affected 
                                                                                                                                                                                   
<http://www.irdirc.org/governance-structure-members/>; Chris Wilson, “Policies and research funding” in 
Orphan Drugs (Elsevier, 2013) at 179. doi:10.1533/9781908818393.145 
47 Ibid at 180.  
48 Ibid at 180. Also in: Aymé S, Lau L, Peixoto S, Unni D, Höhn S, Mills A, Eds., “State of Play of 
Research in the Field of Rare Diseases: 2014- 2015”, September 2015 at 4, online: 
<http://www.irdirc.org/wp-content/uploads/2015/09/IRDiRC_State-of-Play-2015.pdf> (Accessed April 10 
2015). This latter report “aims to inform stakeholders at large of developments in the field of rare diseases 
research in order to support decisions of policy makers and research funders, as well as informed the rare 
diseases community at large of the achievements and of observed trends which shape the future of 
research and development for rare diseases”. 
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with rare diseases49. In order to achieve statistical power analysis, and to draw adequate 
research conclusions, there needs to be a satisfactory number of patients recruited in 
translational and clinical research projects. These patients are often difficult to recruit 
because they are so few of them. These are some of the reasons why the natural history 
of specific rare diseases is still unknown. There is thus a definite need to increase 
research funding for rare diseases in Canada. As shown in Figure 2, funding statistics 
from the CIHR from 2005 to 2015 reveals that the percentage of grant approvals in the 
Open Operating Grant Program (OOGP) has been lowered from 23% to 18% for years 
2010-201550.  The OOGP supports all areas of health research proposals, including 
randomized controlled trials. Research studies on rare diseases and orphan drug 
proposals fall within this program51.   
This graph also confirms a definite lowering trend for funding R&D, including 
rare diseases. There is thus a clear need to convince the political authorities to provide 
increased research funds for governmental bodies in Canada, in the specific “orphan 
disease field”.  
 
 
 
                                                             
49 Samir Gupta, “Rare diseases: Canada’s ‘research orphans’” (2012) 6:1 Open Med e23. 
50 Canadian Institutes of Health Research Government of Canada, “ARCHIVED – CIHR Open Operating 
Grant Program Competitions – Frequently Asked Questions (FAQ) – 2014 - CIHR”, (21 February 2014), 
online: <http://www.cihr-irsc.gc.ca/e/47960.html>. (Accessed April 2 2016). 
51 Applying to CIHR’s Open Operating Grant Program (OOGP) at Western University online: 
<https://www.uwo.ca/research/_docs/resources/CIHR_OOGP_Guidebook_Winter_2015.pdf>. (Accessed 
June 1 2016). 
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Figure 2. Application and Funding Statistics for the Open Operating Grant 
Program and Other Related Programs 
 
         Source: Canadian Institutes of Health Research 2014 
 
            Among other possibilities to obtain research funds for rare diseases, the approval 
of an Investigator Initiated Research (IIR) grant from the pharmaceutical industry can be 
matched with CIHR funds as part of an Operating Grant: Industry-Partnered 
Collaborative Research program, meaning increased financial support for R&D. This 
program was still in effect as of 201552. However, with this program, difficulties lie in 
the fact that, researchers must first convince the pharma industry of the feasibility and 
novelty of their proposal in order to obtain funds, and in the second phase, convince the 
                                                             
52 Canadian Institutes of Health Research Government of Canada, “CIHR and its partners announce the 
June 2015 Funding Opportunities and Priority Announcements - CIHR”, (24 June 2015), online: 
<http://www.cihr-irsc.gc.ca/e/49215.html> (Accessed April 3 2016) and for more information at Canadian 
Institutes of Health Research Government of Canada, “Commercialization of Research - CIHR”, (16 April 
2012), online: <http://www.cihr-irsc.gc.ca/e/44911.html>. (Accessed April 3 2016). 
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governmental body to accept the proposal. It is a long, cumbersome, and tedious process 
for researchers.  
Nevertheless, this expanding role of academic centres in R&D for rare diseases 
has led to novel partnerships with the pharma industry53 allowing innovative research to 
be pursued. Direct financial research support may also be requested from the 
pharmaceutical/biotechnology companies. If approved by the company, an agreement 
stating all legal considerations such as intellectual property, timelines, publication rights, 
ownership of data, etc. has to be signed by all the parties. It should be emphasized that 
this pharmaceutical funding opportunity remains dependent on the views and long-term 
vision of companies regarding research themes, investment strategies, and desire to work 
with academia.  
1.1.2. Clinical Trials 
Clinical trials are major steps in the process of drug approval and are crucial in 
verifying efficacy and safety. Once a drug discovery is confirmed by a laboratory, it may 
typically take up to 12 years before the drug is approved and marketed in Canada until it 
reaches patients’ needs 54.  
Before clinical trials begin, there is always an evaluation of the return on 
investment on the part of pharmaceutical companies when they decide to invest in the 
manufacturing of orphan drugs. Statistics have shown that the expected return on 
investment of Phase III clinical trials for filed orphan drugs has been evaluated at 1.14 
                                                             
53  David C Pryde & Michael Palmer, eds, Orphan Drugs and Rare Diseases, RSC Drug Discovery 
(Cambridge: Royal Society of Chemistry, 2014) at 26. 
54 “Phases of Development | Pfizer: One of the world’s premier biopharmaceutical companies”, online: 
<http://www.pfizer.com/research/clinical_trials/phases_of_development>. (Accessed April 3 2016). 
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times greater than non-orphan drugs. The main difference for this return on investment 
is due to the clinical trial size. In fact, all phase III clinical trials in 2015 required 44,357 
patients for orphan drugs, whereas it required 426,951 patients for non-orphan drugs55. 
In general, there are specific requirements to efficiently conduct a clinical trial. 
The first basic criterion is that the medical question, which needs to be addressed, is 
valuable and significant for patients. Secondly, the clinical trial must rely on a 
methodology respecting comprehensive and rigorous principles and practice 
guidelines56, which address the medical question, and thirdly, the ethical aspects for 
clinical research must be respected, in particular for the proportionality of risks and 
benefits57.  
In Canada, clinical trials are carried out according to the Food and Drug 
Regulations 58  with provision of Good Clinical Practices 59 . These latter regulations 
emphasize the importance of assuring the protection, the safety and well-being of 
persons participating in clinical trials under strict ethical conditions approved by 
Research Ethics Board (REB), under the Declaration of Helsinki60 and the Tri-Council 
                                                             
55 Supra note 37. 
56 Health Canada Government of Canada, “Guidance for Industry: Good Clinical Practice: Consolidated 
Guideline: ICH Topic E6”, (19 September 1997), online: <http://www.hc-sc.gc.ca/dhp-
mps/prodpharma/applic-demande/guide-ld/ich/efficac/e6-eng.php>. (Accessed April 4 2016) 
57 Ibid, note 45, at 174.  
58 Food and Drug Regulations, C.R.C., ch. 870, s. C.05.010. 
59 Mathieu Gagné, Précis de droit pharmaceutique (Cowansville, Québec: Éditions Y. Blais, 2012) at 50. 
60 “WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects”, 
(19 October 2013), online: <http://www.wma.net/en/30publications/10policies/b3/>.(Accessed April 4 
2016) 
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Policy statement in Canada61. The sponsor always needs to obtain REB approval before 
the start of the clinical trial.    
 
1.1.2.1 Low Number of Rare Disease Patients for Clinical Trials  
Clinical trials in rare diseases raise the key question of the limited number of 
patients affected with a particular disease who can participate in a given trial. This issue 
may affect the second aforementioned goal to use a methodology that respects rigorous 
principles, such as statistical power analysis. The design of the trial must therefore rely 
on alternative statistical approaches62. One approach concerns the “risk-based allocation 
designs” when a randomized trial is not possible. This approach may be a solution for a 
clinical trial designed to evaluate two dosages (high and low concentrations) of an 
orphan drug provided to a group of patients having heterogeneous clinical 
manifestations ranging from an attenuated form (low-risk) to a severe form (high-risk) 
of the disease. Low-risk patients will be randomized in two groups: one will receive the 
high dosage and the other the low dosage, whereas high-risk patients will receive only 
the high dosage of the drug. Standard statistical analyses will be performed for the low-
risk patients. These data will help establish a risk-responsive model, which will enable 
the prediction of expected additional benefits from the high dosage treatment63. Even so, 
these reduced sample groups designed for rare disease clinical trials for drug approval 
might not be accepted by Health Canada. 
                                                             
61 Medical Research Council (Canada), Natural Sciences and Engineering Research Council of Canada & 
Social Sciences and Humananities Research Council of Canada, Tri-council policy statement ethical 
conduct for research involving humans 2014 (2014).  
62 Supra note 45 at 174.  
63 Ibid at 184.  
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In 2012, a comparison between clinical trials in rare diseases (n=2,759) and non-
rare diseases (n=21,329) has revealed major differences between the two groups by 
analyzing data from the Aggregate Analysis of ClinicalTrials.gov (AACT) database64. In 
this study, the results show 83 Canadian rare disease trials and 1,357 non-rare disease 
trials during that particular period. The main differences between these two trial groups, 
e.g. rare diseases and non-rare diseases, in the overall study were in the characteristics in 
the design of the study where a lower percentage of rare disease trials are done in a 
single centre (61.3%) versus non-rare disease trials (72.7%). This is understandable 
considering the difficulty in recruiting rare disease patients in a single centre. It seems 
that clinical trials for rare diseases are mostly phase 1 and phase 2 trials with a high 
percentage of 72.5% compared to 38.5% for non-rare disease trials65. There are more 
studies for early phase I and II clinical trials for rare diseases because they require 
knowledge about drug pharmacokinetics, efficacy, side effects and risk before going 
further with phase III trials. The main goal of rare disease trials is oriented towards 
treatment evaluation in 91.2% of the studies compared to 79.3% in non-rare disease 
trials. Moreover, the evaluation of drug intervention is more common in 79.9% of rare-
                                                             
64 Stuart A Bell & Catrin Tudur Smith, “A comparison of interventional clinical trials in rare versus non-
rare diseases: an analysis of ClinicalTrials.gov” (2014) 9:1 Orphanet Journal of Rare Diseases, online: 
<http://ojrd.biomedcentral.com/articles/10.1186/s13023-014-0170-0>. 
65 Phase I clinical trials are designed mainly to determine the pharmacological actions of the drug and the 
safety (side effects) associated with increasing doses. Pharmacokinetic studies (evaluating drug levels in 
tissues such as blood) as well as drug interaction studies are usually considered as Phase I trials regardless 
of when they are conducted during drug development. Phase I trials are generally conducted in healthy 
volunteers, but may be conducted in patients when administration of the drug to healthy volunteers is not 
ethical. Phase II clinical trials evaluate the efficacy of the drug in patients with medical conditions to be 
treated, diagnosed or prevented and to determine the side effects and risks associated with the drug. If a 
new indication for a marketed drug is to be investigated, then those clinical trials may generally be 
considered Phase II trials. These trials provide preliminary information on the safety and efficacy of the 
drug in patients. Health Canada Government of Canada, “Glossary - Health Canada’s Clinical Trials 
Database”, (29 May 2013), online: <http://www.hc-sc.gc.ca/dhp-
mps/prodpharma/databasdonclin/terminolog-eng.php>. (Accessed June 1 2016) 
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disease trials versus 55.8% in non-rare diseases. Patients affected with rare diseases need 
specific clinical trials for treatment evaluation as well as drug intervention since both are 
often lacking. 
 Rare disease trials often have more single group assignment (63%) than non-rare 
diseases (49%). Moreover, rare disease trials rely on non-randomization in 64.5% versus 
28.4% in non-rare disease trials. The single group assignment and non-randomization of 
clinical trials are mostly resulting from smaller sample size cohorts of rare disease 
patients available for these trials. Open label clinical trials refer to the evaluation of a 
new drug or treatment where both patients and physicians are aware of the type of drug 
received and treatment given. Open label is more frequent in rare-disease trials at 78.7% 
versus 52.2%, considering that often, there are no other alternative treatments and that 
open label trial can provide information regarding drug safety. Rare disease trials are 
also more likely to explore both safety and efficacy endpoints in the same trial in 63.2% 
compared to non-rare disease trials in 45.9%, considering the smaller pool of rare 
diseases patients available compared to non-rare diseases patients. In conclusion, this 
recent study shows major differences in both rare-disease trials and non-rare disease 
trials, in particular in regards to blinding and randomization, which are considered as 
state-of-the art procedures in clinical trials, and which are less used in rare-disease 
studies. This may lead to lower quality design trials, and to concerns about the evidence-
based information provided by these trials, as well as the possibility of random errors66.  
 
 
 
                                                             
66 Supra note 64.  
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1.1.3 Existing Canadian Regulations and Policies for Drugs 
Orphan drugs in Canada fall under the Food and Drug Act67 and the associated 
Food and Drug Regulations 68 , and follow the same approval and marketing 
authorization as any other medication provided for widespread diseases such as diabetes, 
hypertension and hypercholesterolemia. In other words, every drug marketed for 
treatment or prevention of diseases and symptoms in Canada must be approved by 
Health Canada 69 . In order to be approved, the innovator must file a “New Drug 
Submission” (NDS) or a “Supplement to a New Drug Submission” (SNDS), followed by 
registration, if appropriate, to be on a patent list according to the Patented Medicines 
(Notice of Compliance) Regulations or “PM(NOC)”70. The Patent Register consists of an 
alphabetical list of patents and their associated medicinal ingredients, as well as the 
patent expiration dates71. However, a drug may receive marketing authorization without 
the patent featured on the Patent Register for that specific drug, since the submission of 
the patent list is not mandatory72. It stands to reason that, prior to the approval, the 
innovator company must demonstrate the safety and efficacy of the drug by presenting 
exhaustive clinical trial data. The ability to approve a new drug is then subject to the 
discretion of Canada’s Minister of Health, who will issue a Notice of Compliance 
                                                             
67 Food and Drugs Act, R.S.C., 1985, c. F-27 
68 Food and Drug Regulations, C.R.C., ch. 870.  
69 Health Canada Government of Canada, “Drug Products - Main Page - Health Canada”, (26 July 2004), 
online: <http://www.hc-sc.gc.ca/dhp-mps/prodpharma/index-eng.php>. (Accessed April 4 2016). 
70 Patented Medicines (Notice of Compliance) Regulations, SOR/93-133, subsection 4(1) 
71  Health Canada Government of Canada, “Patent Register - Drug Products - Health Canada”, (9 
December 2002), online: <http://www.hc-sc.gc.ca/dhp-mps/prodpharma/patregbrev/index-eng.php>. 
(Accessed April 4 2016) 
72 Even though the drug cannot be found on the Patent register, the patent can be found on The Canadian 
Intellectual Property Office database. In order to apply for a patent, The Canadian Intellectual Property 
Office has the mandate to grant patents in Canada. Health Canada Government of Canada, “Frequently 
asked Questions: Patent Register - Drug Products - Health Canada”, (13 September 2010), online: 
<http://www.hc-sc.gc.ca/dhp-mps/prodpharma/patregbrev/ptnt-faq-mbreg-eng.php>. (Accessed April 4 
2016) 
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(NOC) to the innovator73 . It must be noted, that according to the Food and Drug 
Regulations, a pharmaceutical company introducing a novel drug that contains new 
medicinal ingredients benefits from an 8-year period of exclusivity, which is extended 
for 6 months if information for pediatric use is provided within the first 5 years of the 
protection period74.  Once the NOC is granted, it allows the drug to be marketed in 
Canada.  
At the same time, Health Canada issues a Drug Identification Number (DIN), an 
eight-digit code number, which also allows the manufacturer to market the drug in 
Canada. In conformity with Canadian law, drug product is not permitted to be sold in 
Canada without a DIN. This identification number is a computer-generated code, which 
gives the following product characteristics: the manufacturer; product name; active 
ingredient(s); strength(s) of active ingredient(s); pharmaceutical form; and route of 
administration75.   
Reviews of drug submissions, applications or supplements to government come 
with associated costs, as well as DIN applications. Under the Financial Administration 
Act76 in the 1990s, it was established that Health Canada was authorized to charge 
industry user fees. These fees, which included the costs of review as well as the right to 
sell drugs77, aimed to recuperate the costs of service delivery for drugs and ensure 
“sufficient funding for Health Canada to meet service standards and support access to 
                                                             
73 Supra note 58 s. C.08.002.  
74 Ibid s. C.08.004.1. 
75 DIN also includes over-the-counter drugs, Health Canada Government of Canada, “Drug Identification 
Number (DIN)”, (8 January 2001), online: <http://www.hc-sc.gc.ca/dhp-mps/prodpharma/activit/fs-
fi/dinfs_fd-eng.php> (Accessed April 3 2016). 
76 Financial Administration Act, R.S.C., 1985, c. F-11 
77 Fees in Respect of Drugs and Medical Devices Regulations (SOR/2011-79) 
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drugs for Canadians in a timely manner”78. The fees take into account the actual gross 
revenue according to the sale of the drug and the costs related to the inflation rate. As of 
April 1st 2016, the fees for a pharmaceutical submission and application review of a New 
Active Substance was 335,068 Canadian dollars (Table 1)79.  
Table 1. Health Canada Pharmaceutical Submission and Application Review Fees 
as of April 1, 2016  
 
 
Source: Health Canada 2016 
 
                                                             
78  Health Canada Government of Canada, “Guidance Document: Fees for the Review of Drug 
Submissions and Applications [Health Canada, 2013]”, (1 May 1998), online: <http://www.hc-
sc.gc.ca/dhp-mps/prodpharma/fees-frais/fee_frais_guide-eng.php>. (Accessed April 3 2016). 
79  Health Canada, Government of Canada, “Pharmaceutical Submission and Application Review - 
Funding and Fees - Drugs and Health Products - Health Canada”, (1 April 2014), online: <http://www.hc-
sc.gc.ca/dhp-mps/finance/fees-frais/pharma-eng.php>. 
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Moreover, there is a strong possibility for pharmaceutical companies to submit a 
new drug application in another country offering more favourable incentives. Therefore, 
companies will work with countries where there are more incentives.  
Health Canada should have serious concerns regarding pharmaceutical 
companies focusing on rare diseases, since to an increasing extent, companies are 
looking for a unique niche in the marketplace80. The sales of so-called blockbuster 
drugs, such as sidenafil (Viagra) or atorvastin (Lipitor), are slowing down due to loss of 
patent protection81. Large pharma industries are fundamentally changing in favour of a 
new business model going from “blockbusters to niche busters” 82 . Powerful 
pharmaceutical companies like Pfizer, Novartis, Eli Lilly and GlaxoSmithKline are 
already involved in the rare disease sector where orphan drug legislation exists (but not 
in Canada) in order to develop and commercialize new therapies83.    
There seems to be recurrent strategies on the part of Ministers of Health in 
Canada triggering false hopes in patients affected with rare diseases by announcing 
future policies. In fact, on October 3rd 2012, the Minister of Health, Leona Aglukkaq 
from the then Conservative government, made the following announcement during a 
press conference:   
A regulatory framework designed and used specifically to 
approve drugs to treat small, vulnerable populations will 
more effectively address this need. A key focus of this new 
                                                             
80 Shannon Gibson, Hamid R Raziee & Trudo Lemmens, “Why the Shift? Taking a Closer Look at the 
Growing Interest in Niche Markets and Personalized Medicine: Why the Shift?” (2015) 7:1 World 
Medical & Health Policy 3. 
81 R Collier, “Bye, bye blockbusters, hello niche busters” (2011) 183:11 Canadian Medical Association 
Journal at E697. 
82 Ibid.  
83 Elie Dolgin, “Big pharma moves from ‘blockbusters’ to ‘niche busters’” (2010) 16:8 Nature Medicine 
837. 
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approach will be on international information-sharing and 
collaboration for the development and regulation of orphan 
drugs84. 
 
The Orphanet-Canada reference portal was indeed created. It is now part of global 
Orphanet, and provides information regarding rare diseases for the Canadian 
population85. There are nearly 300 orphan drugs on the market in Europe and the United 
States, but only 50% of these have received market authorization from Health Canada86. 
Still, four years later, this announcement from the Minister of Health has not led to any 
concrete regulatory framework or policies for rare diseases.   
 
1.1.3.1 Heading towards More Transparency: Vanessa’s Law  
 
In hoping for a new approach towards the authorization of orphan drugs in 
Canada, Bill C-17 was deposited in the House of Commons in 2013. It received Royal 
Assent in 2014, and is now known as “Vanessa’s Law87. The law is named after Vanessa 
Young, the daughter of Terrence Young (a Member of Parliament) who died from an 
adverse drug event in 2000. The purpose of this Bill was to amend the Food and Drug 
                                                             
84 Supra note 34; “Pharma in brief - Canada: New orphan drug pathway to be released for comment in 
Canada”, online: <http://www.nortonrosefulbright.com/knowledge/publications/71211/pharma-in-brief-
canada-new-orphan-drug-pathway-to-be-released-for-comment-in-canada> (Accessed April 2 2016).  
85  “Orphanet-Canada Governance”, online: <http://www.orpha.net/national/CA-
EN/index/governance/>.(Accessed April 3 2016). 
86  “Regroupement québécois des maladies orphelines (RQMO) ”, 2014, Québec, online : 
www.rqmo.org/PDF/Document_preparatoire_diner-conference_21_fevrier.pdf (Accessed April 3 
2016). It should be mentionned that there is no orphan drug list available in Canada. It is difficult to know 
the exact number. 
87House Government Bill - Bill C-17 - Royal Assent (41-2) [House Government Bill - Bill C-17 - Royal 
Assent (41-2)]. Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law) (S.C. 2014, c. 24). An Act 
to amend the Food and Drugs Act, This bill was last introduced in the 41st Parliament, 2nd Session, which 
ended in August 2015, “Bill C-17 (Historical) | openparliament.ca”, online: 
<https://openparliament.ca/bills/41-2/C-17/>. (Accessed April 3 2016). 
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Act regarding therapeutic products in order to improve safety. In order to do so, various 
measures were presented such as “to strengthen safety oversight of therapeutic products 
throughout their life cycle; to improve reporting by certain health care institutions of 
serious adverse drug reactions and medical device incidents that involve therapeutic 
products; and to promote greater confidence in the oversight of therapeutic products by 
increasing transparency”88.  
In fact, the introduction of Vanessa’s Law was seen as a breath of fresh air, and a 
new beginning in the transparency process for drug safety in Canada89. A historical 
review shows that since the inception of regulation for pharmaceutical drugs in 1887, 
and for nearly 40 years until the 1920s, specific bulletins identifying contaminated drugs 
(by names, “shop-keeps”) were published. These bulletins were sent to “news media, 
physicians, pharmacists and regulatory scientists” to ameliorate drug preparation90. In 
1920, a restructuration took place with Canada’s new Department of Health and the 
Food and Drugs Act91 was passed. The identification of contaminated pharmaceutical 
drugs was no longer part of the public domain. Even until the 40’s and 50’s, this 
information was kept secret until it reached the legal system92. A more recent example of 
the major consequences on people’s health due to the concealment process involved is 
the “Vioxx® (rofecoxib, from Merck and Co.) scandal”, where the anti-pain drug was 
                                                             
88 Health Canada Government of Canada, “Amendments to the Food and Drugs Act: Guide to New 
Authorities (power to require & disclose information, power to order a label change and power to order a 
recall)”, (25 March 2015), online: <http://www.hc-sc.gc.ca/dhp-mps/legislation/unsafedrugs-
droguesdangereuses-amendments-modifications-eng.php>. Preamble to Vanessa’s Law. (Accessed April 5 
2016). 
89  M Herder, “Reinstitutionalizing transparency at Health Canada” (2016) 188:3 Canadian Medical 
Association Journal  at 218. 
90 Ibid. 
91 Supra note 58  s. C.05.010. 
92 Matthew Herder, “Denaturalizing Transparency in Drug Regulation” (2015) 8:2 McGill JL & Health 
S57; Also, J Lexchin, “Transparency in drug regulation: Mirage or oasis?” (2004) 171:11 Canadian 
Medical Association Journal 1363. 
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provided for arthritis-related ailments. It is estimated that more than half a million US 
citizens93 and tens of thousands of Canadians94 died from cardiac arrest due to “a risk 
that regulatory officials had previous knowledge of but nevertheless kept confidential”95. 
Physicians, as well as patients, were not informed of the serious adverse events directly 
related to Vioxx, even if Merck knew about potential deadly side effects in 1999 before 
launching the drug on the market96.  
Figure 3 shows the number of new active drugs approved in Canada, which 
varied from approximately 60 to 160 drugs from 1985 to 2007, in relation to the 
percentage of withdrawals due to safety reasons over a 12-year span. Results show that 
the percentage of withdrawal for safety reasons varied approximately from 1.7 to 4.2%. 
It is encouraging that withdrawal percentages are reduced from 2000 to 200797. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                             
93  Alexander Cockburn, “When half a million Americans died and nobody noticed”, online: The Week UK 
<http://www.theweek.co.uk/us/46535/when-half-million-americans-died-and-nobody-noticed>. (Accessed 
April 3 2016). 
94 Supra note 89. 
95 Ibid. 
96 Supra note 93. 
97  Joel Lexchin & Canadian Centre for Policy Alternatives, Drug safety and Health Canada going, 
going…gone? (Ottawa: Canadian Centre for Policy Alternatives, Centre canadien de politiques 
alternatives, 2009) at 6. 
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Figure 3. Safety Withdrawals as a Percentage of Drug Approvals from 1985–2007 
 
 
                   Source: Canadian Centre for Policy Alternatives 2009 
 
Moreover, it is worth noting that Health Canada can provide “a public warning 
about a drug without the agreement of the company involved, but it cannot directly 
compel the company to revise the label of its product to reﬂect new safety information”. 
Considering the global growth of the orphan drug market (Figure 4)98, this is an issue 
which should not be taken lightly because of the increased demand of orphan drugs and 
the added necessity for safety measures and warnings to physicians and patients 
involved. Briefly, Figure 4 shows an increase in drug demands for biologics, which are 
complex manufactured products from animals or through the use of animals or 
microorganisms, and non-biologic drugs which are chemically synthesized. Therefore, it 
is quite understandable that orphan drugs, as well as any drug put on the market, should 
be optimally evaluated by Health Canada (and the FDA in the US) before they reach the 
market. 
                                                             
98  Sinéad M. Murphy et al, “Unintended effects of orphan product designation for rare neurological 
diseases” (2012) 72:4 Annals of Neurology 481, at 12. doi:10.1002/ana.23672 
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Figure 4. Global Growth of the Orphan Drug Market  
 
 
  Source: BBC Research 
 
 
Under Vanessa’s Law, the Health Minister in Canada is now authorized to provide 
confidential business information if it involves the safety and protection of its Canadian 
constituents: 
(3) The Minister may disclose confidential business 
information about a therapeutic product without notifying 
the person to whose business or affairs the information 
relates or obtaining their consent, if the purpose of the 
disclosure is related to the protection or promotion of 
human health or the safety of the public and the disclosure 
is to: 
(a) a government; 
(b) a person from whom the Minister seeks advice; or 
(c) a person who carries out functions relating to the protection or 
promotion of human health or the safety of the public 99. 
                                                             
99 Supra note 87 s. 21.1(3). 
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This measure could allow physicians to enquire about adverse events before 
providing a particular drug to a patient or enrolling patients in a research project. 
Furthermore, it could provide information to patients in order for them to give an 
informed consent to research projects involving orphan drugs. Researchers could also be 
better appraised of the potential risks and benefits of a particular drug while performing 
their research studies.   
Even if the safety and protection of Canadian citizens have been promoted with 
Vanessa’s Law, it would have been a good opportunity to introduce a policy framework 
for orphan drugs, but unfortunately, this was not the case100. Even if over the years the 
federal government has been inclined to modify the Food and Drug Act, it seems that 
the orphan drug framework is a persistent issue, which it does not want to tackle101.  
 
1.1.3.2 Canadian Agency for Drugs and Technologies in Health   
 
According to the Canadian Agency for Drugs and Technologies in Health 
(CADTH)102, a document written by Health Canada, in 2012, proposed a definition for 
an “orphan drug” which would rely on the prevalence and the severity of the disease103. 
For example, a child weighing 20 kilograms (Kg) receiving Aldurazyme® (Laronidase), 
                                                             
100 Jill Daley, “Pharma in brief - Status update: Regulatory and policy changes to create orphan drug 
environmentfor Canada”, September 2014, online:  
<http://www.nortonrosefulbright.com/knowledge/publications/120679/pharma-in-brief-status-update-
regulatory-and-policy-changes-to-create-orphan-drug-environment-for-canada>. (Accessed April 2 2016)  
101 Ibid.  
102  Canadian Agency for Drugs and Technologies in Health, “About CADTH | CADTH.ca”, online: 
<https://www.cadth.ca/about-cadth>. (Accessed April 3 2016). 
103 Canadian Agency for Drugs and Technologies in Health, Drugs for rare diseases: evolving trends in 
regulatory and health technology assessment perspectives. Ottawa; CADTH; 2013 Oct [updated 2016 
Feb]. (Environmental scan; issue 42) at 6 Online:  
<https://www.cadth.ca/sites/default/files/pdf/ES0300_Rare_Disease_Drugs_e.pdf > (Accessed April 3 
2016). 
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an orphan drug prescribed in patients affected with a lysosomal storage disorder called 
Hurler disease (Mucopolysaccharidosis type I), and given at 0.5 mg/Kg weight/week by 
infusion will cost $400,000 CAD per year, and for an adult weighing 70 kilos, the cost 
will be $1,200,000 CAD104 per year. Considering the high cost involved for patients 
receiving orphan drugs, it is understandable that the prevalence of an orphan disease 
plays an important role in the process and criteria to obtain access to this orphan drug.  
The CADTH is an independent, non-profit organization with a mission “to 
provide timely, relevant, rigorously derived, evidence-based information to decision 
makers and support for the decision-making processes with areas of focus which include 
assessing the cost and health effectiveness of drugs and health technologies and 
identifying and promoting best practices in drug prescribing and use”105. CADTH was 
created in 1989 (formerly under the name Canadian Coordinating Office for Health 
Technology Assessment “CCOHTA”)) and is financially supported by federal, 
provincial and territorial governments. The independence in CADTH’s decision-making 
was confirmed in 1998 in an Ontario court-case versus the pharmaceutical company 
Bristol-Myers-Squibb Canada106.  
It is worth noting that CADTH plays an important role in rare diseases and 
orphan drugs, since it offers prospective models to provide guidance in the decision-
making process for financing these drugs by establishing the natural history of the 
disease (if available), the optimal time to give a drug to affected patients, and the group 
                                                             
104 Ibid at 21. See also on the same subject: “CIHR New Emerging Team | The Changing Landscape of 
Treatments for Rare Diseases”, online: <http://rare-diseases.ca/>. (Accessed April 3 2016). 
105 “INAHTA | CADTH – Canadian Agency for Drugs and Technologies in Health -Mission”, online: 
<www.inahta.org> (Accessed April 3 2016). See also, Supra note 102.  
106  Bristol-Myers Squibb Canada Inc v Canadian Coordinating Office for Health Technologies 
Assessment, 1998 CanLII 14796 (ON SC) online: <http://canlii.ca/t/1w8r0>. 
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of patients who would benefit from the treatment107. Moreover, since September 2003, 
CADTH is also responsible for the Common Drug Review (CDR). The CDR is a 
“national process that provides participating federal, provincial and territorial drug plans 
with a systematic review of the best available clinical evidence, a critique of 
manufacturer-submitted pharmacoeconomic studies and a formulary listing 
recommendation made by the Canadian Drug Expert Committee (CDEC) or Canadian 
Expert Drug Advisory Committee (CEDAC)”108. It also “provides more consistent and 
rigorous reviews of new prescription drugs, so that public drug benefit coverage will be 
directed to the most cost-effective and therapeutically beneficial drugs. All jurisdictions 
are participating except Québec”109. The CDEC’s recommendations are non-binding to 
drug plans, therefore each province decides on its own drug-listing decisions of the 
CDEC, but also taking into consideration jurisdictional priorities and financial 
resources110.  Considering the various possibilities of drug review that include orphan 
drug as well, Figure 5 provides an accurate flowchart of the overall CDR mechanism 
involved111.  It is a multi-level complex process starting from the submission of the 
application to the final decision upon the CDEC’s final recommendations.  
 
 
 
                                                             
107 Supra note 102.  
108 “Pharmaceutical HTA and Reimbursement Processes - Canada”, online: 
<https://www.ispor.org/HTARoadMaps/CanadaPharm.asp>.  (Accessed April 3 2016). 
109 Health Canada Government of Canada, “ARCHIVED - Common Drug Review - Health Care System”, 
(28 May 2004), online: <http://www.hc-sc.gc.ca/hcs-sss/pharma/mgmt-gest/cdr-emuc-eng.php>. 
(Accessed April 2 2016).  
110 “CADTH Commong Drug Review | Procedure for the CADTH Common Drug Review”, August 2014, 
at 2, online: <https://www.cadth.ca/media/cdr/process/CDR_Procedure.pdf>. (Accessed June 2 2016). 
111 Ibid at 4. 
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Figure 5. CADTH Common Drug Review Process 
Source: CADTH Common Drug Review, 2014  
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There is also the pan-Canadian Oncology Drug Review (pCODR) that reviews 
only cancer drugs. It reviews the clinical evidence, cost-effectiveness in order to make 
recommendations to provinces, (except Québec)112. 
In 2010, the creation of the pan-Canadian Pharmaceutical Alliance (pCPA), was 
part of an endeavor from the Council of the Federation’s Health Care Innovation 
Working Group (HCIWG) aimed at creating “greater value for publicly funded drug 
programs and patients”. Consequently, all brand name drugs considered for funding by 
the CDR are considered for negotiation through the pCPA. Numerous advantages are 
targeted by joining forces with all provinces and territories allowing a “combined 
negotiating power of drug plans”113. The main advantages are the increased access to 
drug treatment options, the possibility to achieve reduced drug costs and consistent 
pricing, and obtain more consistent criteria for drug coverage all over Canada. All 
provinces and territories work together for generic and brand name drugs and, as of 
March 2015, $490 million in annual combined savings was estimated for these drugs114. 
Considerable efforts by CADTH, CDR and pCPA are dedicated to reach better values 
for public drugs, including drugs for rare diseases.  
 
1.1.3.3 Patented Medicine Prices Review Board  
 
In contrast to the CADTH, which has no binding authority but which plays an 
important role regarding public reimbursement, the Patented Medicine Prices Review 
                                                             
112 “CADTH pan-Canadian Oncology Drug Review | CADTH.ca”, online: <https://www.cadth.ca/about-
cadth/what-we-do/products-services/pcodr>. (Accessed April 3 2016). 
113 “Canada’s Premiers - The pan-Canadian Pharmaceutical Alliance”, online: 
<http://www.pmprovincesterritoires.ca/en/initiatives/358-pan-canadian-pharmaceutical-alliance>. 
(Accessed April 6 2016) 
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Board (Board) is an independent quasi-judicial body under the Patent Act115. The Board 
“protects the interests of Canadian consumers by ensuring that the prices of patented 
medicines sold in Canada are not excessive”116. In Sanofi Pasteur Limited v. Canada 
(Attorney General) at paragraph 6, it was stated at the Federal Court that: “It is clear that 
Parliament’s intention in creating the Board was for it to control the market power of the 
monopoly created by the exclusivity of a patent”117, reinforcing the duties of the Board 
towards patents pertaining to a “medicine”. This being said, the Board’s mandate is not to 
set prices for patented medicines sold in Canada, but to make sure that the price a patentee 
is selling the drug for is not, in the Board’s opinion, excessive; therefore the Board is acting 
as a “watchdog”118. However, it has no power to regulate excessive prices of non-patented 
drugs and that includes all non-patented drugs sold in Canada119. To determine if a price is 
excessive or not, the Board collects information provided by the patentee in accordance 
with the regulations120 and conducts price tests. The Board performs a strict and thorough 
evaluation of a specific medicine and also compares the cost of the latter medicine sold in 
Canada with prices from other countries. In order to further explain how the Board 
proceeds in determining whether a price is excessive, it is better to have a concrete example 
of a drug product intended to treat a rare disease. Soliris® (eculizumab) is a drug 
manufactured by Alexion Pharmaceutical Inc. for the treatment of two rare diseases. 
                                                             
115 Patent Act, R.S.C. 1985, c. P-4  
116  Patented Medicine Prices Review Board – “Mandate and Jurisdiction”, (26 June 2014), online: 
<http://pmprb-cepmb.gc.ca/about-us/mandate-and-jurisdiction>. (Accessed April 4 2016) 
117 Sanofi Pasteur Limited v Canada (Attorney General), 2011 FC 859 online: <http://canlii.ca/t/fm9hw>. 
It should be noted that marketing authorization in Canada and patents do not go hand in hand.  
118 Patent Act, supra note 115 SS. 80-87; Pfizer Canada Inc v Canada (Attorney General), 2009 FC 719 at 
para 11 online: <http://canlii.ca/t/24rrg>. The expression “watchdog” was used by Minister of Consumer 
and Corporate Affairs Harvie Andre (See para 60 in Pfizer)     
119  Patented Medicine Price Review Board, “Frequently Asked Questions”, (26 June 2014), online: 
<http://pmprb-cepmb.gc.ca/about-us/frequently-asked-questions> (Accessed April 8 2016); Celgene Corp. 
v. Canada (Attorney General), 2011 SCC 1, [2011] 1 S.C.R. 3 
120 Patent Act, supra note 115, SS. 80-82 
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Paroxysmal Nocturnal Hemoglobinuria (PNH) is a serious and life-threatening condition 
leading to the destruction of red blood cells, and Atypical Hemolytic Uremic Syndrome 
(aHUS) is a serious and debilitating condition causing blood clots in small vessels121. 
Alexion received a NOC from Health Canada in January 2009 for PNH, whereas the 
NOC for aHUS was issued in 2013. Soliris was sold in Canada from 12 June 2009 at a 
marketing price of $224.73 CAD/mL. It was then, and it is still considered one of the 
most expensive drugs in the world122. A Canadian Patent (No. 2189015) was granted to 
Alexion in April 2010, which expired in May 2015123 . Alexion can exercise rights 
according to subsection 79(1) of the Patent Act124. Therefore Alexion is entitled to:  
[…] the benefit of the patent for that invention and 
includes, where any other person is entitled to exercise any 
rights in relation to that patent other than under a license 
continued by subsection 11(1) of the Patent Act 
Amendment Act, 1992, that other person in respect of 
those rights; […]125. 
 
In regards to the patentee, the Board evaluates the pricing information in reference to the 
2010 Compendium of Guidelines, Policies and Procedures (“2010 Guidelines”), and the 
Highest International Price Comparison (“HIPC”) test126. The Board also compared the 
                                                             
121  Matthew A Lambert & William J J Finlay, “Chapter 14. Soliris (Eculizumab): Discovery and 
Development” in David C Pryde & Michael Palmer, eds, RSC Drug Discovery (Cambridge: Royal Society 
of Chemistry, 2014) 401, see supra note 53; “Soliris® (eculizumab) | Alexion, Rare Disease Leader”, 
online: <http://alexion.com/Products/Soliris>. (Accessed April 3 2016)  
122 “The real cost of the world’s most expensive drug”, online: <http://www.cbc.ca/news/thenational/the-
real-cost-of-the-world-s-most-expensive-drug-1.3126338>. (Accessed April 3 2016) 
123 According to Patent Act, supra note 115, s. 83(7):“No order may be made under this section in respect 
of a former patentee who, more than three years before the day on which the proceedings in the matter 
commenced, ceased to be entitled to the benefit of the patent or to exercise any rights in relation to the 
patent”. That said, the Board can make an order since it falls within the three year period after the expired 
patent: 
124 Patent Act, supra note 115 s. 79(1) 
125 Ibid.  
126  Patented Medicine Prices Review Board, “Compendium of Policies, Guidelines and Procedures - 
Updated June 2015”, (30 April 2014), online: <http://www.pmprb-cepmb.gc.ca/view.asp?ccid=492>. 
(Accessed April 3 2016) 
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price of Soliris sold in other countries, to the National Average Transaction Price (N-
ATP). In its statement of Allegations, the Board alleged that Alexion was selling Soliris 
“at a price higher than in the United States, where Soliris was sold below the 
international median price among the comparator countries”127. Moreover, Alexion was 
given the opportunity to adjust the price of Soliris, which they declined. In a reply 
argument, Alexion stated that the allegations of the Board were outside the raised 
pleadings, and therefore, Alexion filed a notice of application at the Federal Court of 
Canada. In addition, Alexion went a step further and challenged the Board’s power 
alleging that it was invalid, under sections 83 through 87(1) of the Patent Act128, because 
it exceeded the authority granted to the federal government pursuant to the Constitution 
Act, 1867129. This case is still pending before the Court. Nevertheless, it raises the 
question of how powerful and unwilling pharmaceutical companies, such as Alexion, a 
US company, are to decrease the price of their drugs. Moreover, it comes to mind that 
the Board has limited power over patented medicine.  Big pharmaceutical companies 
have the means and strategies to argue for an extended length of time in Court in order 
to maintain excessive prices for drugs. In fact, Alexion’s reported net product sales was 
$665 US million for Soliris in the first quarter of 2016130.  
In recent years, exorbitant prices have reached new highs when patents for 
pharmaceutical drugs expire. Prices for old, off patent drugs are at levels that no one has 
                                                             
127 Patented Medicine Prices Review Board, “Statement of Allegations of Board Staff | in the matter of the 
Patent act, R.S.C., 1985, c. P-4, as amended and | in the matter of Alexion Pharmaceuticals Inc (“the 
Respondent”) and the medicine “Soliris” ” January 15 2015. 
128 Patent Act, supra note 115.  
129 Constitution Act, 1867, 30 & 31 Vict., c.3 (R.-U.) 
130  “Alexion Reports First Quarter 2016 Results | Alexion Pharmaceuticals, Inc”, online: 
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results>.(Accessed April 3 2016) 
 
  
 
 
38 
ever expected before. An example of this is Turing Pharmaceuticals, “the company has 
the power to set a high price for Daraprim because the drug’s limited patient population, 
the absence of competing manufacturers, and a lack of therapeutic alternatives have all 
created an effective monopoly”131. In fact, the price of Daraprim, a medication to treat 
life-threatening infections went from $13.50 to $750 US per pill, an increase of 5500% 
for a drug off patent since the 1970s132. In Canada, the Board has no authority once 
drugs are off patent and expired for longer than 3 years, therefore, pharmaceutical 
companies are paving the way to increase prices at exorbitant levels133. 
 
1.1.3.4 Special Access Programme (SAP) 
 
Health Canada has for a long time neglected the possibility of creating specific 
orphan drug legislation. In a policy statement in 1996, Health Canada evaluated the issue 
regarding rare diseases and decided to reject the possibility of any orphan drug 
legislation on the grounds that the system already in place was sufficient. The Health 
Canada status quo in decision-making stems in part from the fact that over 63% of US 
designated orphan drugs were available in Canada134. Moreover, the analysis of Health 
Canada’s decision led to the following statement: 
[…] (ii) the high costs of orphan drugs could be an 
obstacle to patient access; and (iii) the Canadian 
                                                             
131 Naren P Tallapragada, “Off-patent drugs at brand-name prices: a puzzle for policymakers” (2016) 3:1 
Journal of Law and the Biosciences at 239.  
132 The Globe and Mail, “Experts raise alarm over high drug prices, could force new rules”, online: 
<http://www.theglobeandmail.com/news/national/experts-raise-alarm-over-high-drug-prices-could-force-
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133 Patent Act, supra note 115 s. 83(7) 
134 Orphan Drug Policy. Ottawa (ON): Drugs Directorate, Health Canada; January 16 1997. [letter sent to 
associations] File no: 96-037419; Durhane Wong-Rieger, “Canada’s long journey toward an Orphan Drug 
Framework”, (2013) no. 20(2) Advocate, at 20. The Orphan Drug Framework has still not been 
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population was not large enough to support significant 
research and development in the area”135.  
 
This clearly shows that Canadian federal authorities were depending on the US for R&D 
for orphan drugs and accepted these latter drugs in Canada when they were approved in 
the US. The statement referring to the fact that the Canadian population was not large 
enough to support R&D is a total misconception and bad use of taxes provided by 
Canadians for their health system. Put bluntly, relying on resources of another country 
before investing in R&D for orphan drugs might not be in the best interest of the 
Canadian healthcare system. Furthermore, it was mentioned in the 1996 statement: 
“There has not been significant pressure from industry or special interest groups in 
Canada to develop an Orphan Drug policy”136. 
Canadians had access to orphan drugs that were either marketed through the 
regular process or approved through the SAP, previously called Emergency Drug 
Release Programme, which has been in effect since 1966. In our opinion, the rationale 
for lacking an orphan drug policy was, and still is, probably due to the existence of the 
SAP.   
Health Canada’s Special Access Programme: 
[…] considers requests for access to drugs that are 
unavailable for sale in Canada from practitioners treating 
patients with serious or life-threatening conditions when 
conventional treatments have failed, are unsuitable or 
unavailable.137  
                                                             
135 Richard Y. CHEUNG, Jillian C. COHEN et Patricia ILLINGWORTH, " Orphan drug policies: implications 
for the United States, Canada, and developing countries ", (2004) 12 Health Law J 183 at 190. 
136 Supra note 134 at 9. 
137  Health Canada, “Special Access Programme – Drugs”. Online: <http://www.hc-sc.gc.ca/dhp-
mps/acces/drugs-drogues/sapfs_pasfd-eng.php>. (Accessed April 2 2016) Guidance Document for 
Industry and Practitioners - Special Access Programme for Drugs Ottawa, Health Canada, 2013, online: 
<http://www.hc-sc.gc.ca/dhp-mps/acces/drugs-drogues/sapg3_pasg3-eng.php> (Accessed April 2 2016). 
See also supra note 59 at 114. 
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Orphan drugs that have yet to be authorized in Canada fall under the SAP, under 
articles C.08.010 and C.08.011 of the Food and Drug Regulations, which is part of the 
Sale of New Drug for Emergency Treatment138:  
 
C.08.010 (1) The Director may issue a letter of 
authorization authorizing the sale of a quantity of a new 
drug for human or veterinary use to a practitioner named in 
the letter of authorization for use in the emergency 
treatment of a patient under the care of that practitioner, if: 
 
a) the practitioner has supplied to the Director information 
concerning: 
      
i) the medical emergency for which the drug is 
required; 
 ii) the data in the possession of the practitioner 
with respect to the use, safety and efficacy of that 
drug; 
(iii) the names of all institutions in which the drug 
is to be used, and 
(iv) such other data as the Director may require; 
and 
 
(b) the practitioner has agreed to: 
 
(i) report to the manufacturer of the new drug and 
to the Director on the results of the use of the drug 
in the medical emergency, including information 
respecting any adverse reactions encountered, and 
(ii) account to the Director on request for all 
quantities of the drug received by him. 
 
(1.1) The Director shall not issue a letter of authorization 
under subsection (1) for a new drug that is or that contains 
a restricted drug as defined in section J.01.001. 
 
(2) The Director shall, in any letter of authorization is-sued 
pursuant to subsection (1), state 
(a) the name of the practitioner to whom the new 
drug may be sold; 
(b) the medical emergency in respect of which the 
                                                             
138 Supra note 58, s. C.08.010 and s. C.08.011.   
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new drug may be sold; and 
(c) the quantity of the new drug that may be sold 
 to that practitioner for that  emergency. 
 
 
C.08.011 (1) Notwithstanding section C.08.002, a 
manufacturer may sell to a practitioner named in a letter of 
authorization issued pursuant to section C.08.010, a 
quantity of the new drug named in that letter that does not 
exceed the quantity specified in the letter. 
 
(2) A sale of a new drug made in accordance with 
subsection (1) is exempt from the provisions of the Act and 
these Regulations. 
 
In order to access a drug via SAP, a practitioner, usually a licensed physician must 
complete and submit a multipart Special Access Request (SAR) form. The SAR form 
contains the practitioner and shipping information, the drug and manufacturer 
information, the patient information, as well as the clinical rationale for requesting the 
drug, including references for its safety and efficacy and three attestations for the 
requesting practitioner139. The SAP overstates that it processes most requests within 24 
hours of receipt, although a triage system is used and processing time may take longer 
depending on the volume of SARs received. It is pertinent to mention that the request is 
only for an exact amount of the drug for the treatment of a single patient and cannot 
extend beyond a maximum of six months. If the treatment is for a longer period of time, 
it will require a second request form. Once the screening and reviewing process is 
completed, the SAP will issue one of the following decisions: authorization, incomplete, 
cancellation, withdrawal or denial. In a recent court case, it was decided that the Court 
cannot intervene in terms of discretionary regulation according to article C.08.010 
                                                             
139 Health Canada Government of Canada, “Health Canada’s Special Access Programme: Special Access 
Request - Form A”, (2 August 2002), online: <http://www.hc-sc.gc.ca/dhp-mps/acces/drugs-
drogues/sapf1_pasf1-eng.php>. (Accessed April 2 2016) 
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regarding the non-obligation to deliver SAP authorizations in the SAP programme140. 
The reason for not intervening is that it would be illegal and in violation of the 
provisions according to the aforementioned regulations “which stipulate certain 
conditions that must be met by a physician requesting access before the Director General 
can exercise his discretion”141. 
Notwithstanding the decision, if the practitioner’s request is authorized, he can 
therefore ask for the drug from the manufacturer. However, the manufacturer is not 
compelled in any way to accept the request and has the right to place restrictions or 
conditions on the release of the drug.  
A major issue revolves around the fact that the SAP has clearly created an 
administrative burden on the practitioner that is time-consuming and labour-intensive, it 
is thus a marked disadvantage, in this case, for patients with rare diseases142. Moreover, 
the treatment for rare diseases is often given throughout the lifetime of the patient and, if 
authorized by the SAP, the practitioner has to fill out requests that only last for six 
months143. In a normal scenario, one can imagine a practitioner working in a large 
medical centre having forty patients or more with several rare diseases and continuously 
having to complete forms, twice a year for each patient, over time. This is a tremendous 
administrative burden for the physician and the healthcare system, considering the 
paperwork and different administrative officers involved. Ironically, the Minister of 
Health in Canada, in 2012, recognized that the SAP was problematic regarding orphan 
drugs:    
                                                             
140 Delisle v Canada (Attorney General), 2004 FC 788 online: <http://canlii.ca/t/1jhdk>. 
141 Ibid at paragraph 14.  
142 Personal communication from physicians treating many patients with rare diseases.  
143 Supra note 137.  
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Today, when an orphan drug is not available in Canada, 
the patient’s doctor can apply individually for each patient 
through Health Canada’s Special Access Programme. 
While facilitating access - the current approach also 
represents a significant burden to the healthcare system144. 
 
A thorough analysis of articles C.08.010 and C.08.011 of the Food and Drug 
Regulations mentioned above shows that they were designed for new drugs, as well as 
for the emergency treatment of a patient. SAP enables access to new drugs not yet on the 
Canadian market where physicians can monitor closely patients for adverse drug 
events145. In fact, physicians need to provide a medical follow-up on the outcome of 
treatment with respect to the requested drug.  
According to the Access to Information Act146, an application was submitted to 
Health Canada to obtain a list of every drug where a SAP request was granted for the 
year 2013 (Appendix 1). This list contains the product name, as well as the number of 
requests authorized for each of the drugs listed, which are shown according to the 
prescription dose. Therefore, one specific drug might have three different doses, thus 
leading to three different entries (requests) in the list provided by Health Canada. From 
January 1st until December 2013, a total of 431 drugs were submitted and authorized via 
the SAP. Unfortunately, this list did not distinguish orphan drugs from non-orphan 
drugs, therefore there are no specific indications for orphan drugs in Canada. 
Hence, the key question is: how many of these drugs, listed by Health Canada, 
had or have designations for orphan drugs in Europe and the USA? In order to answer 
this question we devised a table compiling data from drugs, which have been granted an 
                                                             
144 Supra note 34.  
145 Teva Canada Limited v. Canada (Health), 2012 FCA 106 (CanLII)  
146 Access to Information Act, R.S.C., 1985, c. A-1. 
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orphan drug designation either by the Orphanet database147 or by the FDA database148 
(Appendix 2). This table is comprised of different categories, namely the drug or product 
name and the alternative drug name; the orphan drug number from Orphanet if available; 
the country of orphan designation; the dose; and the number of SAP requests authorized 
during a specific year. Our results for 2013 show that the total number of requests for 
orphan and non-orphan drugs authorized by SAP is 14,532. Orphan drug accounted for 
4,912 (33.8%), and 9,620 (66.2%) for non-orphan drug SAP authorizations (Figure 6).  
 
Figure 6. Comparison of the Percentages between the Orphan and Non-Orphan Drug 
Authorized Requests through the Special Access Programme by Practitioners in Canada 
for 2013 
 
          Source: Our analysis 
                                                             
147  “Orphanet: Orphan drugs”, online: <http://www.orpha.net/consor/cgi-bin/Drugs.php?lng=EN>. 
(Accessed April 4 2016). 
148 U.S. Food and Drug Administration, “Search Orphan Drug Designations and Approvals”, online: 
<https://www.accessdata.fda.gov/scripts/opdlisting/oopd/>. (Accessed March 17 2016). 
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The table in Appendix 2 also shows that for one specific drug, there might be 
two countries or more of origin designations. Nevertheless, only the selection of Europe 
and US designations were taken into account in this table. For example, Naglazyme® 
(galsulfase from BioMarin Pharmaceuticals Inc.), is provided for mucopolysaccharidosis 
type VI, (also called Maroteaux-Lamy syndrome) patients. This rare genetic lysosomal 
storage disorder, has a designation in the US while the designation in Europe was 
eventually withdrawn. Another example is the drug Orfadin (nitisinone) provided by the 
Swedish Orphan Biovitrum company for alkaptonuria or tyrosinemia type I patients. 
This drug has a designation in the US and Europe for alkaptonuria, but in Europe it had 
the designation withdrawn for tyrosinemia type I. Orfadin is usually prescribed in 
Québec (and elsewhere) for tyrosinemia type I patients, considering the founder effect 
(i.e. when a group of individuals comes from a few members of an original population 
carrying a gene with a unusually high frequency) known in the province, and 
consequently the very high incidence of 1/16,667 live births, and 1/1,846 in the specific 
region of the Saguenay-Lac-Saint-Jean region for this disease (worldwide average 
incidence for tyrosinemia type I is 1/100,000)149.     
 There were a total of 431 drugs in the SAP list. Out of these, 127 were orphan 
drug designated (Figure 7). A total of 90 of these have or had (because of an expiration 
date exclusivity) an orphan designation drug in the US. In Europe, 62 have an orphan 
drug designation. The major discrepancy between the total number of SAP orphan drugs 
(n=127) in Canada and the ones already approved in the US (n=90) and Europe (n=62) 
reveals a major administrative burden in Canada for patients to have access to the same 
                                                             
149 Mariève Simoncelli et al, "Cost-Consequence Analysis of Nitisinone for Treatment of Tyrosinemia 
Type I" (2015) 68:3 Can J Hosp Pharm 210. 
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drugs, which have already been authorized and distributed throughout other countries. 
This is mainly due to the fact that US and Europe both have specific legislation 
encompassing these drugs. Unfortunately, Canada relies on the complex, time-
consuming and case-by-case basis “SAP” to allow access to these same orphan drugs for 
rare disease patients. 
 
Figure 7. Number of SAP Orphan Drug Designations in US and Europe Compared to 
Total SAP Drugs for 2013  
 
Source: Our analysis 
 
However, a question then arises: are all drugs available through SAP new or 
experimental drugs? In response to this question, the SAP has established in a policy 
statement the following:  
Special access by Canadian health practitioners to 
unauthorized drugs is intended for serious or life-
threatening conditions where conventional therapies have 
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failed, are unsuitable, or are unavailable either as marketed 
products or through enrollment in clinical trials150.  
 
However, the example of Prussian Blue (distributed by Heyl Chemisch-Pharmazeutische 
Fabrik Gmbh), which is authorized via the SAP process, is not a new drug. In fact, 
Prussian Blue has been used clinically since the 1960’s and approved by the FDA as an 
orphan drug since 2003. Since the 1960’s, the clinical use of Prussian Blue relates to its 
orphan drug usage. It plays a major role in trapping radioactive/non-radioactive thallium, 
and radioactive cesium in the intestine to avoid internal radioactive contamination151. 
Prussian Blue shows that some of these drugs are definitely not novel drugs. Therefore, 
SAP is a poor fit considering that it does not distinguish between “old” and “new” 
orphan drugs. In fact, Prussian Blue was requested and authorized twice in 2013 through 
the SAP (See Appendix 1). 
It is clear that the importance of drug regulations is to ensure safety and efficacy 
for patients. However, might the SAP just be a bypass for pharmaceutical companies 
when drugs are not marketed in Canada? Assuming a drug previously sold in Canada, 
yet withdrawn from the market not for safety and efficacy issues, but simply because it 
was unprofitable to the marketer: could the SAP be a bypass to reintroduce the drug at 
more favorable conditions for the marketer152? Among others, pharmaceutical orphan 
                                                             
150 Supra note 137. 
151 U.S. Food and Drug Administration. “Guidance for Industry, Prussian Blue Drug Products— 
Submitting a New Drug Application, FDA, January 2003 Clinical Medical”, at 1, Online: 
<http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072020.
pdf> (Accessed April 4 2016). 
152 The example of cycloserine and pyrimethamine, available through SAP, both of which were previously 
sold in Canada, until they were withdrawn from the market. The reason of withdrawal was not for reasons 
of safety or efficacy but by the decision of the marketer. We supposed that the SAP could be a favorable 
option for pharmaceutical companies since the SAP prevents the process of a New Drug Application for a 
pharmaceutical company and therefore avoids the fees related to the application. 
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drugs that have never been patented, or marketed in Canada therefore fall into an abyss, 
where Canadian authorities cannot control excessive costs for these orphan drugs since it 
is not under the authority of the Patented Medicine Prices Review Board (Board) 
mentioned previously153. The example of Thiola®, an off-patent orphan drug medication 
for cystinuria, a rare genetic disease causing kidney stones, was successfully requested 
75 times in 2013 through the SAP. There has been a significant price increase from US 
$1.50 per tablet to $30 per tablet, leading patients to pay an estimated cost of $100,000 
per year154. At the time, the price of Thiola® was not controlled by the Board since it 
was not patented in Canada, being an off-patent drug. Unfortunately, the Board had no 
power to control the excessive price which remains at the same price in 2016 leading to 
difficulty for patients to have a reimbursement of the drug155.    
Although orphan drugs can be authorized through SAP, the reimbursement of 
these drugs is still another major issue for patients considering their high prices. The 
burden then becomes a provincial responsibility. “All developed countries with universal 
healthcare systems provide universal coverage for prescription drugs – except 
Canada”156.  It is time to rethink pharmacare policies in Canada, since the situation 
involves limited allocation by provinces for public subsidies for prescription drugs, and 
                                                             
153 Supra note 119 at 4: “When C obtained the Canadian patent in relation to Thalomid in 2006, the 
Patented Medicine Prices Review Board (“Board”) advised C that it now had jurisdiction to request 
pricing information from C from the time it first sold Thalomid through the SAP in 1995.”  
154 “Imprimis Pharmaceuticals Begins Dispensing Lower Cost Alternative to Thiola®”, (2 May 2016), 
online: Investor Relations - Imprimis Pharmaceuticals, Inc  
<http://imprimispharma.investorroom.com/2016-05-02-Imprimis-Pharmaceuticals-Begins-Dispensing-
Lower-Cost-Alternative-to-Thiola>.(Accessed June 3 2016) 
155  ICI Radio-Canada.ca Radio-Canada, “Prix des médicaments : des patients pris en otage”, online: 
<http://ici.radio-canada.ca/audio-video/media-7415567/prix-des-medicaments-des-patients-pris-en-
otage>. (Accessed June 5 2016) 
156 Steven G Morgan, Jamie R Daw & Michael R Law, Rethinking Pharmacare in Canada ([Toronto, 
ON]: C.D. Howe Institute, 2013) at 1. 
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therefore the remaining costs have to be financed either, out-of-pocket or through private 
insurances. 
Some limitations were encountered in this SAP analysis. First, data provided by 
Health Canada were supposed to be for drugs considered as pharmaceutical, biologic, 
and radio-pharmaceutical products. Nonetheless, alternative medications were also 
encountered in the list provided, such as medical maggots or medicinal leeches. These 
latter medications were requested 21 times and 120 times, respectively, under SAP and 
were included in the total drugs evaluated in Figures 6 and 7 as non-orphan drugs. Also, 
some products, such as 714X (trimethylaminohydroxybicycloheptane chloride) 
requested successfully 21 times through the SAP, is an unconventional therapy for 
cancer, and was included in the data provided by Health Canada, even if no clinical trials 
were done and it is banned in the US157. As stated previously and in accordance to 
Health Canada’s SAP list, we counted as three medications, a product having three 
different doses. For example, the drug afatinib (BIBW 2992) had 30, 40, 50 mg was 
compiled thrice. 
    In 2012, after the announcement of a regulatory framework for orphan drugs 
in Canada, an initial draft discussion document was released158. The objective of this 
draft discussion was to “provide context and policy intent for the proposed drug 
regulatory framework including the details of the proposal”159 . Even until now, no 
concrete regulatory framework has yet to be implemented in Canada. 
  
                                                             
157 Elizabeth Kaegi, “Unconventional therapies for cancer 6. 714-X”, (1998) 158 CMAJ 1621. 
158 Office of Legislative and Regulatory Modernization. (2012). Initial Draft Discussion Document for a 
Canadian Orphan Drug Regulatory Framework. Retrieved from <http://www.orpha.net/national/data/CA-
EN/www/uploads/Initial-Draft-DiscussionDocument-for-A-Canadian-Orphan-Drug--Regulatory-
Framework.doc>. 
159 Ibid. 
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1.2 At the Provincial Level  
 
In Canada, “the administration and delivery of health care services is the 
responsibility of each province and territory, guided by the provisions of the Canada 
Health Act”160. Federal fiscal transfers are provided to provinces to enable them to fulfill 
their responsibilities161. In order to qualify for a full cash contribution, provinces must 
meet five fundamental criteria: public administration; comprehensiveness, universality, 
portability and accessibility 162 . Accessibility is defined as: “The degree to which 
individuals are inhibited or facilitated in their ability to gain entry to and to receive care 
and services from the health care system. Factors influencing this ability include 
geographic, architectural, transportational, and financial considerations, among 
others” 163 . Moreover, according to the comprehensiveness criterion of the Canada 
Health Act: 
In order to satisfy the criterion respecting 
comprehensiveness, the health care insurance plan of a 
province must insure all insured health services provided 
by hospitals, medical practitioners or dentists, and where 
the law of the province so permits, similar or additional 
services rendered by other health care practitioners164. 
 
Therefore, the Act states that medically necessary services offered in hospitals must be 
provided free of charge. Considering this Canadian infrastructure165, it is thus the role of 
                                                             
160 Canada Health Act, R.S.C., 1985, c. C-6. 
161 Ibid s. 5: “Subject to this Act, as part of the Canada Health Transfer, a full cash contribution is payable 
by Canada to each province for each fiscal year”. 
162 Ibid s. 7 
163 André Côté & Bernard Keating, “What Is Wrong with Orphan Drug Policies?” (2012) 15:8 Value in 
Health 1185. 
164 Supra note 160 s. 9. 
165 Supra note 129 SS 92(7), (13) and (16). 
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each province to have programmes and policies, which are approved for drug 
reimbursement. “The provinces and territories also provide some groups with 
supplementary health benefits not covered by the Act, such as prescription drug 
coverage. The level and scope of coverage for supplementary benefits varies between 
jurisdictions”166. Five Canadian provinces, Alberta, British Columbia, Saskatchewan, 
Ontario, and New Brunswick, have special programs for orphan drug diseases167. In 
order to better understand the legal and policy framework and challenges towards 
orphan drugs in the provinces of Canada, a detailed view of the situation for specific 
provinces will be provided. More specifically, we selected four out of five Canadian 
provinces (Alberta, Ontario, New Brunswick and British Columbia) having specific 
programs for orphan drugs, in order to analyse and examine the differences and 
challenges in public health policy concerning orphan drug reimbursement. In contrast, 
two provinces, Manitoba and Québec, which do not have specific programs for orphan 
drug diseases will be examined in more detail considering the striking differences in 
policy mechanisms for drug reimbursement. As a matter of fact, the province of Québec 
has its own evaluation process for drug reimbursement, whereas the other provinces all 
rely on the CDR. Furthermore, the province of Québec, having French as an official 
language, often publishes literature in French that is not always readily accessible to 
non-French readers, whereas other provinces publish in English. We are thus bringing 
                                                             
166 Health Canada and the Public health Agency of Canada Government of Canada, “Provincial/territorial 
role in health”, (26 July 2004), online: <http://healthycanadians.gc.ca/health-system-systeme-sante/cards-
cartes/health-role-sante-eng.php>. (Accessed April 25 2016) 
167 Devidas Menon, Derek Clark & Tania Stafinski, “Reimbursement of Drugs for Rare Diseases through 
the Public Healthcare System in Canada: Where Are We Now?” (2015) 11:1 Healthcare Policy | 
Politiques de Santé 15. This article provides a comprehensive overview of all the programs in Canada 
regarding orphan drug reimbursement.  
  
 
 
52 
together materials in both languages in order to give the current situation on public drug 
reimbursement programs for rare diseases.    
Regarding the basic principles involved in the evaluation of decisions for 
reimbursement of orphan drugs in Canada and abroad, a recent study provided a 
qualitative insight on these policies. According to the authors, there are ten basic key 
points taken into account by “government policy makers or senior staff of agencies” 
involved in drug review for reimbursement:  
- the eligibility aspect with characteristics of the disease and related drugs; 
- the patient population; 
- the clinical evidence; 
- the cost figures for providing the drug; 
- the cost effectiveness for the evaluation of the economic aspect; 
- the patient and family input for the review process; 
- the composition of the review and decision making committee; 
- the options for reimbursement considering the availability of choices; 
- the factors which are considered in the decisions by the committee; 
- a transparent review process as well as final decisions which should be made 
available to the public168.  
In our view, these key points should be encompassed in all framework and 
policies regarding orphan drugs to aim at fair and unbiased approaches towards patients 
suffering from these rare diseases. It is therefore important that all provinces abide by 
                                                             
168 Hilary Short, Tania Stafinski & Devidas Menon, “A National Approach to Reimbursement Decision-
Making on Drugs for Rare Diseases in Canada? Insights from Across the Ponds” (2015) 10:4 Healthc 
Policy 24 at 28. 
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these key points to insure equity for all Canadian patients affected with rare diseases. If 
not, implementation of the neglected elements should be envisioned.     
 
1.2.1 In Alberta 
Alberta participates in the national CDR for all new drugs recommendations.  
There is a list of over 4,000 drugs (Alberta Drug Benefit List), which defines all 
prescription drugs and drug products that are covered by the ministry’s supplemental 
health plans169. 
There is a specific public program for orphan drug reimbursement that started in 
2009. It is called the “Rare Disease Drug Coverage Program”170 and it is mainly oriented 
towards patients with lysosomal storage disorders. It is part of an ethical and 
compassionate governmental support for these rare diseases171. The drug plan in Alberta 
refers to a rare disease as a lysosomal storage disorder with a frequency of less than 
1/50,000 Canadians172. Lysosomal storage disorders are a group of nearly 50 diseases, 
which result from the accumulation of substrates in the lysosomes (considered as the 
digested system of the cell) due to enzyme deficiencies caused by a gene mutation. They 
present marked phenotypic and genotypic variability, which may lead to severe clinical 
manifestations. Different therapies are possible, but for a few of these diseases, enzyme 
                                                             
169 Alberta Health-Government of Alberta, “Alberta Drug Benefit List (ADBL) Alberta Health”, online: 
<http://www.health.alberta.ca/services/drug-benefit-list.html>. (Accessed April 2 2016) 
170 Alberta Health-Government of Alberta “Alberta drug benefit list rare diseases drug coverage, Section 
2: Rare Diseases Drug Coverage Program”, (2014), Alberta Blue Cross, online: 
https://www.ab.bluecross.ca/dbl/pdfs/dbl_sec2.pdf (Accessed January 24 2015). 
171 Alberta Health-Government of Alberta, Health and Wellness, “Alberta Rare Diseases Drug Program 
Fact Sheet”, December 2008, online: < http://www.health.alberta.ca/documents/Pharma-Strategy-2008-
rare-disease.pdf> (Accessed April 2 2016). See also supra note 104. 
172 Supra note 103. 
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replacement therapy is the treatment of choice at the present time, which is provided by 
infusion once a week or every other week depending on the drug administered and the 
disease involved173 . The Alberta process for orphan drug reimbursement involves a 
group of specialists with experience in genetic diseases who review and provide clinical 
information on rare diseases for individual applications for the rare disease Drug 
Coverage program for reimbursement of specific drugs according to guidelines 
previously established. They then provide their counsel and advice to the provincial 
Expert Committee on Drug Evaluation and Therapeutics (Review Panel)174. It is worth 
mentioning that the Review Panel “must review all drug products not eligible for review 
by CDR. It provides advice and recommendations to the Minister concerning the 
therapeutic value and cost-effectiveness of the drugs”175. 
The Minister of Health of Alberta is the person who decides who will have 
access to the orphan drug under the Alberta government-sponsored program for the 
treatment of rare diseases 176 . Since April 1 2009, orphan drugs are considered for 
coverage by the government for the following rare diseases: Gaucher Disease, Fabry 
disease, Mucopolysaccharidosis Type I (Hurler/Hurler-Scheie diseases), Pompe Disease, 
Mucopolysaccharidosis type II (Hunter disease).  
The initial eligibility criteria are that the patient must have “Alberta government-
sponsored drug coverage, have continuously registered in the Alberta Health Insurance 
Plan for a minimum of 5 years (if the patient is less than 5 years, then the parents must 
                                                             
173 Joe T R Clarke, “Narrative review: Fabry disease” (2007) 146:6 Ann Intern Med 425. 
174 Supra note 171. 
175 Alberta Health-Government of Alberta, “Prescription drug program – Reviews and approvals Alberta 
Health”, online: <http://www.health.alberta.ca/services/drugs-review.html>. (Accessed June 2 2016) 
176 Alberta Human Services Drug benefit Supplement, Section 4, April 2016, Online: 
<https://www.ab.bluecross.ca/dbl/pdfs/hsdbs.pdf> (Accessed April 2 2016). 
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respect this 5-year registration), and meet the clinical criteria for the orphan drug on the 
list”177. Afterwards, physicians in charge of patients with one of the aforementioned rare 
diseases need to complete an application form for each individual, after having advised 
the patient of the forms to be completed and the process of the coverage program. Forms 
are then sent to the Alberta Blue Cross who supports the Review Panel. The multi-step 
process is time consuming and tedious since it involves the evaluation of each 
application by the Alberta Blue Cross. If the form is complete, it is sent to Alberta 
Health in order to verify that the patient meets Alberta Health Care Insurance Plan 
requirement. After confirmation that all requirements are fulfilled, Alberta Blue Cross 
sends the application to the Review Panel for evaluation. After completion of the 
evaluation by the Review Panel, Alberta Blue Cross informs the rare disease specialist 
treating the patient, as well as the patient or parents/legal guardians of the patient, of the 
decision of the Review Panel. If the decision is positive, the date of approval of the 
Review Panel will be the start for the orphan drug coverage eligibility, which is accepted 
for a maximum of one year. It is clearly stated that the approved orphan drug coverage 
depends on clinical outcomes of the patient. Therefore, monitoring of these clinical 
outcomes for patients on a regular-basis is required and the coverage of the treatment 
will cease if the response of the patient is inadequate, or if his clinical situation 
deteriorates according to the withdrawal criteria established in correlation with an 
orphan drug and supported by the Review Panel178. 
Importantly, all 12-month renewals of the prescription of the orphan drug 
necessitate that a new application to the Rare Diseases Drug Coverage program be 
                                                             
177 Ibid. 
178 Ibid. 
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repeated. It is thus the responsibility of the patient (or parents/guardians) and the rare 
disease specialist to re-apply for the drug coverage before the one-year expiration date. 
The prescription quantities are also restricted to monthly supplies to avoid wastage of 
the expensive drugs. It is not possible to ask for supplies of these orphan drugs for a 
longer period, even for vacation holidays. Moreover, there are standard rules to apply 
and must be respected if the patient needs to leave the country. The initial process is thus 
time consuming and labour-intensive considering that a patient might be in need of a 
rapid treatment. If the clinical outcomes are positive, it is also a burden for the physician 
to reapply yearly for each of his patients in order to ensure continuation of the treatment. 
 
1.2.2 In Ontario 
The Ministry of Health in Ontario has developed an innovative framework 
approach for orphan drugs in 2007, considering the lack of a national strategy in Canada, 
called “Drugs for Rare Diseases (DRD)”. This approach is an evidence-based clinical 
strategy also taking into account the needs of patients and the reimbursement costs179. A 
group of clinical and health economic experts were asked by the Ontario Health Ministry 
to develop “a new evaluation framework” for orphan drugs to receive reimbursement by 
the province. They worked together to seek the “best available evidence” to predict the 
benefits or lack thereof of treatment with orphan drugs in patients with rare diseases. 
This approach allows the identification of a cohort of individuals that may benefit from 
                                                             
179 Ministry of Health and Long-Term Care Government of Ontario, “Drugs For Rare Diseases (DRD)- 
Health Care Professionals - MOHLTC”, online: 
<http://www.health.gov.on.ca/en/pro/programs/drugs/how_drugs_approv/review_rare_diseases.aspx>. 
(Accessed April 2 2016) 
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treatment with a specific orphan drug and where coverage of the drug might be 
supported by the province.  
In Ontario, there is a Citizen’s Council with a mandate to “discuss and respond to 
questions or topics posed by the Executive Officer. It produces a specific report in 
answer to these questions or topics”180. The Council’s report is then sent to the Minister 
of Health, the Executive Officer, as well as Ontarians (via the Ontario’s website), so that 
this transparency will help people understand the process and opinions discussed. This 
will be followed by the response of the Executive Officer emphasizing the views of the 
Ministry on how the recommendations will be implemented. Regarding orphan drugs for 
rare diseases, the Citizen’s Council met in 2010 and provided a report to the Executive 
Officer on their views and approaches, which have been incorporated in the “DRD 
review and evaluation framework in Ontario”181.  It is worth to mention that the Ontario 
public drug program is the second largest drug insurance program in North America182.      
In 2006, the Ontario government decided to reform the public drug system by 
initiating the Transparency Drug System for Patients Act, 2006183 which made changes 
to the Ontario Drug Benefit Act184 and the Drug Interchangeability and Dispensing Fee 
Act185. Orphan drugs, as well as all other drugs, will be considered for listing and 
designation once the pharmaceutical manufacturer has submitted a complete application 
                                                             
180 Ministry of Health and Long-Term Care Government of Ontario, “Citizens’ Council - Ontario Public 
Drug Programs - Ministry Programs - Public Information - MOHLTC”, online: 
<http://www.health.gov.on.ca/en/public/programs/drugs/councils/reports.aspx>. (Accessed April 2 2016) 
181 Supra note 179. 
182  “Ontario vs. the pharmacists”, (22 April 2010), online: Macleans.ca 
<http://www.macleans.ca/news/canada/ontario-vs-the-pharmacists/>.(Accessed April 4 2016). 
183 Provinces and territories, Bill 102, An Act to amend the Drug Interchangeability and Dispensing Fee 
Act and the Ontario Drug Benefit Act, 2nd Sess, 38th Leg, Ontario, 2006 (assented to 20 June 2006)  
184 Ontario Drug Benefit Act R.S.O. 1990, c. O.10 
185 Regulation 935 under the Drug Interchangeability and Dispensing Fee Act R.R.O. 1990, Reg. 935: 
GENERAL 
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to the Ministry of Health and Long-Term Care and is compliant with the Ontario Drug 
Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee 
Act 186 . Its specific requirements and guidelines are comprised of “template letters, 
checklists and worksheets” to facilitate the manufacturers’ submission process for 
orphan drugs. The Ministry can always ask the manufacturer for more information 
throughout the review evaluation. Drugs that are not on the Ontario Drug Benefit (ODB) 
program list (and no other drug alternatives exist) must follow the path of the 
Exceptional Access Program (EAP)187. This program aims to “facilitate patient access 
for drugs not funded by ODB. Then, the Committee to Evaluate Drugs (CED), an expert 
advisory committee from the Ministry, will provide recommendations (according to 
specific guidelines and policies) to the Executive Officer, who on behalf of the Ministry 
will decide whether to fund these orphan drugs. The role of the CED is better explained 
as follows: 
Typically the CED recommends consideration through 
EAP for drug products where strong clinical evidence is 
not available to support efficacy and/or cost-effectiveness, 
when compared to other drugs already funded through the 
ODB program188. 
 
The example of one orphan drug called Elaprase® (Idursulfase)189 , given to 
patients affected with Hunter disease (mucopolysaccharidosis type II), is considered for 
coverage after its evaluation by the Executive Officer of the Ontario Public Drug 
                                                             
 
187 Ministry of Health and Long-Term Care Government of Ontario, “Exceptional Access Program - 
Ontario Public Drug Programs - Health Care Professionals - MOHLTC”, online:  
<http://www.health.gov.on.ca/en/pro/programs/drugs/eap_mn.aspx>. (Accessed April 3 2016). 
188 Ibid. 
189 Elaprase is manufactured by Shire, a large pharmaceutical company, Shire, “Elaprase.com - What is 
Elaprase?”, online: <http://elaprase.com/about/>. (Accessed April 2 2016). 
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Programs, because this orphan drug is not listed on the Ontario Drug Benefit Formulary 
under the EAP. The same process applies for patients affected with the less severe and 
moderate forms of Gaucher disease type I and for adult and pediatric patients with 
neurological progressive manifestations of Niemann-Pick type C disease who are treated 
with Zavesca® (Miglustat) 190 , and Naglazyme® (galsulfase) for the treatment of 
Mucopolysaccharidosis type VI (MPS VI disease). 
Another example of an orphan drug, Aldurazyme® (Laronidase) 191  given to 
patients affected with Hurler disease (Mucopolysaccharidosis type I) has a slightly 
different access procedure. The reimbursement process must go through the Inherited 
Metabolic Diseases (IMD) program in order that the drug be evaluated and eventually 
reimbursed by the Ontario Ministry 192 . Patients must meet specific criteria and be 
registered in the IMD program in order to be eligible for funding, and the drug must be 
prescribed by an Ontario physician. 
Fabry disease is another lysosomal storage disorder. Briefly, it is an 
underdiagnosed disease because it presents marked heterogeneity in the phenotype and 
genotype. Even if it is an X-linked disorder, women can also be affected and sometimes 
as severely as men 193 . There are two orphan drugs reimbursed by the Ministry in 
                                                             
190  Zavesca, is given to patients orally and is manufactured by Actelion. “ZAVESCA® [miglustat] 
Capsules, 100mg”, online:  
<https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=19754>. (Accessed April 2 
2016) 
191 Aldurazyme is manufactured by Genzyme, A Sanofi Company, a large pharmaceutical company 
192 Ministry of Health and Long-Term Care Government of Ontario, “Public Drug Programs 
Aldurazyme® (laronidase) – Mucopolysaccharidosis Type I (MPS I) Reimbursement Guidelines Version 
1 – October 2011”, online: 
<http://health.gov.on.ca/en/pro/programs/drugs/how_drugs_approv/docs/aldurazyme_reimb_guide.pdf 
>(Accessed April 4 2016). 
193 Supra note 173. 
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Ontario. One is Fabrazyme® (agalsidase beta from Genzyme, a Sanofi Company)194 and 
the other is Replagal® (agalsidase alfa from Shire)195. Both drugs are infused biweekly. 
The process of reimbursement is different for these two drugs, since in September 2013, 
it was transferred from the University Health Network (UHN) to the Ontario Public 
Drug Programs (OPDP). In Canada, there is a long-term research project called the 
“Canadian Fabry Disease Initiative (CFDI)” to evaluate Fabry patients since 2006196. 
Therefore, the CFDI has been given the mandate to “continue to assess new patient 
applications, annual renewals, and manage the ordering of enzyme replacement therapy 
(ERT) from the manufacturers” 197 . The CFDI has strict evidence-based treatment 
guidelines for patients to be admissible for ERT in Canada198.  
Since 2015, a new program designed for Ontario patients who have their closest 
physician either in Manitoba or in Québec, now have access to the Provincial Borders 
Drug Program (PBDP), which is a public drug program for ODB Program clients who 
require access to EAP products199. Physicians who are licensed either by the Collège des 
médecins du Québec or the College of Physicians and Surgeons of Manitoba may submit 
funding requests on ODB patients for an EAP product, with the relevant clinical 
information and rationale for the application. 
                                                             
194 Fabrazyme® is an enzyme replacement therapy drug provided by infusion to Fabry patients at 1.0 
mg/kg weight every 2 weeks, Genzyme, “Fabrazyme”, online: <https://www.fabrazyme.com/>. (Accessed 
April 5 2016). 
195 Replagal® is an enzyme replacement therapy drug provided by infusion to Fabry patients at 0.2 mg/kg 
weight every 2 weeks, “Shire: List of Products & Therapies”, online:  
<https://www.shire.com/products/product-list>. (Accessed April 5 2016). 
196 S M Sirrs et al, “Outcomes of patients treated through the Canadian Fabry disease initiative” (2014) 
111:4 Mol Genet Metab 499. doi: 10.1016/j.ymgme.2014.01.014.  
197  Michael L. West et al. “Canadian Fabry Disease Treatment Guidelines 2012” Halifax, online: 
<http://www.garrod.ca/wp-content/uploads/Canadian-FD-Treatment-Guidelines-2012.pdf> (Accessed 
April 6 2016).  
198 Ibid. 
199 Supra note 187.  
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Ontario has also a Compassionate Review Policy for life-, limb- or organ-
threatening conditions under rare circumstances where the Executive Officer will 
consider requests for drugs in the absence of a final funding decision under special 
criteria, namely no other alternatives through the EAP, or because the patient failed all 
appropriate non-pharmacological alternatives200. 
The Citizen’s Council has played an important role in representing the public’s 
view in a report on topics posed by the Executive Officer. The report is then taken into 
account by the Ministry, and in the case of rare diseases, it provided a compassionate 
aspect for affected individuals. This is a good endeavour on the part of the Ontario 
Ministry to listen to its constituents. The orphan drug policies in Ontario have been 
updated regularly. Nevertheless, it remains a complex program for patients to have 
access to and for physicians to fill out the administrative documents over time for each 
patient. 
1.2.3 In New Brunswick 
Certain orphan drugs are reimbursed in New Brunswick for specific rare 
diseases, mostly lysosomal storage disorders. The coverage plan is in partnership with 
Ontario with the DRD framework in order to review orphan drug applications with the 
best available evidence. Therefore, the DRD plan in New Brunswick refers to the same 
drugs as in Ontario and the requests submitted by physicians in New Brunswick are 
evaluated by the external medical experts from the Ontario Public Drug program with 
the same clinical criteria. Eligibility criteria are that patients must be permanent 
                                                             
200 Ibid.  
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residents of New Brunswick and have a Medicare Card201. The coverage plan is for the 
following diseases: Aldurazyme® (laronidase) for the treatment of Hurler and Hurler-
Scheie forms of Mucopolysaccharidosis I (MPS I); Elaprase® (idursulfase) for the 
treatment of Hunter's Syndrome; Ilaris® (canakinumab) for the treatment of Cryopyrin-
Associated Periodic Syndrome (CAPS); Myozyme® (alglucosidase alfa) for 
infantile/early and adult/late onset Pompe disease, Naglazyme® (galsulfase) for the 
treatment of Mucopolysaccharidosis type VI (Maroteaux-Lamy, MPS VI) 202  and 
Zavesca® (miglustat) for the treatment of Niemann-Pick Type C (NPC) disease.   
 
1.2.4 In Manitoba 
In Manitoba, all drugs must firstly be approved by Health Canada. Afterwards, 
there is a standard review procedure through the national CDR and the Manitoba Drug 
Standards and Therapeutics Committee (MDSTC)203. It is worth noting that Manitoba is 
an active member of the CDR204. Therefore, a new drug (or combination of drugs) needs 
to be filed with the CDR Directorate. The MDSTC is an autonomous group selected by 
the Minister of Health upon recommendations by the College of Physicians and 
Surgeons of Manitoba, Doctors Manitoba, the Manitoba Pharmaceutical Association, 
and the University of Manitoba. This Committee is thus sovereign from the government, 
                                                             
201Government of New Brunswick, “New Brunswick Drugs for Rare Diseases Plan”, (08:44:39.0), online: 
<http://www2.gnb.ca/content/gnb/en/services/services_renderer.201352.New_Brunswick_Drugs_for_Rar
e_Diseases_Plan.html>. (Accessed April 4 2016).  
202  Naglazyme (galsulfase) is an enzyme replacement therapy drug provided by infusion to patients 
affected with MPS VI. The drug is manufactured by BioMarin Pharmaceutical Inc, “About 
NAGLAZYME”, online: <http://www.naglazyme.com/about-naglazyme/>. (Accessed April 4 2016). 
203 Government of Manitoba “Drug Formulary Review Process | Manitoba Drug Benefits and 
Interchangeability Formulary | Manitoba Health, Seniors and Active Living | Province of Manitoba”, 
online: <http://www.gov.mb.ca/health/mdbif/review.html>. (Accessed April 5 2016). 
204  Therapeutics Initiative “[61] What is the Common Drug Review?”, (31 December 2006), online: 
<http://www.ti.ubc.ca/2006/12/31/what-is-the-common-drug-review/>. (Accessed April 4 2016). 
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and is comprised of six health care professionals (three physicians and three 
pharmacists) who propose “recommendations on drug interchangeability and on the 
therapeutic and economic value of drug benefits”205. A manufacturer who wants his new 
drug to be accepted for drug coverage must submit the drug application to the MDSTC. 
This latter Committee will consider the recommendations of the CDR, but also take into 
account recent scientific publications, similar drugs, expected cost, and benefits for the 
health of patients before making a recommendation for benefit listing. In order for a 
drug to be considered for listing on the Manitoba Formulary, a utilization management 
agreement (UMA) must be signed: 
The UMA provides a statement of the benefit of the 
product as compared to currently listed products, as well as 
cost impact projections, assurances of appropriate 
promotion and provision for health outcomes research206. 
  
  
Finally, the Manitoba Minister of Health, after reviewing the recommendations 
from the MDSTC, the health review from Manitoba and the signed UMA gives the final 
approval for benefits under the Pharmacare drug benefit program. The Minister will then 
sign the Specified Drug Regulation and the Manitoba Drug Benefits and 
Interchangeability Formulary. Pharmacare is comprised of three parts. The 3rd part of 
Pharmacare is dedicated to Exception Drug Status (EDS) coverage which is specific for 
each patient regarding his particular clinical situation. The patient’s physician must 
apply for the provincial coverage of these drugs. Reapplication each year for the same 
                                                             
205 Supra note 203. 
206 Supra note 203. 
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orphan drug is necessary207. Also, recommendations are formulated by the MDSTC. 
Orphan drugs are part of EDS and must meet strict criteria before being reviewed. One 
of these criteria is that the drug is prescribed:  
[…] because it is required in the diagnosis or treatment of 
an illness, disability, or condition rarely found in 
Manitoba. Evidence, including therapeutic and economic 
evidence, provided to the Minister in accordance with the 
criteria established by him or her, supports a specific 
treatment regime which includes use of the drug or other 
item208.  
 
Again the process in Manitoba for orphan drug reimbursement is time-
consuming and involves substantial bureaucracy for the physician involved in treating 
rare disease patients.   
1.2.5 In Québec  
Similar to all provinces, all drugs must be approved by Health Canada for its 
commercialization, thus respecting the efficacy, safety and quality of drugs. Contrary to 
other provinces who rely on CDR, Québec has its own evaluation process for 
reimbursement with the “Institut national d’excellence en santé et en services sociaux” 
(INESSS)209. It is noteworthy to mention that only medications which are part of the 
Régie d’assurance maladie du Québec (RAMQ) 210 are covered by the Prescription Drug 
                                                             
207  “Drug Benefit Programs”, online: <http://www.drugcoverage.ca/en-ca/Provincial-
Coverage/manitoba/drug-benefit-programs>. (Accessed April 4 2016) 
208 Supra note 203. 
209  Loi sur l’Institut national d’excellence en santé et en services sociaux, chapitre I-13.03, Online: 
https://www.inesss.qc.ca/fileadmin/doc/INESSS/DocuAdmin/Lois_Politiques/Loi_INESSS.pdf (Accessed 
April 5 2016). 
210 An Act respecting the Régie d’assurance maladie du Québec, CQLR, chapter R-5.   
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Insurance plan, which was devised in 1997 for the needs of the health of the population 
of Québec211:  
The purpose of the basic plan is to ensure that all persons 
in Québec have reasonable and fair access to the 
medication required by their state of health. 
To that end, the plan provides for a minimum level of 
coverage for the cost of pharmaceutical services and 
medications, and requires a financial participation on the 
part of persons or families covered by the plan depending, 
in particular, on their economic situation212.  
 
 
 
Needless to say that the RAMQ, under the authority of the Minister of Health 
and Social Services, “administers the public health and prescription drug insurance 
plans: it informs the public, manages the eligibility of persons, remunerates health 
professionals and ensures the secure flow of information213”.  Everyone in Québec must 
be covered by the Prescription Drug Insurance plan which can either be private or 
public214. INESSS must provide an updated list of medications according to section 60 
of the Prescription Drug Insurance plan215. 
The process (see Summary of process for the registration of a medication on the 
RAMQ list in Figure 8) begins with the drug manufacturer submitting an application 
containing all pertinent information concerning studies performed by its company. 
INESSS will then evaluate this application and rely on other complementary studies 
                                                             
211 Act Respecting Prescription Drug Insurance (RSQ, ch. A-29.01), s. 1. 
212 Ibid. s. 2. It is important to highlight the fact that this article mentions that only a minimum level of 
coverage for the cost of pharmaceutical services and medications is covered by the plan leading to a major 
dichotomy with orphan drugs for rare diseases. 
213  Régie de l’assurance maladie du Québec, Government of Québec, “Mission | RAMQ”, online: 
<http://www.ramq.gouv.qc.ca/en/regie/Pages/mission.aspx> (Accessed April 6 2016); See also supra note 
210.  
214 Supra note 211, ss. 15,15.1,16-18,78. 
215  Ibid, s. 60; Regulation respecting the list of Medications covered by the basic prescription drug 
insurance plan, CQLR c A-29.01, r 3. 
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during the process. If the application is judged to be receivable, INESSS inscribes a 
worksheet with the medication to be evaluated on its website for 30 days in order to 
receive comments from patients, health professionals, and the population in general. All 
comments are provided to the members of the Scientific Committee called “Comité 
scientifique de l’évaluation des médicaments pour des fins d’inscription” (CSEMI) who 
will proceed with the evaluation. All drug applications are evaluated by professionals at 
INESSS and also by the Scientific Committee. This Committee is comprised of 
physicians/clinicians, pharmacists, ethicists, managers and members of the general 
public, as well as pharmacoeconomists. Often, external expertise is requested. INESSS’s 
analysis is based on the following criteria:  
(1) the reasonableness of the price charged; 
   (2) the cost-effectiveness ratio of the medication; 
(3) the impact that entering the medication on the list will have on the 
health of the general public and on the other components of the health 
and social services system; and 
(4) the advisability of entering the medication on the list, given the 
purpose of the basic prescription drug insurance plan216. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                             
216 Supra note 209 s.7. 
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Figure 8. Summary of the Process for the Registration of a Medication on the RAMQ 
List217. 
 
 
  
       Source: INESSS 
 
After a rigorous evaluation, the Committee provides its recommendations to the Board 
of directors at INESSS, and then to the Minister who decides whether to approve the 
updated list:  
 […] Only a medication from a manufacturer accredited by 
the Minister may be considered for entry on the list. 
However, the Minister may enter on the list the medication 
of a manufacturer who has not been granted accreditation 
                                                             
217  Institut national d’excellence en santé et en services sociaux Government of Québec, “INESSS: 
Evaluation process and criteria”, online:  
<https://www.inesss.qc.ca/fileadmin/doc/INESSS/Inscription_medicaments/Processus/Evaluation-
medic_EN_28082013.pdf>. (Accessed April 6 2016). 
  
 
 
68 
if the medication is unique and essential. […]218.  
 
The List of Medications comprises exceptional medications, such as orphan 
drugs, “for which coverage is provided under the basic plan only in the cases, on the 
conditions or for the therapeutic indications determined in the regulations of the Minister 
and therefore, recognized by INESSS. These conditions may vary depending on whether 
coverage is provided by the RAMQ or under a group insurance or an employee benefit 
plan”219. Certain drugs for rare diseases are on the list of exception drugs (médicaments 
d’exception) administered by the RAMQ which gives the right to reimbursement. These 
drugs must also meet very specific criteria. Physicians wishing to prescribe exception 
drugs can do it through a specific code. It appears that for all persons who are covered 
by the RAMQ, the number of prescriptions of “médicaments d’exception” went from 
342,866 in 1998 to 8,6 million in 2010, generating an increasing cost by the RAMQ 
from 32 to 623 million Canadian dollars220. Therefore, between 1998 and 2010, there 
was a substantial increase of approximately 1500%, which was higher than the 200% 
growth of drug expenditure for that same period of time221. 
If one or more drugs are not featured on the List of Medications, there is also a 
program called “Patient d’exception”, which allows under exceptional circumstances, 
patients to have reimbursement of drugs. This program is considered as a last resort for 
debilitating medical conditions significantly affecting the health of a patient. In order to 
                                                             
218 Supra note 211, s. 60. 
219  Institut national d’excellence en santé et en services sociaux, Government of Québec, “INESSS: 
Exceptional Medications”, online: <https://www.inesss.qc.ca/en/activities/drug-products/evaluation-
process-and-criteria/exceptional-medications.html>. (Accessed April 4 2016) 
220  Mélanie Bourassa Forcier, Projet de viabilité - Contrat pour l'accès aux médicaments et pour 
l'innovation au Québec (CAMI), CIRANO Project Reports, Centre Interuniversitaire de Recherche en 
Analyse des Organisations (CIRANO), (2014) at 16 
221 Ibid. 
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benefit from the program, the attending physician must fill an authorization request. The 
expert committee in pharmacy of the RAMQ then evaluates the request on the basis of 
specific criteria222.  Over the years, there also seems to have an increase in cost for 
“Patient d’exception”. In 1998, the cost was $1,000,647 for 3,625 patients whereas it 
$53,554,155 for 13,975 patients in 2009223. It seems that there is an increased need for 
programs such as “Patient d’exception”. However, the RAMQ can still refuse an 
authorization for a specific drug. The patient may then ask for a revision while providing 
new elements to consider, or if it does not suffice, the decision can be upheld at the 
“Tribunal administratif du Québec”224.  
Nevertheless, an innovative report published in 2012 suggested possibilities for 
governmental authorities, public insurers, to conclude “Product Listing Agreements 
(PLA) with pharmaceutical companies in order to reduce clinical and/or financial 
uncertainties regarding reimbursement of drugs”225.  In November 2011, a pilot project 
suggested by INESSS to evaluate the possibilities of such an agreement was done with 
three anti-cancerous drugs. INESSS’s conclusions submitted to the Ministry of Health 
after thorough evaluation of this pilot project showed an opening for future risk sharing 
agreements between the government and pharmaceutical companies226. It should be 
noted that financial agreements between the Minister of Health and Social Services and 
                                                             
222 GG c Québec (Régie de l’assurance maladie du Québec), 2010 QCTAQ 06450. 
223 Supra note 220 at 17-18 
224  Institut national d’excellence en santé et en services sociaux Government of Québec, “Patient 
d’exception | RAMQ”, online: <http://www.ramq.gouv.qc.ca/fr/professionnels/medecins-
omnipraticiens/medicaments/medicaments-patient-exception/Pages/patient-exception.aspx>.(Accessed 
April 5 2016); M.R. c. Régie de l’assurance maladie du Québec, 2006 C, CanLII 74661 (QC TAQ); HD c. 
Québec (Régie de l’assurance maladie), 2013, CanLII 19946 (QC TAQ); G.J. c. Québec (Régie de 
l’assurance-maladie du Québec), 2004 C, CanLII 66734 (QC TAQ)  
225 Mélanie Bourassa Forcier, Ententes entre gouvernements et compagnies pharmaceutiques (Montréal, 
Québec: CIRANO, 2012).  
226 Ibid at 25. 
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pharmaceutical companies are made possible according to the RAMQ227, whereas 
clinical agreements would be possible for medications provided in hospitals according to 
the Loi sur les services de santé et services sociaux228. 
A specific mandate was given to INESSS in 2010 in Québec to establish a 
strategy for the management of rare diseases229. During the same year, the Minister of 
Health and Social Services, Yves Bolduc stated during the congress for the 
“Regroupement québécois pour les maladies orphelines” (RQMO): 
Quand on devient malade, on n’en est pas responsable, 
surtout quand c’est une maladie génétique. Les Québécois 
et Québécoises ont le droit de recevoir les traitements qu’il 
leur faut, quelle que soit leur maladie. Comme société, on 
est capable de l’assumer: ce sont des maladies rares, les 
traitements coûtent plus cher, mais il y en a moins. C’est 
une question d’équité 230. 
 
             At the same time, a committee was supposed to be implemented to work on 
strategies for rare disorders in Québec. Unfortunately, this committee never saw the light 
of day. It seems that nothing has changed in the last 6 years regarding strategies for 
orphan diseases and treatment with orphan drugs. The process to access orphan drugs is 
still the same in Québec and there is no improvement to make it simpler for patients with 
rare diseases and their physicians.  
 
                                                             
227 Supra note 210 s. 52.1. 
228 Act respecting health services and social services, c. S-4.2, s. 118. 
229 Supra note 26 
230 Ibid at 3. 
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1.2.6 In British Columbia 
  
            British Columbia has a general reimbursement drug process called BC 
Pharmacare. Orphan drugs are part of a special program under the authority of the 
“Expensive Drugs for Rare Disease Advisory Committee (EDRD),” with a role to 
provide recommendations to the Minister of Health about reimbursement. EDRD is a 
multidisciplinary committee comprised of doctors, pharmacists, ethicist, health 
economics and representatives from provincial drug plan. The Minister has the final 
decision about reimbursement of these orphan drugs231.    
In practice, and as discussed with a BC physician treating patients affected with 
rare diseases, it is a complicated process in that none of the drugs are listed on the 
provincial formulary other than Myozyme for infantile Pompe disease (not late onset), 
which means they are not reimbursed for all cases. However, all the drugs, except the 
Morquio IVA drug, are being reimbursed through the provincial EDRD program. There 
are treatment guidelines (basis of criteria) for all drugs and if a physician brings a patient 
to the committee, they are reviewed using those guidelines, and then the committee 
makes a recommendation to the province as to whether or not they should funded. This 
allows physicians to still advocate even if the patient is not likely to benefit from the 
treatment. This removes the physician from the need to be a gatekeeper. Most of all, the 
committee recommends to fund and the province then funds. The cases that were turned 
down by the committee were all cases that wouldn't have benefited from therapy. The 
process works well although it generates extensive paperwork. It seems that the BC 
                                                             
231 Supra note 167. 
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process is well accepted by involved physicians due to this mechanism which allows 
both advocacy and reason at the same time. At the present time, CFDI Fabry disease 
patients do not go through this committee, but likely will in the future considering they 
are treated on the basis of criteria. 
 
 
1.2.7 Inequities between Provinces for Rare Disease Coverage   
  
 Pompe disease is a rare lysosomal storage disorder due to an enzyme deficiency 
leading to accumulation of glycogen in the lysosomes in body cells. The clinical 
manifestations of the disease lead to a broad spectrum with progressive muscle 
weakness, with an eventual loss of muscle function, respiratory and heart problems 
causing death 232 . The incidence is about 1/40,000 and is characterized by marked 
phenotypic and genotypic heterogeneity. Treatment is possible with enzyme replacement 
therapy of the drug Myozyme® (Genzyme, a Sanofi Division) infused every two weeks.  
This disease has recently been the subject of recent media attention because it 
affected two brothers living in different Canadian provinces: one brother, who is 64 
years old, lives in Manitoba where government reimbursement of Myozyme is possible, 
and his brother, who is 61 years old, lives in British Columbia (BC) where the drug is 
not covered by the BC Health system233. The cost of Myozyme may reach $600,000 
CAD per year/patient. The brother who lives in British Columbia has stated that the 
                                                             
232 Barry J Byrne et al, “Pompe disease: design, methodology, and early findings from the Pompe 
Registry” (2011) 103:1 Mol Genet Metab 1. doi: 10.1016/j.ymgme.2011.02.004. 
233 Ben Spurr, “Inequities between provinces in treating rare diseases | Toronto Star”, thestar.com, online: 
<https://www.thestar.com/news/canada/2016/02/08/inequities-between-provinces-in-treating-rare-
diseases.html>. (Accessed April 20 2016). 
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system is unfair because the same type of treatment should be offered in both provinces. 
A spokesperson from the Ministry of Health in British Columbia would not comment on 
this specific case but stipulated that “the Ministry considers requests to cover Myozyme 
on an exceptional last-resort, case-by-case basis” and that some patients have received 
coverage of the drug234. The Manitoba government has stated that at least five persons 
affected with Pompe disease have received full reimbursement of Myozyme. The lack of 
consistency in the reimbursement programs throughout Canada is a major issue 
considering the consequences on the health of Canadian citizens affected with rare 
diseases. Such inequities may be encountered with patients having to move from one 
province to the other.  
A similar case emerged in relation to cystic fibrosis and the orphan drug 
Kalydeco® (ivacaftor) with a cost of $1,600 a day per affected patient. Alberto Galina, 
the project director of Million Dollar Meds, a collaborative synergy between the 
University of British Columbia’s graduate school of journalism and the school's 
pharmaceutical sciences department, has investigated the reimbursement of this drug 
which is accepted in BC but not in Ontario235. The disparity between provinces and the 
lack of a national framework has led to inequities among Canadian citizens. Table 2 
shows drugs for rare diseases for different provinces and their provincial coverage as 
part of a general reimbursement process. Moreover, we would like to emphasize that 
some of these drugs are accepted on a case-by-case basis by provinces according to their 
own conditions.  
                                                             
234 Ibid.  
235 CBC News British Columbia, High drug prices for rare diseases subject of UBC journalism project, 
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Table 2. Drugs for Rare Diseases for Different Provinces and their Provincial 
Coverage as Part of General Reimbursement Processes.  
 
: Covered by the province; X: Not covered by the province; ---: No information found 
Source: Our analysis 
 
            According to the universality criterion for the health system in Canada, all 
insured residents are entitled to the same level of health care, on uniform terms and 
conditions, to the publicly funded health services covered by the provinces236. Will there 
be a uniformity in the availability and accessibility of orphan drugs across Canada? Will 
the treatment of a life-threatening disorder be discontinued because the orphan drug is 
not reimbursed in a specific province? Will the patient have to go through a Kafkaesque 
bureaucracy to have his medication reimbursed despite the delays and the major risks on 
his health? One must conclude that inequities arise due to different orphan drug 
strategies for each province, as well as different reimbursement policies, and in the end, 
different treatment options for patients.  
 
                                                             
236  “The Health of Canadians: The Federal Role - Final Report”, online: 
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2. What Has Been Done About Orphan Drugs Elsewhere 
 
Even in 2016, Canada is still reluctant to address problems regarding orphan drugs. 
Indeed, considering the striking need for financial support in research regarding rare 
diseases, there is limited interest for pharmaceutical companies to invest in R&D in 
Canada237. Furthermore, differences between provinces in terms of drug reimbursement 
have generated discrepancies for Canadians to have access to orphan drugs. On the other 
hand, some countries have developed policies to address the same issues decades ago. 
The US, Japan, Australia and the European Union (EU) were proactive in adopting 
specific legislation for orphan drugs. The focus of this work will be mainly on orphan 
drug policies developed by the US and the EU. 
 
2.1. The US Orphan Drug Act 
 
The US were pioneers in creating a legal framework in the subject of orphan 
drugs. The efforts to legislate Orphan drugs took a faster turn when media started to 
reveal the exasperation of patients who, due to market demands, were seeing their last 
therapeutic resort held hostage238. This media frenzy was brought to the attention of the 
famous television actor Jack “Quincy” Klugman by his brother, Maurice Klugman239. In 
1981, Maurice, a writer who himself suffered from a rare cancer, wrote an episode of 
“Quincy” about Tourette’s syndrome and the orphan drug problems 240 . Tourette’s 
syndrome (TS) is a neurological chronic disorder with early symptoms occurring in 
                                                             
237 Supra note 49. 
238 Asbury, supra note 9 at 111. 
239 Joshua Green, “Jack Klugman’s secret, lifesaving legacy”, The Washington Post (25 December 2012), 
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240  Quincy, M.E. Jeffrey Hayden, Season 6, episode 14, Seldom Silent, Never Heard (1981). 
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childhood characterized by involuntary movements and repetitive vocal tics241. One of 
the treatments for TS is Pimozide, a neuroleptic drug often used to treat psychiatric 
disorders. TS was at the forefront of the media because it was not available in the US but 
available in Canada in 1980242. At this time, Representative Henry Waxman (D) of 
California, chairman of the Subcommittee on Health and the Environment of the House 
Committee on Energy and Commerce, invited Jack Klugman to testify before the US 
Congress in order to build momentum for a bill. The hearing was held in the upcoming 
days after the “Quincy” broadcasting of the orphan-drug episode. Jack Klugman did as 
he had done in the episode, arguing on behalf of legislation for orphan drugs. In fact: 
 […] in a brilliant instance of life imitating art, Klugman 
took industry and government to task in full public view 
before a crowded press section and television cameras. 
Federal and industry orphan-drug efforts immediately 
began to speed up. Before this dramatic stimulant to public 
awareness of orphan drug problems, however, much had 
transpired to lay a foundation for action”243.  
 
Even if the Waxman bill sailed through the House, it had very little chance to pass the 
Senate since a number of key senators were opposed to the tax credit provision. 
Klugman and his “Quincy” team then wrote another episode about orphan drug 
legislation, which aired at the time the bill was being examined by the Senate. This time, 
the episode featured a fictitious heartless senator, who was deferring an orphan drug bill. 
Quincy confronted the heartless senator in his office while showing him, out the 
window, more than 500 patients affected with rare diseases marching toward the Capitol 
                                                             
241  “Tourette Syndrome Fact Sheet”, online: <http://www.ninds.nih.gov/disorders/tourette/detail 
_tourette.htm>. (Accessed June 4 2016) 
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and having signs such as “We Want the Orphan Drug Act”244. The “Quincy” episodes 
made a positive difference in the debate since, it seems that Klugman’s appearances and 
dedication were the single most significant catalyst to stimulate public policy in the 
whole orphan drug saga245.  
Thanks to Klugman and the National Organization for Rare Disorders (NORD), 
a federal voluntary health organization, on January 4 1983, President Ronald Reagan 
signed the Orphan Drug Act creating incentives for pharmaceutical manufacturers to 
develop drugs for rare diseases. The Orphan Drug Act of 1983 provided tax and market 
incentives, however it only applied to drugs and biologicals246. At the time, the strategy 
behind the legislation in order to receive an orphan designation was that: “[…] there is 
no reasonable expectation that the cost of developing and making available in the United 
States a drug for such disease or condition will be recovered from sales in the United 
States of such drug”247.  
2.1.1 Incentives Provided by the Orphan Drug Act 
Sponsors who, under FDA guidelines, precisely requested and were granted an 
orphan designation could receive incentives provided by the Act. It then received a 
seven-year period of marketing exclusivity effective on the date of FDA approval. This 
being said, multiple sponsors could receive designation for the same orphan drug (same 
condition). However, on a first come, first served basis, it was implemented that just the 
first sponsor received exclusive rights to market the orphan drug and only after the 
                                                             
244 Quincy, M.E. Georg Fenady, Season 8, episode 3, Give Me Your Weak (1982). 
245 Asbury, supra note 9 at 125. 
246 Orphan Drug Act, supra note 18. 
247 Ibid s. 526(2). 
 
  
 
 
78 
seven-year period has expired can another version of the same drug be approved by the 
FDA (that also included generic applications). The pharmaceutical company could also 
receive, as a general rule, a tax credit “for the taxable year an amount equal to 50 percent 
of the qualified clinical testing expenses for the taxable year 248 ”. There were also 
incentives in terms of research grants each year for expenditure of four million US 
dollars for clinical testing of orphan treatments. Initially, the ODA had not defined a US 
prevalence for what it considered as a rare disease. The closest description of a type of 
rare diseases or conditions was stated by the Congress and found in Section 1(b)(1):  
there are many diseases and conditions, such as 
Huntington's disease, myoclonus, ALS (Lou Gehrig's 
disease), Tourette syndrome, and muscular dystrophy 
which affect such small numbers of individuals residing in 
the United States that the diseases and conditions are 
considered rare in the United States;249  
 
Congress already recognized the small number of individuals as a challenge. In order to 
designate a drug as an orphan drug and implement Section 526 of the ODA, the interim 
guidelines were decided with a prevalence of less than 100,000 people in the United 
States250. There were discussions, later on, whether to include a definition for “rare 
disease” in the ODA instead of guidelines. Advocacy groups raised public concerns to 
increase the number of orphan drugs covered for rare diseases. It was then agreed by the 
Congress, under the Amendments of 1984, to clarify for pharmaceutical companies, the 
approval by the FDA of the designation of an orphan drug251. Rare disease or condition 
was defined as "which (A) affects less than 200,000 persons in the United States, or (B) 
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affects more than 200,000 in the United States and for which"252 “there is no reasonable 
expectation that the sales of the drug treatment will recover the costs”253. Throughout the 
years, a number of incentive mechanisms and initiatives have been implemented to 
improve the initial Act. In 1990, an effort by the Congress to pass legislation to 
differentiate orphan drug development from others in terms of commercial value was 
vetoed by President Bush254. In 1992, Congress continued to support incentives for 
orphan drug and biologic product review by waving the filing fees255. In 2002, the Rare 
Disease Act256 and Rare Disease Orphan Product Development Act257 were signed into 
law. The NIH Office of Rare Diseases (now the Office of Rare Diseases Research) was 
given the mandate “to support regional centers of excellence for clinical research into, 
training in, and demonstration of diagnostic, prevention, control, and treatment methods 
for rare disease”258. Since 1983, the US orphan drug model succeeded in developing and 
marketing rare diseases for more than 400 drugs and biologic products, whereas only 10 
products were approved before that 259 . Arguments against the ODA after its 
implementation were not frequent. In fact foreign countries have tried to emulate it260. 
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Furthermore, patient access to orphan drugs has hardly been denied261. That said, the law 
is far from perfect and brings its own problems and caveats.  
2.1.2. The US Reimbursement Procedure 
Although the access to orphan drugs has hardly been denied, the reimbursement 
procedure in the US is another matter. Payers have no distinct reimbursement process 
for orphan drugs compared to non-orphan drugs. As a result, the pattern for coverage 
plans differs greatly from one orphan drug to the other. Payers have traditionally 
accepted to reimburse orphan drugs without considerable restrictions262. However, due 
to the high prices of orphan drugs, payers have transitioned from fixed co-payments per 
prescription to co-insurance leaving the cost burden to patients263. “Medicaid coverage 
and reimbursement policies for orphan drugs vary from state to state. Medicare patients 
seeking orphan drugs face limitations on reimbursement and potentially high out-of-
pocket costs”264. In the US, patients affected with rare diseases are consequently seeking 
for Patient-assistance programs offering financial assistance in order to afford their 
orphan drugs 265 . It seems that management tactics that payers apply, such as co-
insurance, are not only for orphan drugs but for non-orphan drugs as well -creating 
general concerns to ensure patient access.  
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2.1.3. The Salami Slicing Effect  
While the ODA created opportunities in research and drug development, 
pharmaceutical companies also exploited marketing strategies to increase profit. A good 
example is salami slicing, which “has to do with taking a drug for a particular indication 
that does not qualify for orphan drug designation and slicing that indication into a 
number of narrower ones which do qualify. Thus, a manufacturer may be able to obtain 
broad, but unwarranted, exclusivity for its drug”266. 
The salami slicing effect for drug development approach also implies that: 
[…] companies target “rare subsets of common diseases to 
acquire orphan status for many similar indications for a 
single drug. In doing so, companies can profit from a 
larger patient population while retaining orphan drug 
incentives, but without providing a commensurate increase 
in patient access to rare disease treatments267. 
 
 
An example of a stratification of a disease is breast cancer, which is not considered a 
rare disease268. In fact, it is a practical example of the salami effect since researchers 
have recently found a rare subset of breast cancer patients, and these patients respond 
differently to cancer treatment approaches 269 . The authors suggest that patients be 
stratified into subtypes according to alterations in the genome which might lead to 
increase efficacy of therapy and a better understanding of the pathophysiology of the 
disease. The treatment for this rare subset of breast cancer patients can therefore qualify 
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267 Westerly Luth, Sarah Ali-Khan, Tania Bubela, “Canada’s Orphan Drug Framework: Lessons from the 
United States, Europe and Japan”, PACEOMICS, Oct. 2015, at 6, online: <http://paceomics.org/wp-
content/uploads/2015/10/Canadas-Orphan-Drug-Framework.pdf> (Accessed June 4 2016) 
268 Supra note 35 at 758. 
269 Brian D Lehmann & Jennifer A Pietenpol, “Identification and use of biomarkers in treatment strategies 
for triple-negative breast cancer subtypes” (2014) 232:2 J Pathol 142. doi:10.1002/path.4280. 
  
 
 
82 
for an orphan drug designation since it meets the criteria.  
A second issue arising from the salami slicing effect regards a drug having 
indications for both rare and common diseases. A clever marketing strategy would be for 
the pharmaceutical company to obtain the designation for the orphan drug in the first 
instance in order to profit from all the incentives offered, and afterwards, market the 
drug for common diseases270. Unfortunately, patients affected with common diseases 
will not receive the drug at the same time as those with rare diseases, which presents a 
major ethical problem. The strategy being that companies will first benefit from the 
orphan drug incentives authorized by the ODA, and when the designation is accepted, 
companies will apply for the larger market.  
 As often said: “Nothing is perfect”. The ODA has increased the number of 
marketed orphan drugs for American citizens over the years. On the other hand, it has 
also paved the way for clever marketing strategies that in the end are not always good 
for patients. Originally, the Orphan Drug Act aimed at providing incentives for 
pharmaceutical companies to develop drugs for rare diseases. Nowadays, with orphan 
drugs becoming remarkably profitable 271 , and with pharmaceutical companies 
dominating the market with their specific drugs, it might be imperative that the Orphan 
Drug Act be updated to prevent a monopolization of the market by large pharma.    
 
2.2 The European Legislation 
In Europe, the slow development of orphan drug legislation was not due to a lack 
of interest, but mainly because the EU had to be “created” with legislation, rules, 
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agreements, and infrastructures established between all countries272. Now, the European 
Union is comprised of 28 European countries working in partnership economically and 
politically273. It is a unique association where these countries have partly renounced their 
sovereignty to EU institutions. Numerous decisions are thus made at the European 
level274.  
Historically, European Organization for Rare Diseases (EURORDIS), a 
federation of patient’s associations which is active in improving the quality of life of 
patients affected with rare diseases, 275  played a major advocacy role for the 
implementation of the legislation.  
The European Commission has estimated that 5,000 to 8,000 rare diseases exist 
in the EU and that 27 to 36 million people might be affected276. On December 16 1999, 
the European Parliament and the Council of the European Union passed a law on orphan 
medicinal products (same as the term orphan drug)277. This Regulation:   
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[…] sought to protect the interests of RDs patient 
community by incentivising research and orphan drug 
development. Recognising that RD patients’ basic needs 
were not being met, the EU adopted a rights-based 
approach for RD patients, underlining that they ‘should be 
entitled to the same quality of treatment as other patients’. 
The Regulation aims to regulate and encourage innovation 
in the field of orphan diseases. It does so by establishing ‘a 
Community procedure for the designation of medicinal 
products as orphan medicinal products and to provide 
incentives for research, development and placing on the 
market of designated orphan medicinal products’ 278 .  
  
 
 
The European Union judiciously decided on a uniform approach for all countries 
when they passed the orphan medicinal product regulation. The EU wanted to benefit 
from the advantages of the broadest possible market while avoiding the dispersion of 
resources which are often scarce. Global contribution from countries also help in 
coordinating proactive actions directly aimed at the well-being of rare disease patients.  
Therefore, following the signing of the Regulation (EC) No 141/2000, the 
community-wide regulations on orphan medicines came into force in April 2000 with 
the Regulation (EC) No 141/2000 of the European Parliament and of the Council and the 
implementing Commission Regulation (EC) No 847/2000 279 . The purposes of the 
legislation provided “ incentives for the research, development and marketing of orphan 
medicinal products that the pharmaceutical industry would be unwilling to develop 
                                                                                                                                                                                   
sufficient return to justify the necessary investment;and (b) that there exists no satisfactory method of 
diagnosis, prevention or treatment of the condition in question that has been authorised in the Community 
or, if such method exists, that the medicinal product will be of significant benefit to those affected by that 
condition. 
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under normal market conditions”280. The aims were quite similar to the Orphan Drug 
Act.  
However, a key point in the legislation concerns the prevalence of individuals 
affected with rare diseases which was clearly defined by the EU (and is different from 
the US) as follows: 
[…] a prevalence of not more than five affected persons 
per 10 thousand is generally regarded as the appropriate 
threshold; medicinal products intended for a life-
threatening, seriously debilitating or serious and chronic 
condition should be eligible even when the prevalence is 
higher than five per 10 thousand281; 
    
A centralized Community procedure is used to introduce an orphan drug onto the 
market via article 7 of the Regulation (EC) No 141/2000282. The process for obtaining 
“orphan-medicinal-product designation” must respect a strict timetable which begins 
with a 3-month notification of intention to submit, followed by a 2-month pre-
submission meeting where validation questions can be negated, and then the submission 
itself. The application (with specific forms and formatting required) goes through a 
scientific evaluation and review in a 90-day procedure. The application form requires 
details of the condition targeted, the proposed orphan drug indication, the medical 
plausibility, the justification of the life threatening nature of the condition, as well as the 
reference documentation, the information from databases, the prevalence and the 
incidence of the disease. It also requires the potential return on investment, the existence 
of other methods of diagnosis, prevention and treatment and as to why they are not 
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satisfactory. In addition, a justification of significant benefit, a description of the stage of 
development of the product and details of current regulatory and marketing history is 
also requested. All of this is accompanied by a complete scientific bibliography. The 
application is sent by individuals or companies to the European Medicines Agency 
(EMA, the Agency) via the Committee for Orphan Medicinal Products (COMP). This 
Committee is nominated by the European Commission. It is comprised of experts 
appointed by Member States, members on the EMA’s recommendation, patients’ 
organization representatives and non-voting COMP members283. The involvement of 
EURORDIS is also important at this stage of the application because “it facilitates the 
preparation of European Public Assessment Reports (EPARs) in the review process of 
marketing authorization applications of new medicines for rare diseases”284. In addition, 
EURORDIS takes part in reviewing public summaries of COMP opinion documents for 
orphan drug applications 285 . It terms of practical impact, this demonstrates the 
involvement of patients’ organizations in the orphan drug process.  
A single marketing authorization is granted and valid throughout the EU, 
offering the largest possible EU market. It is worth noting that this centralized process is 
now obligatory for orphan medicinal products since 2005286.  
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2.2.1 Incentives Provided by the Regulation (EC) No 141/2000 
 
  Incentives for the development of drug treatments for rare diseases in the EU are 
similar to the ones in the US. Market exclusivity for the EU is 10 years, plus an 
additional 2 years of pediatric exclusivity for studies that qualify, whereas it is only 7 
years in the US. The EU market exclusivity “prevents another application for a market 
authorization (MA) (and also the extension of an existing MA) for the same therapeutic 
indication, for a similar medicinal product”287. The market exclusivity is an important 
incentive but it comes into effect only when the MA is finalized in the EU. As in the 
US, there is an assistance for protocols and follow-up on the procedure, a 
reduced/waived regulatory fees, and a tax credit on clinical trials. However, the EU does 
not provide grant programs to subsidize research, which is a major difference from the 
US288. 
Five years after the implementation of the EU legislation (April 2000 to April 
2005), there were 458 applications submitted to obtain an orphan designation. Of these, 
268 products received a designation for over 200 different rare conditions. To clarify, 
submitting an application for an orphan drug designation provides a special status to a 
drug to treat a rare disease. Overall, the legislation for orphan drugs seems to be 
functioning well with the incentives provided. The number of applications has increased 
regularly from 2000 to 2004. In 2004, the number of approvals (75) was nearly 3 times 
the number of withdrawals (22).    
A more recent report revealed that from 2000 to September 2015, the EMA has 
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received 2,302 applications for orphan designations, and of these the European 
Commission approved 1,544. Moreover, as of 2015, “1,227 orphan designations are 
active, as some decisions have expired and some products have been withdrawn by the 
sponsor”289. It might seem to be a high number of designations, but only 1% of rare 
diseases are covered by authorized drugs290. Data in Figure 9 aims to show a global 
major difference for the ratio of total designation/approval rate between US and EU. It 
shows that 14.9 % of orphan drug designations are approved in the US, whereas only 
6.4% are approved in the EU.  
 
Figure 9. Comparison between Total Orphan Drug Designations and Approval in the US 
and EU  
 
 
    Source: Our analysis from Hall and Carlson’s data.   
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            Again nothing is ideal in these complex processes and some aspects need to be 
improved. Negative comments about the long 6-month EU timeframe and the 
complexity of the process during the overall application procedure have been 
criticized291.  
 
2.2.2 The EU Reimbursement Procedure 
 
The reimbursing procedure is also a major issue in the EU as it keeps patients 
from obtaining access to the orphan drug. Let us not forget that the last phases of the 
development and marketing of a drug is the patient gaining access to the orphan drug, 
receiving the drug as soon as possible after approval, and that the reimbursement of the 
cost be covered292. In EU, the reimbursement process differs according to members of 
the EU. In some cases “reimbursement is provided on approval, whereas in others, the 
procedures might take up to 4 years, while requiring the company to provide the product 
on a compassionate use basis in the meantime, due to the serious nature of the diseases 
to be treated”293. In some EU countries such as Sweden and Spain, the complexity of the 
process lies in the fact that the responsibility for providing healthcare has been 
transferred to regional authorities. Therefore, there might be disparities between patients 
to access the orphan drug even in different regions of the country, as in Canada, making 
it particularly complicated for them294. Another problem is that the Health Technology 
Assessment procedures are not well-adapted and they sometimes do not respect the 
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“payer’s criteria” for orphan drug reimbursement. This is mainly due to the high cost of 
the drugs, but also related to issues in showing benefits of the treatment (referred as 
clinical added value)295.      
Interestingly, the FDA and EMA have recently started working together to 
devise joint procedures for orphan drug designations. This has led to a uniform and 
common application form called “Common EMEA/FDA Application Form for Orphan 
Medicinal Product Designation” which is available for pharmaceutical companies 
(sponsors) applying for an orphan drug status in EU, as well as in the US. Moreover, 
upon common agreement, only one annual report may be submitted by sponsors for 
orphan drugs designated for both entities in order to simplify the process and eliminate 
the duplication of efforts296.  
Figure 10 shows comparisons between orphan drug designations and orphan 
drug approvals on a yearly basis in the US and EU since the inception of legislation in 
1983 and 2000, respectively. Over the years, the increasing trend for orphan drug 
designations is similar for EU and US, whereas the orphan drug approvals is always 
higher in the US on a yearly basis (Figure 10). 
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296 Jyoti Tiwari, “Navigating through orphan medicinal product regulations in EU and US--similarities and 
differences” (2015) 71:1 Regul Toxicol Pharmacol 63; The annual report “provides information on the 
status of the development of orphan medical products, including a review and status of ongoing clinical 
studies, a description of the investigation plan for the coming year, any anticipated or current problems in 
the process, difficulties in testing, and any potential changes that may impact the product’s designation as 
an orphan product”. “Press Announcements - International Collaboration: FDA and European Medicines 
Agency Agree to Accept a Single Orphan Drug Designation Annual Report”, online: 
<http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm202300.htm>.(Accessed June 8 
2016) 
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Figure 10. Yearly Comparison of Orphan Drug Designations and Orphan Drug Approval 
for EU and US  
 
    Source: J. Tiwari, Regulatory Toxicology and Pharmacology 2015   
 
3. Orphan Drug Framework Proposal for Canada: A Possible Solution? 
 
A Canadian study recently reported data on the changes happening in Canada 
regarding access to US-approved orphan drugs from 1997 to 2012. Their evaluation of 
data focused on regulatory and temporal access to orphan drugs. Their results have 
shown a paradigm shift in Health Canada’s policies. In fact, in 1997, while 63% of US-
approved orphan drugs received regulatory approval in Canada, the study reveals an 
increase to 74% from 1997 to 2012. “The majority of those drugs (150 of 206, or 73%) 
were approved for the same indication as the corresponding US orphan drugs” 297 . 
Moreover, their results revealed that the time to review an application in order to have 
access to an orphan drug is significantly longer in Canada (423 days) compared to the 
US (341 days). However, Canada does not have the same resources as the FDA to 
                                                             
297 It should be mentionned that the US-approved orphan drugs that did not receive regulatory approval in 
Canada are not part of the 74%, but were, and always are, available through the Special Access Program. 
Matthew Herder & Timothy Krahn, “Some Numbers behind Canada’s Decision to Adopt an Orphan Drug 
Policy: US Orphan Drug Approvals in Canada, 1997–2012” (2016) 11:4 Healthcare Policy | Politiques de 
Santé 70 at 75.  
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accelerate the process298. Nevertheless, there seems to be a change in Health Canada’s 
policy and the regulatory approval of US-approved orphan drugs. Why has there been 
such a shift? We propose different reasons which might explain these changes.   
First, the global growth of the orphan drug market has been regularly expanding 
(See Figure 4). Accordingly, the number of applications for the approval of orphan drugs 
for rare diseases has increased considerably over the last 20 years, creating a greater 
burden on the evaluation process.  There is thus a willingness from Canadian authorities 
to rely more and more on the US, given the availability of their US-approved orphan 
drugs.   
Moreover, we have earlier emphasized that in 2013, a total of 431 drugs were 
part of the SAP list in Canada. We also revealed a major discrepancy between the total 
number of SAP orphan drugs (n=127) in Canada and the ones already approved in the 
US (n=90) and Europe (n=62). We can assume that since there is legislation for orphan 
drug approvals in US and Europe, Health Canada has probably reoriented its policies 
over the years to facilitate regulatory approval of orphan drugs in Canada by relying 
again on the US-approved orphan drug procedure. Therefore this might explain the 11% 
increase of US-approved orphan drugs that received regulatory approval in Canada over 
the last 15 years.  
Pressure from advocacy groups, such as CORD, is focused on the affordability 
and sustainability of access to orphan drugs299. CORD’s approach mirrors the already 
                                                             
298 Ibid at 78.  
299 Canadian Organization for Rare Disorders “CORD: Assuring Affordability and Sustainable of Access 
to Orphan Drugs” (2015) online : <http://new.raredisorders.ca//content/uploads/CORD-Assuring-
Affordability-and-Sustainable-of-Access-to-Drugs-for-Rare-Diseases-copy.pdf> (Accessed April 20 
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existing legal framework in US and Europe and based on the fact that rare disease 
patients must “have access to the right drug in a timely fashion”300. 
The underlying problem lies in the cost of orphan drugs versus the small number 
of affected individuals with rare diseases. The debate would probably be less heated if 
the drug administered to patients was equivalent to the cost of an aspirin (about 0.05 
cent/tablet).  
 
3.1 Towards a Personalized Medicine Approach  
 
 The concept of personalized medicine is not new, since patients are usually 
treated individually, in their best interest by their physicians. But nowadays, what is 
new is the advancement of knowledge in the science and technology fields that has 
paved the way for genomics, proteomics, metabolomics, imaging technology, and novel 
pharmaceutical treatments. Suffice to say that orphan drugs are no exception when it 
comes to personalized medicine in the treatment of rare diseases.  
In depth knowledge about the genome has revealed that for one specific disease 
there might be a marked heterogeneity in the phenotype as well as the genotype. This 
leads to the fact that two siblings in the same family, with the same parents having the 
same mutation might have different phenotypes, which will lead to different outcomes 
                                                             
300 Ibid. 
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of the disease 301 . How can these novel improvements help in detecting patients, 
diagnosing them and treating them in the best way possible?  
The FDA has described personalized medicine as follows: 
The term “personalized medicine” is often described as 
providing “the right patient with the right drug at the right 
dose at the right time.” More broadly, “personalized 
medicine” may be thought of as the tailoring of medical 
treatment to the individual characteristics, needs and 
preferences of a patient during all stages of care, including 
prevention, diagnosis, treatment and follow-up302.  
 
Figure 11 shows a schematic diagram of the basic principles underlying personalized 
medicine303. The left side of the figure shows that in a “non-personalized” medicine 
approach, patients are all treated in the same way with a uniform dose of medication 
notwithstanding the specific clinical features of a patient. By contrast, a personalized 
medicine approach will specifically target the mutation of the patient and the 
correlations with disease severity and progression and hopefully offer the appropriate 
treatment according to the genotype. Since most rare diseases have a genetic 
component, the concept of personalized medicine becomes a significant asset for the 
Canadian healthcare system offering better medical strategies while using orphan drugs. 
 
                                                             
301 M Rigoldi et al, “Intrafamilial phenotypic variability in four families with Anderson-Fabry disease: 
Intrafamilial phenotypic variability in Fabry disease” (2014) 86:3 Clinical Genetics 258. doi: 
10.1111/cge.12261.  
302 U.S. Food and Drug Administration, “Paving the Way for Personalized Medicine, FDA’s Role in a 
New Era of Medical Product Development”, October 2013, online:  
<http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PersonalizedMedicine/UCM372421.pdf
> (Accessed April 15 2016). 
303 Hong-Guang Xie & Felix W Frueh, “Pharmacogenomics steps toward personalized medicine” (2005) 
2:4 Personalized Medicine 325.  
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Figure 11. Schematic Diagram of the Basic Principles Underlying Personalized Medicine 
 
Source: Personalized Medicine 2005 
 
This aforementioned figure illustrates the challenges found in treating patients affected 
with rare diseases and the selection of orphan drugs. As part of a personalized medicine 
focus, many questions come to mind: Who should receive the orphan drug? At what 
dose? At which frequency? If two orphan drugs are available on the market for the same 
disease, is one treatment better than the other? What are the criteria to access the drug? 
Should each province decide on the accessibility of the drug? Should the federal 
government be involved in deciding which orphan drug for a specific disease is 
reimbursed or not? Who can afford it? At what price? 
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3.2. Who Should Receive an Orphan Drug? 
 
A core question when evaluating patients affected with rare diseases is who 
should receive the treatment with the orphan drug? This question is crucial because it 
involves an equity principle for patients affected with rare diseases in Canada to receive 
adequate treatment. This basic principle is part of the national (federal) health insurance 
program in place in Canada in conjunction with the provinces. It is often referred to 
“Medicare” and is: 
[…] designed to ensure that all residents have reasonable 
access to medically necessary hospital and physician 
services, on a prepaid basis. Instead of having a single 
national plan, we have a national program that is composed 
of 13 interlocking provincial and territorial health 
insurance plans, all of which share certain common 
features and basic standards of coverage. Framed by the 
Canada Health Act, the principles governing our health 
care system are symbols of the underlying Canadian values 
of equity and solidarity304. 
 
Emphasis should be put on the words “equity and solidarity”.  These Canadian values 
are particularly relevant when it comes to funding orphan drugs. Article 3 of the Canada 
Health Act states that: “It is hereby declared that the primary objective of Canadian 
health care policy is to protect, promote and restore the physical and mental well-being 
of residents of Canada and to facilitate reasonable access to health services without 
financial or other barriers”305. According to this legislation, patients affected with rare 
                                                             
304 Supra note 160; See also Health Canada Government of Canada, “Canada’s Health Care System 
(Medicare) - Health Canada”, (16 May 2005), online: <http://www.hc-sc.gc.ca/hcs-sss/medi-assur/index-
eng.php>. (Accessed May 2 2016). 
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diseases needing orphan drugs should also have their fair share of the health budget and 
a right to effective and high-quality care. It was stated that there should be a “basic 
moral and public policy commitment to non-abandonment of individuals with needs for 
highly specialized health care when making policies for rationing and resource 
reallocation, even in resource constrained settings”306.  
The second aspect to be considered while evaluating who should receive an 
orphan drug concerns the medical evaluation of the patient. This is an important phase to 
determine if a patient should receive the drug or not. In principle, these aspects should 
be addressed notwithstanding the cost of the drug.  
We thus believe that there should be well-established criteria or guidelines to 
decide who should receive an orphan drug for a specific rare disease. These guidelines 
should be implemented in a uniform way and be applicable to all provinces in Canada 
for each specific disease, without discrimination due to age and gender. 
We would like to describe a step-by-step procedure to ensure robust guidelines 
on who should receive orphan drugs for rare diseases. The process to establish these 
guidelines should start with a pan-Canadian (national) scientific committee having the 
expertise in the rare disease at stake with the goal to define evidence-based specific 
guidelines for the targeted disease. The members of the committee should have 
experience in treating patients and have expert knowledge on all aspects of the disease. 
This committee comprised of physicians and specialists treating these patients, as well as 
                                                             
306 C A Gericke, “Ethical issues in funding orphan drug research and development” (2005) 31:3 Journal of 
Medical Ethics 164. doi: 10.1136/jme.2003.007138 
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scientists, would first review the literature in order to gather the most recent information 
on: 
- the clinical and scientific aspects of the disease; 
- the natural history of the disease; 
- the age at onset of symptoms; 
- the impact and outcomes of treatment; 
- the adverse events encountered related to treatment; 
- the risk factors for patients receiving treatment; 
- the contraindications and/or cessation of the treatment; 
- the potential benefits of the treatment; 
- the biomarkers to evaluate the efficacy of treatment307; 
- the comparison of dosage for the treatment, if applicable. 
 The guidelines should be determined in an unbiased manner, and without 
possible or foreseeable conflicts of interest on the part of members of the scientific 
committee. These guidelines should always be reviewed each year in order to offer the 
highest standard of care for patients taking into account the advancement of technologies 
and the growing medical and scientific knowledge of the disease.  
An example of this process has already been implemented in Canada, for only one 
rare disease, Fabry disease, a multisystemic lysosomal storage disorder. As mentioned 
                                                             
307 Christiane Auray-Blais et al, “Urinary biomarker investigation in children with Fabry disease using 
tandem mass spectrometry” (2015) 438 Clin Chim Acta 195. 
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previously in section 1.2.2, CFDI was devised in 2006308, as part of a clinical trial in 
Canada. Before that, in 2005, an expert committee proposed recommendations for 
diagnosis, management and enzyme replacement therapy in Canada as part of a first 
draft for Canadian Fabry guidelines309. The committee then stipulated that: 
The establishment of Canadian guidelines for the diagnosis 
and management of Fabry disease will serve as an initial 
model for the establishment of a national process for 
guideline development for other lysosomal storage 
diseases as well as other rare genetic diseases. Further 
outcome studies in patients who have had therapy 
commenced early in their disease will be needed to refine 
these guidelines. Although it is hoped that early initiation 
of therapy i.e. prior to significant disease manifestations or 
complications, may result in improved outcomes for 
patients, this has yet to be systematically studied. In 
addition, further studies are necessary to establish the 
optimum dose of recombinant enzyme that will lead to 
prevention of storage or reversal of specific disease 
manifestations. The role of enzyme replacement therapy 
for Fabry disease in childhood also requires systematic 
investigation. For all of these reasons, we urge that 
Canadian patients with Fabry disease be entered into a 
confidential registry that will capture demographic and 
treatment status to direct future research and refinement of 
treatment. 
 
 
The ongoing CFDI study has a control group which is essential to compile natural 
history data to allow the evaluation of the effects of therapy treatment. The CFDI also 
has a registry that is independent of pharmaceutical companies involved in the treatment 
of Fabry patients and of government influence310. The registry is comprised of various 
demographic data such as age, gender, and clinical data related to manifestations of the 
                                                             
308 S Sirrs et al, “Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative” 
(2010) 99:4 Molecular Genetics and Metabolism 367. doi: 10.1016/j.ymgme.2009.11.001.  
309 Lorne A. Clarke et al, “Fabry Disease: Recommendations for Diagnosis, Management, and Enzyme 
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disease (renal, cardiac, cerebrovascular diseases). A registry containing reliable data 
becomes an incredible tool to evaluate the efficacy of treatment, and the overall follow-
up of patients, as well as to ameliorate the care of patients, and eventually the healthcare 
system. Considering the low number of affected rare disease patients, it will also help 
achieve larger cohorts for clinical research.  It was stated that “confounding the paucity 
of available research, many rare diseases are often classiﬁed within broader diagnostic 
categories, which results in difﬁculties creating reliable data registries”311. 
In our opinion, well-defined guidelines for each rare disease would definitely 
address the question of who should receive the drug. Longitudinal clinical trials 
involving patients affected with rare diseases would also address major issues such as 
the ideal dose provided to patients, as well as the optimal dose frequency, this being part 
of a personalized medicine approach.  
Another key question: if two competitive orphan drugs are available on the 
market for the same disease, is one treatment better than the other? A multicenter 
clinical trial involving the highest number of affected patients, would allow better 
statistical power analysis and responses to this query.   
We therefore recommend the implementation of a committee who would devise 
guidelines for each rare disease to determine who should receive an orphan drug. These 
guidelines should first be devised through clinical trials, and then would be implemented 
as novel healthcare policies for the regular practice of physicians.  
                                                             
311 Fishman Jesse C & Skrepnek Grant H, “Pharmacoeconomic analyses of treatments for rare disease” 
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3.3. Should Each Province Decide on the Access to Orphan Drugs? 
  
The major hurdle to gain access to orphan drugs is the cost of the drug and its 
reimbursement. In fact, governmental authorities are reluctant to provide reimbursement 
for expensive orphan drugs for life-long treatment, even if they are for a small number 
of patients.  
As described previously in section 1.2, different procedures/strategies have been 
instigated in each province in Canada for patients affected with rare diseases to access 
orphan drugs. Above all, these processes are cumbersome and time-consuming. This 
was confirmed by the study of Menon and colleagues who compared the mechanisms in 
place throughout Canada for orphan drug reimbursement and evaluated the impact on 
the access to these drugs 312 . The study shows that there are formal and informal 
processes to access orphan drugs and that some provinces have dedicated programs for 
orphan drugs, but in the end, there is no agreement on access between 
provinces/territories. This leads to problems of access to orphan drugs at various levels. 
Patients who move from one province to the other might have to start the whole access 
procedure from the beginning, and might subsequently have the province deny the 
application because the drug is not reimbursed in this particular province. Patients might 
have to cease the treatment of life threatening diseases for an undefined period that 
might cause clinical manifestations, which would not otherwise have happened. The 
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follow-up of these patients might be difficult to assess by physicians, if patients 
frequently interrupt treatment. 
 It was correctly stated that “the availability of and access to orphan drugs play a 
key role in determining whether patients will receive adequate and efficient 
treatment”313. This latter study comprised of 11 countries, which are Australia, Canada, 
England, France, Germany, Hungary, the Netherlands, Poland, Slovakia, Switzerland 
and the US, was devised to examine their pharmaceutical markets for four rare diseases 
(pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic 
myeloid leukaemia). Briefly, results revealed that: 
Although the present study showed some variations 
between countries in selected indicators of availability and 
access to orphan drugs, virtually all of the drugs in 
question were available and accessible in our sample. 
However, substantial co-payments in the US and Canada 
represent important barriers to patient access, especially in 
the case of expensive treatments such as those analysed in 
this study314. 
 
The co-payment plan in Canada varies according to provinces. It can involve various 
private and public payers for medications and extensive direct costs to patients “by way 
of deductibles, co-payments or co-insurances”315.    
In conclusion, provinces should have a uniform procedure to decide who should 
have access to orphan drugs, as part of a global Canadian model in an alliance with the 
federal government. Working together to establish a formal agreement between 
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provinces and financial support from the federal government would be beneficial 
because it would regroup resources which are often limited and target a wider orphan 
drug market. It will also avoid time-consuming uncoordinated measures for the 
healthcare system and patients.  
3.4 The Pharmacoeconomic Aspects for Orphan Drugs  
 
 
The subject of very expensive orphan drugs for patients with rare diseases related 
to pharmacoeconomics has been discussed for a number of years. In a society where 
resources are scarce, it becomes imperative to “identify, measure and compare the cost 
and consequences of drug therapy to healthcare systems and society”316. The cost and 
reimbursement of orphan drugs for life-threatening diseases remain problematic and 
should be prioritized for patients, politicians, legislators, pharmaceutical industry 
leaders, health care professionals (general practitioners, medical specialists, 
administrative officers, etc.), and academic researchers.  
3.4.1 CADTH: a Possible Paradigm Shift? 
Discussion about access to orphan drugs and reimbursement have been recurring 
in Canada since there is no official orphan drug policy. A good example of this refers to 
March 2016 where the CADTH published a new recommendation framework putting the 
emphasis on clinical considerations, unmet need and “real-world evidence”:  
In exceptional cases where there is uncertain clinical and 
pharmacoeconomic evidence, the CADTH drug expert 
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committees may issue a recommendation to reimburse 
with clinical criteria and/or conditions, due to practical 
challenges in conducting robust clinical trials and 
pharmacoeconomic evaluations and in the presence of 
significant unmet medical need. In these situations, 
although there is uncertainty with the clinical evidence, 
the available evidence must reasonably suggest that the 
drug under review could substantially reduce morbidity 
and/or mortality associated with the disease. Significant 
unmet clinical need is identified on a population or 
subpopulation basis (i.e., not on an individual basis) 
through the CDR and pCODR processes317.  
  
This possible CADTH paradigm shift might be due to the low recommendation rate for 
reimbursement of orphan drugs in Canada compared to other countries for the same 
drugs. Also, discrepancies from five Canadian jurisdictions were found on health 
technology assessment (HTA) showing a lack of concordance:  
It should also be noted that there was a considerable lack 
of concordance in HTA decisions between the different 
agencies. For the drugs reviewed by all five jurisdictions, 
there was only a 33.3% concordance in decisions, 
suggesting a lack of standardization in the methods used to 
assess the strengths and weaknesses of the limited clinical 
and economic data available for orphan drugs. This was 
particularly apparent in orphan drug reimbursement 
concordance between CDR and Quebec. In this case 
concordance was only 68%, reflecting variable 
interpretation of common efficacy data in a health care 
system with presumably similar cost constraint 318 .    
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Drugs-at-CADTH_McKesson.pdf> (Accessed May 28 2016). 
318 Ibid. 
  
 
 
105 
Additionally, after CDR submissions in Canada, the positive recommendation rate for a 
same drug compared to other countries revealed major discrepancies: in Australia 
(88.1%), in Scotland (60%), in New Zealand (62%), and in Québec (66%), where for the 
latter, the HTA system is independent from CDR because of INESSS319.  
We find these statistics particularly troubling. At the present time, it seems that 
Canadian patients are not receiving reimbursement for some orphan drugs for rare 
diseases which are accepted elsewhere. Therefore, there is a lack of concordance for the 
evaluation of reimbursement. This definitely leads to inequities among Canadian citizens 
affected with rare diseases compared to other countries.   
3.4.2 Cost-Effectiveness Analysis for Orphan Drugs: Is It the Best Solution?  
 
Efforts concerning orphan drug economic evaluations aimed at guiding decisions 
for drug reimbursement, including the cost, have been hampered by specific features that 
are inherent to rare diseases. It has been rightly stated that: 
The economic evaluation of orphan drugs is inhibited by 
the existence of often limited and weak clinical data at 
launch time. In the context of rare diseases, it may prove 
difficult to recruit a sufficient number of patients and 
medical centers in clinical trials, thus raising costs. Orphan 
drug trials (in for example the field of oncology) may be 
halted early on ethical grounds when an interim analysis 
demonstrates clinical superiority of the orphan drug in 
terms of an intermediate outcome measure such as 
progression-free survival. It has been recommended to 
allow greater use of surrogate outcome measures for 
orphan drugs if clinical data are incomplete, but impose at 
the same time a commitment to continue research320.  
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Nevertheless, different conventional techniques have been used to determine the 
cost effectiveness of orphan drugs. One technique particularly used by healthcare 
administrators/decision makers is the cost-effectiveness analysis (CEA). This technique 
provides “policy comprehensive information regarding treatment alternatives concerning 
differences in resource consumption and cost as a function of economic, clinical, or 
humanistic outcomes”321. Within the CEA, a statistical tool used is the incremental cost-
effectiveness ratio (ICER) that involves the comparison of new technologies. Such 
technologies include novel treatment, novel orphan drugs, clinical interventions, other 
new diagnostic procedures to current treatment, and other standards of care. In other 
words, ICER takes into account the opportunity cost associated with using numerous 
therapeutic alternatives. Different pharmacoeconomic tools can be used separately, or in 
combination when evaluating cost effectiveness of an orphan drug:  
Although clinical outcomes such as mortality (e.g., life-year 
gained, LYG) often constitute the basis of CEA, extensions 
beyond this methodology utilizes the quality-adjusted life-
year (QALY) in a framework designated a cost-utility 
analysis (CUA); the CUA incorporates both the length of 
life with the quality of that life. Additionally, a cost-beneﬁt 
analysis (CBA) monetizes a change in health effect 
associated with a new intervention to yield a relative cost 
per treatment intervention versus alternatives322. 
 
Nonetheless, these aforementioned tools are not ideal for determining the cost 
effectiveness of orphan drugs for rare diseases. In fact, threshold values for these tools 
might be misrepresenting the cost effectiveness evaluation, as they do not take into 
considerations such as the availability of ﬁnancial resources, the access to treatment, the 
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efﬁcacy of treatment, the will to pay, and budget justiﬁcations/restrictions 323 . 
Additionally, the equity-weighing factor “to allow all persons the ability to live a normal 
life span” should be taken into account for QALY, since it is an important criterion.  As 
“for patients with rare diseases, assigning a weighted QALY may better reﬂect society’s 
willingness to make equity-based adjustments in certain circumstances for the 
distribution of health care resources”324. 
Another strong critique on the cost-effectiveness of treatment for rare diseases 
indicates that “it is virtually impossible to assess cost-effectiveness of treatments for rare 
diseases using conventional criteria”325. Why is it this way? Well, mainly because of the 
rarity of these diseases. In fact, due to the small number of patients affected with rare 
diseases, it is difficult to achieve statistical power analysis to establish the benefits of an 
orphan drug therapy. In addition, these rare diseases show a marked variability in the 
genotype and phenotype affecting multiple systems with variable clinical outcomes in 
patients. Hence, it becomes difficult to show a distinct effect of the therapy on the 
mortality rate or morbidity. “In many patients, the most common causes of morbidity are 
inherently difficult to quantify. This is true, for example, of Fabry disease, a lysosomal 
disorder in which irregular episodes of severe pain are one of the most consistent causes 
of morbidity326”. 
In our opinion, these cost-effectiveness evaluation tools of orphan drug for rare 
diseases are clearly not adapted to help governmental authorities and healthcare 
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professionals in Canada to decide on the funding of drugs, and the subsequent 
reimbursement process. We strongly believe that a comprehensive framework for cost-
effectiveness adapted specifically for rare diseases is necessary to better reflect the 
overall picture regarding the funding of orphan drug to ensure fairness, consistency and 
transparency for rare disease patients.  
3.4.3 Framework for Guidance for Public Orphan Drug-Funding 
Taking in mind the inconsistencies in the positive recommendation rates for 
orphan drugs throughout Canada and other countries, as well as issues with the cost-
effectiveness, a questions arises: would a framework to evaluate orphan drug for rare 
diseases be a solution for public funding of these drugs in Canada? In our opinion, 
considering the lack of guidance for public orphan drug-funding for rare diseases in 
Canada, such a framework becomes a possible solution. 
In fact, a model framework was devised in 2012 at the request of the Ontario 
Ministry of Health and Long-term Care, the objective being to offer “guidance for public 
drug-funding policy from the payer perspective” 327 . This evaluation was deemed 
necessary because of the limitation in obtaining information with randomized clinical 
trials on the effectiveness of a novel orphan drug for rare diseases. Unfortunately, the 
scientific literature does not provide guidance in this rare diseases context. The authors 
recognized that “The Canadian provinces and territories have attempted to develop a 
national strategy, but in the absence of a funding commitment from the federal 
government, this work has stopped, and so provincial funding recommendations 
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considering efﬁcacy and value for money in a conventional manner are typically 
negative328. Therefore, a committee called Drugs for Rare Diseases Working Group was 
created for this study and comprised of nine experts: three members from the Ontario 
Ministry of Health and Long-term Care (the Executive Ofﬁcer and two pharmacists), 
two physicians, a pharmacist, a health economist, a pharmacoeconomist, a pediatrician-
geneticist treating children affected with inborn errors of metabolism in children, and an 
ad-hoc ethicist. There were seven steps to the framework:  
Step 1: conﬁrm that the disease to be treated with an orphan drug is really rare; 
Step 2: understand the pathophysiology, natural history, and health problems of  
      the disease; 
Step 3: understand the probable value of the orphan drug; 
Step 4: evaluate the possible clinical effectiveness of the orphan drug; 
Step 5: evaluate cost consequences and prepare a funding recommendation; 
Step 6: validate the orphan drug model by having it reviewed by other disease 
 experts and stakeholders; 
Step 7: continuously review and add novel information on the natural history of 
the disease, the cost or effectiveness of the orphan drug therapy and its impact329. 
This evaluative model was applied to Hunter’s disease (MPS Type II) for the 
assessment of idursulfase, an orphan drug provided by infusion to the patients. Hunter’s 
disease is a lysosomal storage disorder leading to either a severe, progressive 
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neurological and respiratory form of the disease (MPS type IIA) or an attenuated form of 
the disease with musculoskeletal abnormalities but without cognitive involvement (MPS 
type IIB). The framework evaluation led to the conclusion that patients affected with 
MPS type IIB receiving the orphan drug idursulfase therapy would have reduced 
progression of the disease by 10%, 20% and 50% and might have a longer life 
expectancy of 1.32, 2.93 and 10.66 years, whereas the life expectancy would have been 
only 0.03, 0.06, 0.16 considering that the drug does not reduce the progression of the 
disease for an 11-year old MPS type IIA patient having the more severe form of the 
disease330.   
 The cost of idursulfase is estimated at $375,000 CAD per patient. Even if a 
detailed cost analysis was not possible, the framework evaluation study led to a concrete 
public funding decision of the orphan drug by the Ontario Minister:    
Detailed cost analysis was not done because the drug was 
not considered cost-effective by conventional criteria even 
in the most extreme model scenarios. However, the 
potential life expectancy gains in type B patients were 
considered highly valued. This was reviewed and 
approved by the Executive Officer, and a funding 
algorithm was developed for negotiation with the 
manufacturer (step 5). A review of the Markov model by 
content expert physicians was conducted. This led to 
revision of some assumptions and general approval of the 
process and its results. The framework was also presented 
to and approved by the Ontario Public Drug Programs 
Citizens’ Council (step 6). Negotiations with the 
manufacturer led to the public funding of idursulfase in 
Ontario for patients 6 years or older without 
neurocognitive symptoms, while the manufacturer 
manages requests for funding for patients younger than 6 
years of age in whom the potential effects on life 
expectancy were far less certain. This has provided an 
estimate of the annual cost of idursulfase to Ontario Public 
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Drug Programs prioritized to those patients most likely to 
benefit. No new information informing the model has been 
identified to date (step 7). 
 
In conclusion, this framework revealed that even in the context of dealing with a 
rare disease, where the patient may have various clinical outcomes (severe and 
attenuated forms of the disease), treated by a very expensive drug, with no adequate 
randomized clinical trials, it is possible to address public funding issues which lead to 
fair and transparent decisions in the aforementioned Ontario study. In the situation 
involved, the framework tried “to identify an evidence-derived “middle-ground” that is 
an improvement over arbitrary decisions based on either the absence of specific data or 
political expediency”331.   
In our opinion, guidance frameworks for public orphan drug-funding 
reimbursement should be established for rare diseases across Canada directed by an 
expert pan-Canadian (national) committee who would have the expertise in each rare 
disease evaluated.    
3.4.4 Financial Repayments for Profitable Orphan Drug Designations 
 Highly US profitable orphan drug designations defined as those with an annual 
global sales of more than one billion $US (blockbuster drugs) are numerous. From data 
up to 2009, 43 orphan drugs were part of that group. From these, 18 were approved 
uniquely as orphan drugs and reached the one billion sales status within the 7-year 
                                                             
331 Ibid. 
  
 
 
112 
exclusivity market period allowed for orphan drugs332. Some of these drugs have five or 
more orphan drug designations each (e.g. Novoseven, Neupogen, Gleevec, 
Remicade)333. Using the analysis of corporate reports, it was shown that 33 orphan 
designated drugs have record sales of $100 to $999 million US, where 19 are approved 
as orphan drugs exclusively in the US. It shows that the orphan drug market is more and 
more profitable, even with a low number of affected patients. Besides, some drugs 
having the same molecular active chemicals (e.g. interferon, somatropin and 
levocarnitin) can receive as many as 33 orphan designations per orphan drug with the 
intention to offer treatment to larger populations, which might be in violation of the 
prevalence defined by the ODA of fewer than 200,000 individuals334. Therefore, these 
blockbuster drugs become quite profitable probably due to all these various designation 
possibilities335.  
In the event of an orphan drug regulatory framework in Canada, it would be 
important to control the high cost of orphan drugs by price control-measures and 
repayments from companies who largely benefit from these lucrative orphan drug 
revenues. One of these might be a compensation sales tax on orphan drugs for 
companies having blockbuster drugs within 8 years of the market exclusivity, as well as 
those having high revenues that could be determined by the Board. This would be in 
accordance with the Japanese situation where it is an obligation for pharmaceutical 
companies to pay a “1% sales tax on orphan drugs with annual profits exceeding 100 
                                                             
332 Olivier Wellman-Labadie & Youwen Zhou, “The US Orphan Drug Act: rare disease research 
stimulator or commercial opportunity?” (2010) 95:2-3 Health Policy 216.  
333 Ibid. 
334 Ibid. 
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million yen (or $1,200,000 CAD) until government subsidies received by manufacturers 
have been repaid”336.  
In Canada, this repayment process could be managed by the Board and would 
allow support for the process evaluation of orphan drugs, as well as provide funding 
grants for R&D on orphan drugs.  
Another important measure would be to control the prices for orphan drugs. 
Considering the global growth of the orphan drug market and the impact of high price 
drugs on the access for rare disease patients, there is a strong need to have an 
international consensus on the control of these prices. Countries around the world, under 
the tutelage of an international committee on orphan drug, could be responsible to adopt 
policies to regulate prices. This approach would bring a robust negotiable power because 
of country regrouping and offer the same price for orphan drugs to patients affected with 
rare diseases wherever they are.   
 
3.5 Recommendations and Measures for Implementation of a Policy Framework 
for Orphan Drugs 
 
As previously mentioned, in 2012, a regulatory framework for orphan drugs in 
Canada was released as an initial draft discussion337. Although there has yet to be an 
implemented framework for orphan drugs, it is critical to address certain points for 
future recommendations.  
                                                             
336 Ibid. 
337 Supra note 158. 
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The definition of the term rare disease is an important one as mentioned 
previously, since it is used for the definition of an “orphan drug”. It also represents a 
criterion to allow sponsors to apply for an orphan drug designation. According to the 
Canadian draft submitted on December 13 2012:  
Definitions would include a definition of the term “orphan 
drug” to mean a drug that meets the following criteria: 
a. The drug is intended for the diagnosis, treatment, 
mitigation or prevention of a life-threatening, seriously 
debilitating, or serious and chronic disease or condition 
affecting not more than five in 10 thousand persons in 
Canada; and  
b. The drug is not currently authorized by the 
Minister or if currently authorized, it will provide a 
potentially substantial benefit for the patient 
distinguishable from the existing therapy. 
  
It seems that the broad definition of a rare disease is following the steps of the European 
legislation. The reason for this limit of fewer than 5 cases per 10,000 inhabitants in 
Europe originally, was to have a threshold value just below the cost-benefit for a 
pharmaceutical company of new drugs that were not profitable338 . That being said, 
would the same measure be a good fit for Canada? Especially knowing that “most 
prevalence figures currently available in the literature refer to the so-called prevalence at 
birth, a term that is not always uniformly applied”339. The rare disease status according 
to the prevalence of the disease varies from country to country. It is really up to 
governmental authorities to determine the cut-off value for the prevalence. Furthermore, 
criteria under the orphan drug definition have to be met in order to qualify for an orphan 
drug designation. This might lead to major shortcomings, because the definition is 
                                                             
338 Supra note 45 at 21. 
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clearly not universal. In fact, the US prevalence is fewer than 200,000 meaning 0.075 
per cent of the total population whereas the European Union used 0.05 per cent of the 
total population340.  
In our opinion, and similar to others341, before implementing new legislation for 
orphan drugs, one option is to increase the control of the Patented Medicines Review 
Board to the extent of the SAP. We have previously stated that the mechanisms used by 
the Board have been inadequate in terms of prices since it is limited to patented drugs 
and even then, it has limited power to act or control exorbitant prices. Consequently, the 
Board should serve as a “guardian” for patented orphan drugs, but also for old off-patent 
drugs whose prices have increased due to financial reasons. That said, if a legislation is 
proposed in the future, it is worth taking into consideration that orphan drug programs 
could lead to new patents (even on old substances) and therefore would bring them back 
under the supervision of the Board –creating a certain control over prices.  
However, there is still a possibility of commercial and ethical abuses when a new 
drug off the market is reinstated as an orphan drug. In fact, the situation of a 
pharmaceutical drug previously on the market that was eventually discontinued, then it 
received an orphan drug designation (either on the same trade name or not) has occurred 
numerous times in the US342.  For example, Baclofen a drug who was approved in 1977, 
later discontinued, and then obtained an orphan drug designation in 1987 and 1991 with 
                                                             
340 Bao-cheng Liu et al, “A cross-national comparative study of orphan drug policies in the United States, 
the European Union, and Japan: towards a made-in-China orphan drug policy” (2010) 31:4 J Public Health 
Policy 407. 
341 Garret Kent Fellows & Aidan Hollis, “Funding innovation for treatment for rare diseases: adopting a 
cost-based yardstick approach” (2013) 8 Orphanet J Rare Dis 180; Eve A Roberts, Matthew Herder & 
Aidan Hollis, “Fair pricing of ‘old’ orphan drugs: considerations for Canada’s orphan drug policy” (2015) 
187:6 CMAJ 422. 
342 Discontinued Pharmaceutical drugs that obtained a new life as orphan drugs are: aminosidine, 
Gabbromicina, Paromomycin, cromolyn and Gastrocrom which are part of 26 others. Supra note 332. 
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a final approval for orphan drug in 1992343. In addition, as mentioned previously, the 
ODA incentives have led to the salami slicing effect, a situation that should be not taken 
lightly by Canadians authorities. 
On the other hand, what about the risk of getting an orphan drug patent for an 
existing off-label use, thereby potentially increasing price and decreasing access? In our 
opinion, different recommendations should be implemented in Canada as part of a policy 
framework to remove barriers to access orphan drugs for rare diseases. These 
recommendations would target all provinces and offer a uniform process that would 
benefit all Canadian citizens affected with rare diseases. These recommendations could 
be part of a Canadian policy framework.   
 
Recommendation 1. Governmental funding for academic research should be increased 
in Canada to gain knowledge on the natural history and pathophysiology of rare 
diseases, as well as for orphan drug development.  
Recommendation 2. A personalized medicine approach should be implemented to 
improve all stages of care for patients affected with rare diseases, including detection, 
diagnosis, treatment with orphan drugs and follow-up.  
Recommendation 3. Due to the infrequency of rare diseases, a registry containing 
reliable data should be implemented in Canada for each rare disease, to assess the 
prevalence of the disease, the efficacy of treatment, the overall follow-up of patients, as 
well as to achieve larger cohorts for clinical research studies. 
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Recommendation 4. A pan-Canadian (national) scientific committee should be 
implemented for each specific rare disease to establish evidence-based guidelines for 
patients to access orphan drugs uniformly in all provinces. These guidelines (accessible 
online) should be reviewed regularly to offer the highest standard of care for patients.    
Recommendation 5.  A formal agreement with a centralized procedure, between 
provinces and the federal government providing financial support, should be established 
for public orphan drug funding reimbursement for each rare disease, under the direction 
of an expert pan-Canadian (national) committee.  
Recommendation 6. The Patented Medicines Review Board in Canada should serve as 
a “guardian” for prices of patented orphan drugs, but also for old off-patent drugs. The 
Board should extend its control over the Special Access Programme.  
Recommendation 7. The Board should determine a compensation sales tax on orphan 
drugs for companies having blockbuster drug revenues within 8 years of the market 
exclusivity. 
Recommendation 8. A worldwide consensus to control orphan drug prices should be 
established under the tutelage of an international committee responsible for adopting a 
policy framework to regulate prices.  
 
Conclusion  
 
The societal challenges and political debate surrounding orphan drug for patients 
affected with rare diseases has been going on incessantly in Canada. Many countries 
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have implemented orphan drug legislation, but Canada is still lagging behind. However, 
is there a need for a pan-Canadian (national) orphan drug framework? 
In order to respond to this question, we need to understand that multiple factors 
reflect the complexity of these rare diseases, which affect a small number of patients. In 
fact, there is still no consensus for countries to arrive at a specific prevalence indicating 
the rarity of these diseases. There is also a lack of information on the natural history and 
pathophysiology of many rare diseases. Marked heterogeneity in the phenotype and 
genotype of most rare diseases increases the complexity of monitoring, management and 
follow-up of affected patients. This contributes to difficulties in designing robust clinical 
trials to assess safety and efficacy of orphan drugs with a statistical power analysis.  
The purpose of this thesis was to evaluate some of the difficulties regarding the 
legal and policy framework, considering the fact that there is no orphan drug legislation 
in Canada, but also to evaluate how to reduce barriers and improve access to orphan 
drugs for rare diseases. 
 Considering that in Canada, the administration and delivery of health care 
services is under the responsibility of each province, our analysis showed that the 
application process for patients to access orphan drugs is time-consuming and labour-
intensive. There are also major discrepancies between provinces to reimburse orphan 
drugs. Some drugs are accepted on a case-by-case basis by provinces according to their 
own conditions. A concrete example of differences between provincial coverage regard 
the orphan drug (Myozyme) for Pompe disease patients, which is reimbursed in 
Manitoba but not covered in British Columbia. Moreover, a study revealed that the 
recommendation rate for orphan drugs in Canada was lower than other countries for the 
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same drugs and that the health technology assessment varied within Canada. We found 
these statistics particularly troubling because it seems that Canadian patients are not 
receiving reimbursement for some orphan drugs for rare diseases which are accepted 
elsewhere. The lack of concordance for the evaluation of reimbursement leads to 
inequities for  Canadian patients affected with rare diseases compared to other countries.   
 The evaluation of the US and the EU orphan drug legislation helped to 
understand the intricacies of policy mechanisms. It also provided incentives to 
pharmaceutical companies involved in the development and marketing of orphan drugs 
and also led to comprehend limitations of such legislation.   
Advocacy groups are lobbying for orphan drug legislation in Canada via CORD, 
but even if there is an eventual legal framework in Canada for orphan drugs, there still 
might be recurrent problems in terms of reimbursement decisions. A reason for this is 
that provinces are responsible for their own delivery of health care services. Creating a 
centralized procedure to authorize orphan drugs similar to the US and European models 
will not fix everything. Having a legal framework with incentives for developing drugs 
might however increase R&D funds for orphan drug development. Nonetheless, the 
decentralised procedure for drug pricing and decision-making for reimbursement might 
still be a burden for patients between provinces to have access to these drugs. In terms of 
orphan drugs for rare diseases and the Canadian health policy-makers involved, it is 
crucial to differentiate between market approval and market access. One does not lead to 
the other, and unfortunately, Canada is way behind on both compared to other countries.  
In our opinion, before implementing a legal framework, we need to address 
current problems. Therefore, we propose explicit recommendations in a policy 
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framework that will remove some barriers and improve access to orphan drugs; increase 
governmental funding for academic research; implement a personalized medicine 
approach for patients affected with rare diseases, including detection, diagnosis, 
treatment with orphan drugs and follow-up; implement a registry containing reliable data 
for each rare disease; implement a pan-Canadian (national) scientific committee for each 
specific rare disease to establish evidence-based guidelines for patients to access orphan 
drugs uniformly in all provinces; establish a formal national agreement by an expert pan-
Canadian (national) committee for public orphan drug funding for each rare disease; 
increase the role and control of the Patented Medicines Review Board in Canada for 
prices of patented orphan drugs and also for old off-patent drugs; establish a 
compensation sales tax on orphan drugs for companies having blockbuster drug 
revenues; and establish a worldwide consensus to regulate orphan drug prices with an 
international committee adopting a policy framework to regulate prices.  
Upon considerations of these recommendations, the final strategy would be to 
address all these recommendations before implementing a legal framework in Canada.   
 
 
 
 
 
 
  
 
 
121 
Appendices 
Appendix 1. Summary of SAP Authorizations for January-December 2013 in eSAP 
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Appendix 2. Compiled data from SAP drugs with an orphan drug designation, either by 
the Orphanet or the FDA database 
Summary of SAP Authorizations for January-December 2013 in eSAP 
Product name  Alternative 
name 
Dose Orphan 
designation  
Orphan 
designation  
Orpha 
number  
Number of 
requests 
Authorized 
      14532 
18f-fdopa  18f-fluorodopa     1 
3,4-
diaminopyridin
e 
  10mg USA  Europe 
ORPHA82347 
92 
714X trimethylamino
hydroxybicyclo
heptane 
chloride 
63mg/ml   
 
21 
ABT-333  25mg   
 
1 
ABT-450 ritonavir, ABT-
267 
   
 
1 
Abthrax raxibacumab 50mg/ml   Europe 
ORPHA410394 
1 
Acthrel corticorelin 
ovine triflutate 
20µg/ml USA   
 
25 
ACTIMMUNE interferon 
gamma-1b 
0.2mg/m
l 
USA    
 
42 
Actiq  fentanyl citrate 800µg   
 
1 
Adagen pegademase 
bovine 
2501U/
ml 
USA   
ORPHA100845 
16 
Adcetris brentuximab 
vedotin 
50mg USA Europe Europe: 
ORPHA299952 
USA: 
ORPHA398790 
13 
Additive 
Solution 
Formula 3 
    
 
1 
afatinib  BIBW 2992 30mg USA   USA: 
ORPHA413782 
43 
afatinib  BIBW 2992 40mg USA   USA: 
ORPHA413782 
125 
afatinib BIBW 2992 50mg USA   USA: 
ORPHA413782 
41 
Alinia nitazoxanide 500mg USA   ORPHA34106 28 
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Alinia nitazoxanide 1,2g USA   ORPHA34106 14 
Ambien  zolpidem 
tartrate 
10mg   
 
2 
Ammonul sodium 
phenylacetate 
and sodium 
benzoate 
  USA   
ORPHA87861 
29 
Ammonul sodium 
phenylacetate 
and sodium 
benzoate 
10% USA   
ORPHA87861 
13 
amoxapine  50mg   
 
1 
Anadrol-50 oxymetholone 50mg   
 
3 
Anafranil clomipramine 12,5mg/
ml 
  
 
8 
Ancotil flucytosine 1%   
 
12 
Ancotil flucytosine 500mg   
 
91 
Andractim  
(androstanolon
e gel) 
    
 
4 
Antivipmyn  
(polyvalent 
equine anti-
viper serum) 
    
 
5 
Apo-Cisapride cisapride 
monohydrate 
10mg   
 
494 
AquADEKs  
Chewable 
Tablets 
    
 
2 
AquADEKs  
Pediatric Liquid 
    
 
237 
AquADEKs  
Softgels 
    
 
226 
AQUASOL A 
Parenteral 
(water-miscible 
vitamin A 
paImitate)  
 50000US
PU/ml 
  
 
1 
Arcalyst   rilonacept 220mg USA Europe 
ORPHA95344 
27 
Aristospan triamcinolone 
hexacetonide 
20mg/ml   
 
586 
  
 
 
133 
ARRY-334543  100mg   
 
2 
artesunate   110mg USA Europe ORPHA88970 2 
AtroPen  2mg   
 
3 
atropine sulfate  1%   
 
1 
atropine 
sulphate 
 0,1mg/m
l 
  
 
1 
atropine 
sulphate 
 2mg/ml   
 
1 
Aubagio teriflunomide 14mg   
 
4 
Azactam aztreonam 1g USA Europe ORPHA83687 215 
aztreonam   1g USA Europe 
ORPHA83687 
2 
aztreonam   2g USA Europe ORPHA83687 1 
Banocide diethylcarbama
zine 
50mg   
 
19 
Berotec HFA fenoterol 
hydrobromide 
100µg   
 
1 
bicaVera  2,30%   
 
19 
bicaVera  4,25%   
 
1 
BioThrax 
(anthrax 
vaccine) 
    
 
2 
Biotin-8  8mg   
 
43 
black widow  
antivenin 
(equine) 
latrodectus 
mactans 
6000U   
 
11 
Bosutinib   100mg USA Europe 
ORPHA229458 
18 
Botulism Antitoxin  Behring 
(botulism antitoxin type A, type B, 
and type E) 10?  
  USA   
ORPHA405648 
20 
Brevibloc esmolol 
hydrochloride 
10mg/ml   
 
25 
Brevital 
Sodium 
methohexital 
sodium 
500mg   
 
139 
  
 
 
134 
Brolene propamidine 
isethionate 
1mg/ml   
 
33 
Bumex bumetanide 0,5mg/m
l 
  
 
18 
Buphenyl sodium 
phenylbutyrate 
250mg USA Europe 
ORPHA25062 
11 
Buphenyl sodium 
phenylbutyrate 
500mg USA Europe 
ORPHA25062 
5 
Buphenyl sodium 
phenylbutyrate 
250mg USA Europe 
ORPHA25062 
56 
Buphenyl sodium 
phenylbutyrate 
500mg USA Europe 
ORPHA25062 
36 
caffeine citrate 
- Sandoz 
  10mg/ml   Europe 
ORPHA133569 
342 
caffeine citrate 
- Sagent 
  20mg/ml   Europe 
ORPHA133569 
1 
Calcium 
Gluconate 
 10%   
 
24 
Calcort deflazacort 6mg   
 
318 
Capastat 
Sulfate 
capreomycin 1g   
 
1 
Carbaglu carglumic acid 200mg USA Europe ORPHA35161 22 
Cardene IV  nicardipine 
hydrochloride 
0,1mg/m
l 
  
 
10 
Cardene IV nicardipine 
hydrochloride 
0,2mg/m
l 
  
 
12 
Catapres clonidine 
hydrochloride 
150µg/m
l 
  Europe 
ORPHA275660 
68 
Catapres clonidine 
hydrochloride 
0,1mg/m
l 
  Europe 
ORPHA275660 
1 
Catapres clonidine 
hydrochloride 
0,2mg/m
l 
  Europe 
ORPHA275660 
9 
Celontin methsuximide 300mg   
 
45 
Ceprotin 
(protein c 
concentrate)  
  1000IU USA   
ORPHA24899 
2 
Ceprotin 
(protein c 
concentrate) 
  500IU USA   
ORPHA24899 
7 
Chemet  succimer 100mh USA   
 
19 
  
 
 
135 
ChiRhoStim 
(synthetic 
human 
secretin) 
 16µg   
 
24 
chlorothiazide 
sodium 
 0,5g   
 
8 
cidofovir  75mg/ml   
 
43 
cilengitide   8mg/ml USA   ORPHA81687 3 
cilostazol  100mg   
 
18 
Clopine  clozapine 50mg/ml   
 
1 
Clorpactin 
WCS-90  
sodium 
oxychlorosene 
2g   
 
10 
CMX-001     
 
1 
cobicistat  150mg   
 
11 
Cometriq cabozantinib 20mg  USA   ORPHA394243 1 
Cometriq  cabozantinib 80mg USA   ORPHA394243 1 
Corlopam fenoldopam 
mesylate 
10mg/ml   
 
1 
Cortef hydrocortisone 5mg   ORPHA352511 13 
Cortirel corticorelin 100µg USA   
 
2 
Coumadin  warfarin 
sodium 
5mg   
 
2 
CroFab 
(crotalidae 
polyvalent 
immune fab 
(ovine)) 
 1g   
 
10 
Cyclomydril clyclopentolate  
HCI and 
phenylephrine 
HCI 
   
 
62 
Cyclomydril clyclopentolate  
HCI and 
phenylephrine 
HCI 
   
 
12 
Cystagon cysteamine 
bitartrate 
150mg USA   
ORPHA24962 
114 
  
 
 
136 
Cystagon cysteamine 
bitartrate 
50mg USA   
ORPHA24962 
70 
D3-Vicotrat  cholecalciferol  N/A  ORPHA371794 1 
dabrafenib  50mg   
 
3 
dabrafenib  75mg/ml   
 
2 
Dacogen decitabine 50mg USA Europe 
ORPHA77330 
4 
DAS181  13mg   
 
2 
Decuprate bis-choline 
tetrathiomolybd
ate 
30mg   
ORPHA414762 
3 
defibrotide   200mg USA Europe 
ORPHA85388 
33 
Demerol  meperidine 50mg/ml   
 
26 
Demser metyrosine 250mg   
 
5 
Depacon - 
Abbott 
valproate 
sodium 
100mg/
ml 
  
 
62 
Depacon - 
AbbVie 
valproate 
sodium 
100mg/
ml 
  
 
102 
Depakote 
Sprinkle 
Capsules - 
Abbott 
divalproex 
sodium 
125mg   
 
78 
Depakote 
Sprinkle 
Capsules - 
Abbvie 
divalproex 
sodium 
125mg   
 
168 
DepoCyt cytarabine 10mg/ml N/A  ORPHA45976 4 
dextrose    10% in 
0,2% 
chloride 
  
 
19 
Diacomit stiripentol 250mg   Europe 
ORPHA41778 
36 
Diacomit stiripentol 500mg   Europe ORPHA41778 7 
Diamox SR acetazolamide 250mg   
 
1 
Diaphin  diamorphine 
hydrochloride 
   
 
20 
Diazepam 
Autoinjector 
diazepam  usp 5mg/ml   
 
4 
  
 
 
137 
Dibenzyline phenoxybenza
mine  
hydrochloride 
10mg   
 
84 
Dimaval  DMPS 100mg   
 
1 
Dimaval DMPS 50mg/ml   
 
1 
Ditripentat-Heyl calcium 
trisodium 
pentetate 
0,2g/ml   
 
1 
Dodecavit hydroxocobala
min acetate 
5mg/ml   
 
24 
Dogmatil sulpiride 200mg   
 
239 
dolutegravir  50mg   
 
8 
dopamine 
hydrochloride 
 40mg/ml   
 
19 
doxycycline 
hyclate 
  5mg/ml   Europe 
ORPHA35266 
147 
DuoDote atropine and 
pralidoxime 
chloride 
   
 
6 
Durezol difluprednate 0,05% USA   ORPHA394517 2 
edetate 
calcium 
disodium 
 5%   
 
11 
Edronax reboxetine 
methanesulfon
ate 
4mg   
 
17 
Emgrast-M sargramostim 500µg   
 
2 
Enlon edrophonium 
chloride 
10mg/ml   
 
20 
ENMD-2076  225mg   
 
1 
enzalutamide MDV-3100 40mg   
 
11 
epinephrine 
hydrochloride 
 1 mg/ml   
 
1 
Epogen  epoetin alfa 20000U/
ml 
  
 
2 
etomidate  2mg/ml   
 
30 
etomidate 
injection 
 2mg/ml   
 
3 
  
 
 
138 
Etomidate-
Lipuro 
 2mg/ml   
 
567 
Etopophos  etoposide 
phosphate 
100 mg   
 
53 
Excegran zonisamide 100 mg   
 
22 
F-18 
Fluorodeoxyglu
cose 
    
 
1 
Factor VII 
Concentrate 
(human 
coagulation 
factor VII) 
 600IU   
 
41 
Factor X P 
Behring 
(human 
coagulation 
factor IX and X) 
    
 
2 
Factor XI 
Concentrate 
(human 
coagulation 
factor XI) 
 1000IU   
 
25 
Fareston toremifene 
citrate 
60mg USA   
 
3 
Fasigyn tinidazole 500mg USA   
ORPHA57037 
21 
Fasinex triclabendazole 250mg   
 
2 
Felbatol felbamate 120mg/
ml 
USA   
ORPHA24982 
6 
Felbatol felbamate 600mg USA   
ORPHA24982 
104 
Ferriprox deferiprone 500mg USA Europe 
ORPHA42568 
99 
Fibrogammin P 
(human 
coagulation 
factor XIII) 
 1250IU   
 
30 
Fibrogammin P 
(human 
coagulation 
factor XIII) 
 250IU   
 
118 
Firazyr icatibant 
acetate 
10mg/ml USA Europe 
ORPHA82439 
24 
  
 
 
139 
floxuridine  500mg   
 
3 
Folotyn  pralatrexate 40mg/ml USA Europe ORPHA90183 1 
Foscavir foscarnet 
trisodium  
hexahydrate 
24mg/ml   
 
197 
Fosfocina sodium 
fosfomycin 
   
 
2 
Freeze-Dried 
Glutamate 
BCG vaccine 
    
 
5 
Fucidin  sodium 
fusidate 
250mg   
 
29 
Fycompa  perampanel 12mg   
 
6 
Fycompa perampanel 4mg   
 
5 
Fycompa perampanel 6mg   
 
2 
Gabitril tiagabine 
hydrochloride 
16mg   
 
2 
Gabitril tiagabine 
hydrochloride 
4mg   
 
5 
Galzin zinc acetate 25mg USA    ORPHA56897 1 
Galzin zinc acetate 50mg USA    ORPHA56897 11 
Gattex teduglutide 5mg USA  Europe ORPHA101257 1 
gentamicin-  
preservative 
free 
 10 
mg/mL 
  
 
1 
Glycophos Sodium 
Glycerophosph
ate 
   
 
20 
Glypressin terlipressin 
acetate 
1  mg   
 
1 
Gonapeptyl 
depot 
triptorelin 3,75mg   
 
2 
guanethidine  
monosulphate 
 10 
mg/mL 
  
 
5 
guanfacine 
hydrochloride 
 1 mg   
 
98 
guanidine 
hydrochloride 
 125mg   
 
4 
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Haemocomplet
tan P 
fibrinogen 1 g   
ORPHA131045 
7 
Hemofil M 
(antihemophilic 
factor (human), 
factor VIII) 
 1000IU   
 
2 
Hemopure 
(hemoglobin 
glutamer-250  
(bovine)) 
    
 
1 
heptavalent 
botulism 
antitoxin 
(equine) 
  7500U USA    
ORPHA405648 
1 
Humulin R 
(regular human 
insulin) 
 500U/ml   
 
133 
Hyalase hyaluronidase 1500IU   
 
61 
Hycamtin topotecan 
hydrochloride 
1 mg   
ORPHA131290 
1 
hydroxocobala
min acetate 
 1 mg/ml   
 
69 
HyperRHO S/D 
Full Dose 
(Rho(D) human 
immune 
globulin) 
 1500IU   
 
4 
Hypurin Bovine 
Lente (bovine 
insulin zinc 
suspension) 
 1001U/
mL 
  
 
10 
Hypurin Bovine 
Neutral (neutral 
bovine insulin) 
 1001U/
mL 
  
 
9 
Hypurin Bovine 
Protamine Zinc 
(protamine zinc 
bovine insulin) 
 1001U/
mL 
  
 
3 
I-123 MIBG     
 
15 
I-131 MIBG     
 
80 
I-131 sodium o-
iodohippurate   
 250MBq   
 
1 
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lkorel nicorandil 10mg   
 
317 
llomedin iloprost 
trometamol 
 
13,4µg/
mL 
  
ORPHA103178 
3 
llomedin  iloprost 
trometamol 
33,5 
µg/mL 
  
ORPHA103178 
13 
lmpavido miltefosine 50mg USA Europe 
ORPHA65974 
2 
lncrelex mecasermin 10mg/m
L 
USA Europe 
 
4 
lndolar SR indometacin 75mg   
 
1 
indomethacin 
for injection 
 1 mg   
 
41 
inotuzumab 
ozogamicin 
  3,5mg   Europe 
ORPHA282211 
1 
IPL-504 retaspimycin 
hydrochloride? 
   
 
1 
lstodax romidepsin 10mg USA    
 
44 
lsuprel isoproterenol 
hydrochloride 
0,2mg/m
L 
  
 
1 
Jetrea ocriplasmin  
2,5mg/m
L 
  
 
6 
Kalydeco ivacaftor 150mg USA Europe 
ORPHA139922 
2 
Kit for the 
preparation of 
Technetium 
Tc99m 
Mebrofenin 
    
 
198 
KOATE-DVI 
(Antihemophilic 
factor (human)) 
 250IU   
 
1 
K-Phos Neutral  250mg   
 
22 
K-phos No.2     
 
8 
K-phos Original     
 
1 
Krystexxa pegloticase 8mg/mL USA   
 
2 
Lafepe 
Benznidazol 
 100mg   
 
3 
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Lamprene clofazimine 50 mg USA   ORPHA24950 72 
L-citrulline  600mg   
 
7 
LDK378  150mg   
 
7 
Leukine sargramostin 
powder 
250µg USA   
 
22 
Leukine sargramostin 500µg/m
L 
USA   
 
1 
levetiracetam  100mg/
mL 
  
 
3 
Lexiscan regadenoson 0,08mg/
mL 
  
 
24 
Lodosyn carbidopa 25mg   
 
41 
Lorenzo's Oil     
 
1 
Lullan perospirone 8mg   
 
2 
LuMark Lu-177 
trichloride 
   
 
67 
Lumitene beta-carotene 30mg   
 
6 
Mag-tab SR  84mg   
 
3 
Marplan isocarboxazid 10mg   
 
1 
Mectizan ivermectin 3mg   
 
330 
Medical 
Maggots 
    
 
21 
medicinal 
leeches 
    
 
120 
Mephyton phytonadione 5mg   
 
42 
mepolizumab SB-240563 250mg USA Europe ORPHA84164 1 
Mestinon pyridostigmine 
bromide 
12mg/m
L 
  
 
3 
Metanor flupirtine 
maleate 
100mg   
 
2 
Metopirone metyrapone 250mg   
 
21 
metreleptin   11mg USA Europe 
ORPHA300654 
2 
midostaurin PKC412 25mg USA Europe ORPHA66150 4 
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Mifeprex mifepristone 200mg   
 
2 
Mifepristone 
Linepharma 
 200mg   
 
1 
monoclonal 
antibody 
chimeric  14.18 
 5mg/ml   
 
4 
motesanib  25mg   
 
2 
Mustargen  Mechlorethami
ne 
hydrochloride 
   
 
1 
Mylotarg gemituzumab 
ozogamicin 
5mg USA Europe 
ORPHA42780 
 
3 
Mytelase ambenonium 
chloride 
10mg   
 
3 
Naglazyme galsulfase 1 mg/ml USA   ORPHA65852 21 
Natacyn natamycin 5%   
 
76 
Nembutal 
Sodium 
Solution 
pentobarbital 
sodium 
50mg/ml   
 
33 
Nesacaine - 
MPF 2%  
chloroprocaine  
HCI - 
preservative 
free 
20mg/ml   
 
1 
nifurtimox  120mg   
 
2 
Nimoral Nimorazole     Europe ORPHA24584 4 
Nimoral Nimorazole 500mg   Europe ORPHA24584 16 
Nipent pentostatin 10mg USA    
 
3 
niraparib     
 
4 
Norchol-131 I-131 
iodomethyl 
norcholesterol 
   
 
13 
Normosang 
(human hemin) 
  25mg/ml   Europe 
ORPHA25128 
1 
Northera droxidopa 200mg USA    
ORPHA393911 
3 
Notezine diethylcarbama
zine 
100mg   
 
5 
Nulojix Belatacept 250mg USA    
 
57 
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Nydrazid isoniazid 100mg/
ml 
  
 
1 
obinutuzumab   25mg/ml USA Europe ORPHA317257 6 
omacetaxine 
mepesuccinate 
Synribo 3,5mg USA   
ORPHA368193 
245 
Omegaven 
(fish oil) 
 0,1g/ml   
 
258 
Oncaspar pegaspargase 750IU/m
l 
USA   
ORPHA25045 
1 
Oral 
transmucosal 
fentanyl citrate 
 800µg   
 
15 
Orfadin nitisinone 10mg USA Europe ORPHA56899 27 
Orfadin nitisinone 2mg USA Europe ORPHA56899 9 
Orfadin nitisinone 5mg USA Europe ORPHA56899 5 
Ospolot sulthiame 200mg   
 
65 
Ospolot sulthiame 50mg   
 
7 
Oxandrin oxandrolone 10mg   
 
13 
Oxandrin oxandrolone 2,5mg   
 
1 
P32 chromic 
phosphate 
 5mCi/m
L 
  
 
12 
P-32 sodium 
orthophosphate 
    
 
18 
Panhematin 
(hemin) 
    USA   
ORPHA24990 
1 
paraldehyde     
 
17 
Paser aminosalicyclic 
acid 
4g USA   
ORPHA24936 
4 
pasireotide  SOM230B 0,6mg/m
l 
  Europe 
ORPHA101429 
1 
pasireotide   0,9mg/m
l 
  Europe 
ORPHA101429 
4 
Peak K2 menatetrenone 
mk-4 
15mg   
 
47 
Pedea ibuprophen 5mg/ml   
 
1 
Pentostam sodium 
stibogluconate 
100mg/
ml 
  
 
1 
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pertuzumab  30mg/ml   
 
8 
Phospholine 
Iodide 
echothophate 
iodide 
0,13%   
 
88 
physostigmine 
salicylate 
 1 mg/ml   
 
3 
phytonadione  2mg/ml   
 
1 
Picato ingenol 
mebutate 
0,05%   
 
30 
Picibanil OK-432 0,02mg   
 
13 
Picibanil OK-432 0,1mg   
 
37 
Piracetam EG  1200mg   
 
1 
Pixuvri  pixantrone 29mg   
 
16 
Platinol  cisplatin 50mg   
 
8 
Polidocanol aethoxysclerol 1%   
 
6 
Polidocanol aethoxysclerol 3%   
 
3 
pomalidomide   1 mg USA Europe 
ORPHA201839 
296 
pomalidomide   2mg USA Europe ORPHA201839 2 
pomalidomide   3mg USA Europe 
ORPHA201839 
76 
ponatinib   15mg USA Europe 
ORPHA216911 
52 
potassium 
chloride 
    
 
1 
Previscan fluindione 20mg   
 
18 
probenecid  500mg   
 
111 
Proglycem diazoxide 50mg/ml USA   
ORPHA403944 
10 
Proluton Depot hydroxyprogest
erone caproate 
250mg/
ml 
  
 
41 
Protopam 
Chloride 
pralidoxime 
chloride 
1 g   
 
1 
Pyridostigmine 
Bromide 
 30mg   
 
1 
quinidine 
gluconate 
 80mg/ml   
 
25 
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Quinidine 
Sulfate 
 200mg   
 
19 
Quinidine 
Sulfate 
 300mg   
 
1 
Quininject quinine 
dihydrochloride 
300mg/
ml 
  
 
2 
Qutenza capsaicin 8% USA   
 
3 
Radiogardase prussian blue 0,5g USA   
 
2 
Ranexa  ranolazine 1000mg   
 
17 
Ranexa ranolazine 500mg   
 
17 
regorafenib   40mg USA   
ORPHA331088 
10 
Relenza zanamivir 10mg/ml   
 
22 
RENOCIS  DMSA    
 
23 
Renvela  sevelamer 
carboante 
powder 
2,4g   
 
2 
Reolysin     
 
1 
retaspimycin 
hydrochloride 
IPI-504 844,5mg   
 
3 
R-Gene 10 arginine 
hydrochloride 
10%   
 
1 
Ribasphere ribavirin 200mg   
 
128 
Rifadin rifampin 600mg USA   ORPHA25051 42 
RYTHMODAN Disopyramide 100mg   
 
6 
Rythmol propafenone 
hydrochloride 
10mg   
 
2 
Rythmol propafenone 
hydrochloride 
3,5mg/m
l 
  
 
25 
Saflutan tafluprost 15µg/ml   
 
6 
Samyr ademetionine 
sulphate 
tosylate 
400mg   
 
6 
Sandimmune cyclosporine 100mg   
 
6 
Sandimmune cyclosporine 25mg   
 
21 
Sandimmune cyclosporine 100mg/
ml 
  
 
7 
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Sclerosol 
lntrapleural 
Aerosol  
talc 4g USA   
 
18 
Seromycin cycloserine 250mg   
 
21 
simeprevir  150mg   
 
1 
Sirdalud MR  tizanidine 6mg   
 
2 
Sirturo bedaquiline 100mg USA Europe ORPHA394232 2 
SMOFlipid     
 
8 
Sodium Diuril chlorothiazide 
sodium 
0,5g   
 
6 
sodium nitrite   30mg/ml   Europe ORPHA299525 6 
sodium 
phosphate 
USP 
 3mmol/
ml 
  
 
1 
sodium 
thiosulfate 
  250mg/
ml 
USA Europe 
ORPHA237352 
23 
sofosbuvir  400mg   
 
19 
Solian amisulpride 100mg   
 
42 
Solian amisulpride 400mg   
 
60 
Soludactone potassium 
canrenoate 
100mg   
 
3 
Soma carisoprodol 350mg   
 
2 
SourceCF 
Chewables   
 Chewabl
es 
  
 
3 
SourceCF  
Pediatric Drops 
 Drops   
 
1 
SourceCF 
Softgels 
 Softgels   
 
2 
Speciality 
Amino Acid 
Solution  
 Solution   
 
5 
Stablon tianeptine 
sodium 
12,5mg   
 
8 
Sterile Talc 
Powder 
Talc 5g USA    
 
44 
Steritalc large size 
sterile talc 
powder 
4g USA    
 
6 
Sterogyl 15 "H"  ergocalciferol  6000001U/1,5  ml  
 
25 
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Subutex 
Sublingual 
Tablets  
buprenorphine 
hydrochloride 
2mg USA    
 
68 
Subutex 
Sublingual 
Tablets  
buprenorphine 
hydrochloride 
400µg USA    
 
5 
Subutex 
Sublingual 
Tablets 
buprenorphine 
hydrochloride 
8mg USA    
 
71 
Sucraid sacrosidase 8500IU/
ml 
USA Europe 
ORPHA89109 
14 
sulfadiazine   500mg USA    
 
44 
sulfamethoxaz
ole and 
trimethoprim 
 trimetho
prim 
  
 
3 
Sulfamylon mafenide 
acetate 
50g USA   
 
23 
Sulfamylon 
Cream 
mafenide 
acetate cream 
20Z USA   
 
21 
Sulfamylon 
Cream 
mafenide 
acetate cream 
40Z USA   
 
2 
Sustiva efavirenz 30mg/ml   
 
3 
Synastone  methadone 
hydrochloride 
10mg/ml -  1 ml 
Ampoule(s) 
 
 
45 
Synastone methadone 
hydrochloride 
50mg/ml -   1 ml 
Ampoule(s) 
 
 
23 
Synastone methadone 
hydrochloride 
10mg/ml - 5ml 
Ampoule(s) 
 
 
2 
 Synercid quinupristin 
and dalfopristin 
   
 
6 
Syprine trientine 
hydrochloride 
250mg USA Europe 
ORPHA24924 
118 
Targretin bexarotene 1% - 
Eisai 
Inc. 
USA    
 
2 
Targretin bexarotene 75mg - 
Eisai 
Inc. 
USA    
 
10 
Targretin bexarotene 1%  - 
Valeant 
  
 
1 
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Targretin bexarotene 75mg  - Valeant  
 
7 
Tasmar tolcapone 100mg   
 
21 
Taurolin taurolidine 2%   
 
14 
Teflaro  ceftaroline 
fosamil 
600mg   
 
8 
Tepadina thiotepa 100mg USA Europe 
ORPHA86785 
67 
Tepadina thiotepa 15mg USA Europe ORPHA86785 30 
Testred C Ill methyltestoster
one 
10mg   
 
2 
Thiola tiopronin 100mg USA   
ORPHA25073 
75 
thioridazine 
hydrochloride 
 25mg   
 
22 
Thyrel protirelin 0,2mg/m
l 
  
 
23 
Tiapride tiapridal 100mg   
 
1 
Tikosyn dofetilide 125µg   
 
176 
Tikosyn dofetilide 250µg   
 
259 
Tikosyn dofetilide 500µg   
 
221 
Tilade CFC-
free inhaler 
nedocromil 
sodium 
   
 
1 
Timoptic timolol maleate 0,005   
 
57 
trastuzumab 
emtansine 
T-DM1 160mg   
 
56 
Travatan travoprost 
ophthalmic 
solution 
0,00004   
 
3 
Trecator ethionamide 250mg   
 
16 
Treosulfan treosulfan 5g USA Europe ORPHA90799 1 
triCitrasol trisodium 
citrate 
46,70%   
 
4 
Triostat liothyronine 
sodium 
10µg/ml USA    
 
1 
  
 
 
150 
Tript-OH L-5-
hydroxytryptop
han 
100mg   
 
4 
Tript-OH L-5-
hydroxytryptop
han 
50mg   
 
7 
Tript-OH L-5-
hydroxytryptop
han 
25mg   
 
2 
Trisenox  arsenic trioxide 1 mg/ml USA Europe ORPHA41289 75 
trisodium zinc 
pentetate 
Zn-DTPA 211mg/
ml 
  
 
1 
Trobicin spectinomycin 
hydrochloride 
2g   
 
4 
Twin lab Liqui-
E (water 
soluble vitamin 
E) 
    
 
21 
Ultracain D 
(epinephrine 
free) 
articaine 
hydrochloride 
40 
mg/ml 
  
 
1 
Unasyn  3g   
 
1 
uridine 
triacetate 
 250g   
 
1 
Uvadex methoxsalen 2µg/ml USA Europe ORPHA81882 76 
Valdoxan agomelatine 25mg   
 
40 
Vastarel trimetazidine 35mg   
 
2 
Ventavis iloprost 10µg/ml   ORPHA34113 3 
Vercyte pipobroman 25mg   
 
11 
Videx didanosine 4g   
 
4 
Viibryd vilazodone 10mg   
 
1 
Viramune nevirapine 
hemihydrate 
10mg/ml   
 
84 
Virazole  ribavirin 0,1g/ml   ORPHA90805 18 
*VIREAD tenofovir 
disoproxil 
fumarate 
250mg USA   
 
2 
Virgan ganciclovir 0,15% USA   
 
2 
vismodegib  150mg   
 
3 
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Vistide  cidofovir 75mg/ml   
 
46 
Vitamin  E alpha-
tocopherol 
acetate 
2 ml   
 
2 
Viviant  bazedoxifene 20mg   
 
3 
voclosporin   10mg   Europe ORPHA317318 3 
voclosporin   5mg   Europe ORPHA317318 3 
Volumen barium sulfate 0,10%   
 
1 
Voraxaze glucarpidase 1000U USA   ORPHA394551 12 
Wellbutrin  Ir  buproprion 75mg   
 
1 
Wycillin penicillin g 
procaine 
suspension 
1200000
U 
  
 
1 
Xenbilox  chenodeoxych
olic acid 
250mg   Europe 
ORPHA41421 
9 
 Xifaxan rifaximin 550mg USA   
 
770 
Yttrium-90 
Citrate CIS Bio 
International 
    
 
2 
 Zaltrap aflibercept 25mg/ml   
 
2 
Zanosar streptozocin 1 g   
 
34 
Zemplar paricalcitol 5µg/ml   
 
3 
Zentel albendazole 200mg USA   ORPHA24928 1 
Zentel albendazole 400mg USA   ORPHA24928 212 
Zerit stavudine 200mg   
 
6 
Zonegran  zonisamide 100mg   
 
44 
Zonegran zonisamide 50mg   
 
6 
Zovirax acyclovir 3%   
 
159 
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